Meeting

18th Midwest Platelet Conference

midwest platelet conference

Celebrate with DiaPharma at THSNA 2022

Diapharma is proud to celebrate 25 years in the hemostasis and coagulation business at the Thrombosis and Hemostasis Summit of North America (THSNA) this year in Chicago, IL.  We would love to see old friends and meet new acquaintances August 16th – 18th at the Sheraton Grand Chicago in Booth #416.  Our team will be eager to talk all things bleeding, clotting, and demo new technology in platelet function measurements.

SOT ToxExpo 2022

Visit DiaPharma at Booth 1118 to discuss Keratin 18 (K18/CK18) liver and kidney injury biomarkers for early DILI/DIKI prediction. K18 biomarkers have improved sensitivity and specificity over traditional biomarkers. Our K18 M30 Apoptosense® and M65® ELISAs detect apoptosis and necrosis whether caused by drugs, toxins, or disease. Learn about our extensive line of biomarker assays for drug safety studies, including osteopontin, L-FABP, α-GST, NGAL, and Cystatin C. Research use only.


ML-00-00874Rev01

Meet with DiaPharma IN PERSON!! at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo!

Meet with DiaPharma IN PERSON!! at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo!

Explore assays for COVID-19-associated coagulopathy, specialty hemostasis, organ injury, and SARS-CoV-2 serology.

DiaPharma specializes in research and clinical assays for bleeding and clotting disorders, anticoagulation measurement, hemostasis analyzers, and mechanistic biomarkers for liver disease (Nonalcoholic Steatohepatitis, Alcoholic Hepatitis), drug-induced liver and kidney injury, and anti-cancer drug development.

Booth # 317. We can’t wait to see you!


ML-00-00862Rev01

#aacc2021
#diapharma
#coagulationassays
#hemostasisanalyzers
#covidresearch

Non-Alcoholic Steatohepatitis and Liver Fibrosis Therapeutic Agents (NASH-TAG 2020)

Diapharma will attend NASH-TAG 2020 this year. Please click here to schedule a meeting with us or email us directly.


NASH-TAG = NON-ALCOHOLIC STEATOHEPATITIS AND LIVER FIBROSIS THERAPEUTIC AGENTS

Diapharma National Sales Meeting (December 2019)

The University of Texas Southwestern Medical Center 5th Annual Update on Liver Disease


Diapharma will attend The University of Texas Southwestern Medical Center 5th Annual Update on Liver Disease this year. Please click here to schedule a meeting with us or email us directly.


About the UTSW Annual Update on Liver Disease

This activity is a review course intended to update providers on a diverse range of topics in liver disease, including viral hepatitis, fatty liver disease, hepatocellular carcinoma, and liver transplantation. The conference will focus on recent advances published at DDW, AASLD, and EASL this past year. The presentations will be beneficial to all providers caring for liver diseases. The discussion will be centered on cases in order to make the activity interactive and practical, and this activity will include a session on real-life consultation by experts.


UTSW

61st American Society of Hematology (ASH 2019) Annual Meeting & Exposition

 


Diapharma is will attend and exhibit at the 61st American Society of Hematology (ASH 2019) Annual Meeting & Exposition this year. Please click here to schedule a meeting with us or email us directly.

Diapharma Booth 971

Technoclone Booth 969


ASH 2019

The 61st ASH Annual Meeting and Exposition will be the world’s most comprehensive hematology event of 2019. The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field and a global community of more than 25,000 hematology professionals from every subspecialty.



hematology assay test kit chromogenic ELISAAbout ASH

The American Society of Hematology (ASH) is the world’s largest professional society concerned with understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. ASH is dedicated to helping hematologists conquer blood diseases.

The field of hematology has experienced a recent surge in progress thanks to novel technologies, mechanistic insights, and cutting-edge therapeutic strategies that have driven significant and meaningful advances in the quality of care. These foundational insights are reframing modern research with the continued goal of improving outcomes and discovering cures for the most challenging hematologic diseases.

Whereas certain blood disorders have benefited from the tremendous progress in clinical research and development of new therapies, other areas have continuing challenges such as disease heterogeneity and the complex combinations of genetic drivers that have evaded effective treatment to date. A wide variety of blood-related diseases – from malignancies such as lymphoma and leukemia, to non-malignant diseases including hemoglobinopathies, blood platelet, and coagulation disorders, including orphan diseases of the hematopoietic system – continue to be associated hematology assay test kitwith significant morbidity and mortality and demand attention to reduce their burden and improve the quality of care worldwide.

Today, the research community looks to emerging technologies and tools in the areas of genetics and epigenetics, gene therapies, and regenerative medicine to identify areas that have strong potential to make a dramatic impact on patient care across a range of diseases.

The ASH agenda serves as a roadmap for the prioritization of research support across the hematology community, including recommendations for dedicated resources from funding agencies and foundations that will equip researchers today and in the future to make truly practice-changing discoveries. These specific and critically important research questions must be answered to gain the insights that will launch the field into the next generation of care for hematologic conditions.

ASH publishes BloodThe HematologistASH Clinical NewsASH Self-Assessment Program, and the Hematology ASH Education Program.


ASH | ASH 2019 | Facebook | Twitter | LinkedInYouTube | OCCC

The Liver Meeting® 2018 – The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Diapharma will attend and exhibit at The Liver Forum and The Liver Meeting (AASLD) this year. Booth 1224. Please click here to schedule a meeting with us or email us directly.


About The Liver Meeting

The Liver Meeting® provides a forum for the exchange of basic, translational and clinical research in diseases of the liver and biliary tract, and in liver transplantation. The Liver Meeting® creates an arena for the presentation and interchange of opinions on state-of-the-art care and management of the full spectrum of patients with liver disease.

Topics

  • Bile Acid Signaling and Cholestatic Liver Diseases
  • Drug-Induced Liver Injury: Assessing Risk and Predicting Outcome (Hepatotoxicity)
  • NAFLD Progression: A Cross Talk with Microbiome (Nonalcoholic Fatty Liver Disease)
  • Acute and Chronic Kidney Failure in Cirrhosis: Mechanisms to Management (Acute on Chronic Liver Failure and Portal Hypertension)
  • AASLD / ILTS Transplant Course
  • The Critically Ill Patient and Challenges in Liver Transplantation
  • AASLD / ASGE Endoscopy Course
  • New Endoscopic Frontiers in Liver Disease
  • Clinical Research Workshop
  • Microbiome as a Model of Clinical Research: From Stool to Study to Treatment
  • Special Interest Group Programming
  • Improving the Care Continuum for Chronic HCV Infection in 2019 (Hepatitis C)
  • Novel Approaches to Study and Treat Liver Fibrosis (Liver Fibrosis)
  • AASLD / NASPGHAN Pediatric Symposium
  • Acute Liver Failure
  • Clinical Hepatology (Clinical Practice)
  • Updates and Controversies in HBV: Management, HCC Surveillance and Emerging Therapies (Hepatitis B)
  • Regenerative Medicine and the Bio-Artificial Liver (Liver Cell Biology in Hepatic Diseases
  • Current Trends in Liver Regeneration and Repair
  • Precision Hepatology in Clinical Practice
  • Liver Transplantation for NASH: Optimizing Outcomes
  • A New Era of Genomics and Biomarkers in Hepatocellular Carcinoma
  • Clinical vs Science in Personalizing Immunosuppression
  • Emerging Therapies and Current Clinical Trials for Alcoholic Hepatitis (Alcoholic Liver Disease )
  • Social Innovation: Solution-Based Responses to Disparities in Liver Diseases and Liver Transplantation
  • Defining the Role of Hepatologists in Value-Based Care
  • Obesity, Metabolic Syndrome and HCC (Hepatobiliary Neoplasia)
  • Multi-Disciplinary Approach in Reducing Readmissions (Hepatology Associates)
  • Acute on Chronic Liver Failure
  • Genetic Susceptibility to Drug-Induced Liver
  • New AASLD Guidelines: A Summary of New Recommendations for HCC, PBC and ALD
  • Distributed Hepatocytes in Liver Homeostasis and Regeneration
  • Microelimination of Viral Hepatitis
  • Molecular Pathogenesis and Hepatocellular Carcinoma

 



liver biomarker assay test kit ELISA

About the AASLD

The mission of the American Association for the Study of Liver Diseases (AASLD) is to advance the science of hepatology and to promote liver health.

AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment options for millions of liver disease patients. AASLD advances the science and practice of hepatology through meetings such as The Liver Meeting®, educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.

 


AASLDFacebook | Twitter | LinkedIn | YouTube | Instagram | Invitation Postcard

Society of Environmental Toxicology and Chemistry (SETAC) North America 40th Annual Meeting 2019

Diapharma will attend and exhibit at the Society of Environmental Toxicology and Chemistry (SETAC) North America 40th Annual Meeting this year. Please click here to schedule a meeting with us or email us directly.


About The SETAC North America Meeting

SETAC global meetings offer a multidisciplinary forum for scientists and institutions engaged in the study of environmental problems, management and regulation of natural resources, environmental education, and research and development. Cutting-edge scientific presentations and unique learning and networking opportunities help scientists from around the world stay on top of emerging research, regulatory developments and the latest methodologies.

Aquatic Toxicology, Ecology and Stress Response

Explores ecology, ecotoxicol0gy and response to stress of all aquatic systems, including lentic and lotic freshwater systems, estuaries, coastal and marine environments

Terrestrial Toxicology, Ecology and Stress Response

Covers all life forms (avian and mammalian wildlife and other organisms) living in areas from the deserts to the tropics and everything in between

Environmental Risk Assessment

Bridges both aquatic and terrestrial environments, and all potential stressors (physical, chemical, biological and biotechnological) with human and ecological endpoints towards the goal of integrated holistic assessment such as “One Health”

Policy, Management and Communication

Includes all aspects of science application in policy or regulations and management (regulatory science), as well as science commination to stakeholders in diverse audiences

Engineering, Remediation and Restoration

Addresses remediation and restoration of stressor impacted air, water, and soil and sediment, including tools for predicting, monitoring and evaluation; technologies and methods for remediation and restoration; environmental engineering; green remediation; damage assessment; and strategies for management

Chemistry and Exposure Assessment

Comprises all aspects of chemical analysis, monitoring, fate and modeling, green chemistry and alternative chemical assessment

Predictive and Statistical Toxicology

Encompasses in silico and in vitro tools and methods involving adverse outcome pathway (AOP), mode of action, molecular toxicology, OMICs, animal alternative testing, quantitative structural activity relationship (QSARs), high-throughput techniques and emerging approaches for statistical toxicology

Systems Approaches

Uses cross- and trans-disciplinary approaches seeking to address complexity and large-scale issues by applying and integrating concepts such as life cycle assessment, sustainability, ecosystem services, impact assessment and environmental economics. Topics include regional and watershed-scale environmental management, climate change, resiliency and other related areas.

Spotlight Sessions

Address cutting-edge scientific topics, which are related to the central theme of the annual meeting, a topic of regional importance to the location of the annual meeting, currently of high societal concern, contribute to SETAC long-range planning, or stimulate transdisciplinary collaboration.

 


 


toxicology assay test kit ELISA

About SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology (ecotox) .

SETAC publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


SETAC | SETAC-NA | Facebook | Twitter | LinkedIn | YouTube | flickr | MTCCC

13th Annual UCLA Liver Diseases Symposium

liver assay


Diapharma is planning to attend the 13th Annual UCLA Liver Diseases Symposium this year. Please click here to schedule a meeting with us or email us directly.


About the UCLA Liver Diseases Symposium

David Geffen School of Medicine, Dumont-UCLA Transplant Center, Dumont-UCLA Liver Cancer Center, and Pfleger Liver Institute

This symposium will serve as an educational forum for the Southern California physician community for the scientific exchange of information regarding the diagnosis, medical and surgical, and treatment of the most prevalent liver diseases.


Topics

  • Viral Hepatitis and HCC
  • Current antiviral treatment and risk for hepatocellular carcinoma
  • Hepatitis C: current antiviral treatments and risk for hepatocellular carcinoma
  • Metabolic syndrome
  • Hepatic insulin resistance in diabetes
  • Complications of Cirrhosis
  • Hepatic encephalopathy
  • Other manifestations of cirrhosis
  • Hepatology
  • Oncology

UCLA David Geffen SOM | Westin Pasadena

5th Annual Update on Liver Disease

 


Diapharma will attend the 5th Annual Update on Liver Disease this year. Please click here to schedule a meeting with us or email us directly.


 

 

5th Annual Liver Research Day

 


Diapharma is planning to attend the 5th Annual Liver Research Day this year. Please click here to schedule a meeting with us or email us directly.


Topics

  • Wilson disease
  • Copper metabolism and Wilson Disease
  • DNA methylation and Wilson Disease
  • Animal models of Wilson Disease
  • The role of copper in fatty liver
  • Alpha 1 AT deficiency and cystic fibrosis
  • A1AT and the liver
  • Cystic fibrosis and the liver
  • Cholestatic liver diseases
  • Genetics of cholestatic syndromes
  • Genetics of PSC
  • Metabolomics platforms for the study of rare diseases

UC Davis Internal Medicine | Twitter | Facebook | LinkedIn | YouTube

2nd Annual Hemophilia Drug Development (HDD) Summit

 


Diapharma will attend the 2nd Annual Hemophilia Drug Development (HDD) Summit this year. Please click here to schedule a meeting with us or email us directly.


About the HDD

The 2nd Annual Hemophilia Drug Development Summit is dedicated to translating more effective therapies, bringing the right treatments to meet the goals of every subject. From subcutaneous therapies to gene therapies these all have the aim of improving subjects’ quality of life.

This event brings together over 100 of the world’s leading experts and drug developers. They will discuss the development and impact of non-factor products, patient advocacy and engagement strategies, improve testing methods and assays for better measures of response and diagnosis, and the payer and reimbursement strategies to ensure market access.


Workshops

Workshop A

Understanding Immunogenicity in Next Generation Factor Replacement Prophylaxis

Workshop B

Improving Patient Access to Gene Therapy Through Novel Payer and Reimbursement Strategies


Topics

  • Evaluating the impact of non-factor products in a changing hemophilia treatment paradigm
  • Assessing the impact of new therapies on hemophilia patients
  • Clinical development of Concizumab, a monoclonal antibody for subcutaneous prophylaxis for all hemophilia patients
  • American thrombosis and hemostasis network – a national collaborative
  • Application of state-of-the-art laboratory techniques to an ever-changing hemophilia drug landscape
  • Fitusiran, an RNAi therapeutic targeting antithrombin to restore hemostatic balance in people with hemophilia
  • Advancing novel prophylaxis that improves quality of life
  • A tale of two subcutaneous coagulation factors
  • Thrombin generation assay (TGA): one of the most versatile tools in the coagulation assay tool chest
  • Research and development of next generation prophylaxis
  • Significance of neutralizing antibodies in gene therapy in hemophilia
  • Emerging roles of transgene mutations in gene therapy products for hemophilia
  • A stable & durable treatment for pediatric patients with hemophilia
  • Preliminary data for SB-525 for the treatment of severe hemophilia A
  • Data from a prospective study using FVIIIFc for ITI in hemophilia patients with inhibitors
  • Women’s health in von Willebrand Disease
  • Patient advocacy and improving diagnosis of von Willebrand Disease
  • Challenges and considerations in medical affairs for novel hemophilia drug development

HDD | Twitter | Wyndham Boston

Gordon Research Conference (GRC) – Cellular & Molecular Mechanisms of Toxicity: Integration of Emerging Technologies in Mechanistic and Translational Toxicology

 


Diapharma is planning to attend the Gordon Research Conference (GRC) this year. Please click here to schedule a meeting with us or email us directly.


toxicity assaytoxicity assayAbout Gordon Research Conference – Cellular & Molecular Mechanisms of Toxicity: Integration of Emerging Technologies in Mechanistic and Translational Toxicology

This GRC will be held in conjunction with the “Cellular and Molecular Mechanisms of Toxicity (GRS)” Gordon Research Seminar (GRS).

Gordon Research Conference Topics Include

  • A Framework for Toxicology at a Grand Scale
  • Using the Exposome to Study Adverse Events at a Population Level
  • Analytics for Interrogating Exposomes and Phenomes in Disease and Health
  • Diverse Tissues, Diverse Responses: Delving into Organ Toxicity
  • Evaluating Diet-PFAS Interactions in Models of Obesity and NAFLD
  • Environmental PPARγ and RXR Ligands: Selective Agonists that Disrupt Bone and Adipose Homeostasis
  • Flavoring Chemicals and Pulmonary Cellular Toxicological Responses
  • Advances at the Interface of Toxicology and Medicine: Toward Prevention and Treatment of Toxicant-Mediated Disease
  • From the Most Dangerous Dioxin to the Most Profitable Weed Killer: Environmental Risks of Multiple Myeloma
  • MicroRNA Expression as a Biomarker of Acute Lung Injury in Humans
  • Mechanisms of Toxicant Associated Steatohepatitis in Translational Studies
  • Nuclear Receptors Old and New: Novel Pharmacological and Toxicological Targets
  • Nuclear Receptors in Drug Discovery
  • Targeted Nuclear Receptor Modulation of the Gut-Liver Axis in Xenobiotic Biotransformation
  • Hepatocyte Nuclear Factor 4 Alpha: A Novel (and Often Ignored) Toxicant Target
  • Applications of Microphysiological Systems in Toxicological Research
  • Microphysiological Systems, Mechanisms of Action, and Chronotoxicology
  • Translational Applications of Tissue Chip Technologies
  • Application of Organs on Chips in Pharma Industry: The Need, Gaps and the Vision
  • Genetic and Epigenetic Responses to Hydrogen Sulfide Exposure
  • Environmental Exposures and Stem Cell Reprogramming: Understanding Racial Disparities in Triple Negative Breast Cancer
  • Epigenetics and Regulatory Toxicology
  • Testing Beyond Animals: Pushing the Frontiers in Safety Evaluation
  • In Vivo 5-Day Transcriptomics Approach to Estimating Points of Departure
  • From Plates to Human: Validating Assays with Investigative Toxicology
  • Bridging the Gap with RISK21: Risk Assessment in the 21st Century
  • Emerging Technologies and Alternative Testing Strategies
  • Using 3D Organotypic Cultures to Model Cancer Biology and Treatment Response
  • Therapeutic Strategies via Genome Engineering: New Approaches and Challenges
  • Rewiring of the 3D Genome in Inorganic Arsenic-Mediated Carcinogenesis
  • Keynote Session: Utilizing Big Data and Quantitative Systems Modeling to Derive Outcomes
  • Utilizing Big Data and Systems Modeling to Derive a Widely Applicable Predictive Toxicogenomics Space Tool
  • Quantitative Mechanistic High Content Data for Predictive Systems Toxicology Modelling

GRC | Twitter | Facebook

71st American Association of Clinical Chemists (AACC) Annual Scientific Meeting & Clinical Lab Expo

technoclone assay technoclone assay technoclone assay


Diapharma will attend the 71st American Association of Clinical Chemists (AACC) Annual Scientific Meeting & Clinical Lab Expo along with our partner Technoclone this year. Please click here to schedule a meeting with us or email us directly.


About 71st AACC Annual Scientific Meeting & Clinical Lab Expo

technoclone assay

At the 71st AACC Annual Scientific Meeting & Clinical Lab Expo, you’ll have the opportunity to:

  • Connect with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine.
  • Learn about cutting edge technology. The AACC Clinical Lab Expo has more than 200 new product introductions each year.
  • Hear vital research and learn about important changes in the field. With nearly 300 educational opportunities in the form of lectures, plenary sessions, scientific sessions, and roundtable sessions, you can design an educational experience that meets your need to stay ahead of changes in the field.

About AACC

The American Association for Clinical Chemistry (AACC) is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. Our leadership in education, advocacy and collaboration helps lab professionals adapt to change and do what they do best: provide vital insight and guidance so patients get the care they need.



technoclone assay


AACR | Twitter | Facebook | YouTube

12th International Society for Study of Xenobiotics (ISSX 2019)

Xenobiotics measurement assay test kit Xenobiotics measurement assay test kit Xenobiotics measurement assay test kit


Diapharma is planning to attend the 12th International Society for Study of Xenobiotics (ISSX 2019) Meeting this year. Please click here to schedule a meeting with us or email us directly.


About ISSX 2019Xenobiotics measurement assay test kit

ISSX 2019 is a meeting for the entire society that offers a broad ranging program to serve the interests of all its scientific and geographical constituencies.

ISSX 2019 Topics Include

  • Advances in the Role of Transporters in Drug Development
  • Predicting and Verifying Tissue Drug Concentrations Using a Proteomics and PET Imaging Approach
  • Advancing Predictions of Tissue and Intracellular Drug Concentrations Using in vitro and PBPK Modeling Approac hes
  • Influence of Transporter Polymorphisms on Drug Disposition and Response
  • Can BSEP Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk?
  • Transporter DDIs
  • Non-P450 Enzymes in ADMET for Drug Discovery and Development
  • Overview of Non-P450-mediated Metabolism in Drug Development
  • Role of Glucuronidation in Drug Metabolism and Toxicity
  • Enzymology and Clinical Importance of Reductases and Hydrolases
  • Significance of Hydrolases and Aldehyde Oxidase in Drug Toxicity
  • State of the Art PKPD and QSP Modeling
  • Introduction to QSP
  • How to Build a QSP Model in Less than One Hour
  • Application of QSP in Drug Discovery
  • Therapeutic Area Case Study: QSP in Immuno-oncology
  • Therapeutic Area Case Study: QSP in Inflammatory Disease
  • Idiosyncratic Drug-induced Liver Injury
  • The Role of Inflammatory Mediators in Idiosyncratic Drug-induced Liver Injury
  • Clinical Aspects of Hepatocellular and Cholestatic Drug-induced Liver Injury
  • Understanding Genetically-inherited Susceptibility Factors, Including HLA Genotype
  • Use of Pharmacogenomics and Other Patient-specific Factors to Individualize Drug Dosing and Treatment
  • Warfarin: A Paradigm for Individualized Dosing
  • Relevance of Transporter and Metabolic SNPs to Pediatric Treatment
  • CPIC Guidelines and Implementation to Date
  • Personalised Treatment of Cancer
  • State of the Art for Organs on Chips
  • Kidney Organoids for Disease Modeling and High Throughput Screening
  • Real-time Toxicity Assessment on Perfused 3D Epithelial Tubes
  • Tissues on Chips- A Novel Tool for Toxicity and Efficacy Testing on Human Tissue
  • Biofabrication of Liver Constructs for Drug Toxicity Studies
  • Quantitative Pharmacokinetic and Pharmacology Methods and Strategies in the Discovery and Development of Biotherapeutics
  • Development and Application of a PBPK Model for Large Molecules
  • PBPK and PKPD Modeling to Investigate Engineered Antibodies
  • PBPK Models for Predicting Human PK for Monoclonal Antibodies and Other Large Molecule Modalities
  • Systems PK/PD Model Informed Discovery and Development of Cancer Immunotherapy
  • Microbiome-Environment-Drug Interactions: Emerging Tools and Applications
  • Impact of Intestinal Flora on Host Metabolism of Drug, Sugar and Lipid
  • Activity-based Profiling of the Microbiome Response to Chemical Exposures
  • Impact of the Human Gut Microbiome on Drug Disposition
  • Developmental Reprogramming of the Gut Microbiota by Environmental Toxicants
  • Disease Effect on Transporter Regulation and Function
  • Proteomics Based Studies of Disease Effects on the Brain Barrier Transporters
  • Transporters in Polycystic Kidney Disease
  • Liver Transporter Activity in Patients with Renal Disease
  • Advances in the Study of Drug Metabolism
  • Predicting Routes, Sites, and Products of Metabolism
  • Substrate Recognition by Cytochrome P450s
  • Application of in silico DMPK in Drug Discovery and Development
  • Biosynthesis of Drug Candidates and Metabolites
  • Transporter Polymorphisms Drive Inter-ethnic Differences in Drug Response
  • Impact of Racial/Ethnic Differences in Drug Response: Regulatory Perspectives
  • State-of-the-Art Approaches in Drug Metabolizing Enzymes and Transporters (DMET) Biomarker Research: Path from Discovery to Validation
  • Biomarkers for in vivo Assessment of Transporter Function
  • Mechanistic Models for Coproporphyrin I and Creatinine as Endogenous Biomarkers for Transporter Drug-Drug Interactions
  • Knockout Mice, Transcriptomics and Metabolomics Approach for Discovery of Endogenous Biomarkers for Renal Drug Transporters
  • Integrated Quantitative Proteomics and Metabolomics Approach for Discovery and Validation of UGT2B17 Biomarker to Predict Drug Metabolism
  • Biotransformation Mechanisms and Pathways
  • Role of Albumin in Drug Disposition Revisited
  • Albumin-mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates
  • Effects of Albumin on Prediction of Liver Kpuu and Human Hepatic Clearance for Enzyme- and Transporter-Mediated Mechanisms
  • Impact of Albumin and Plasma on the Renal Uptake of OAT1 Substrates
  • Ontogeny of Enzymes and Transporters and their Implications in Pediatric PBPK Modeling to Inform Pediatric Dosing
  • Ontogeny of Human Membrane Transporters: from Data to Application
  • Pediatric PBPK: Dealing with Uncertain Parameters and Deciding on Success Criteria for Predictability
  • ‘Virtual Children’ to Inform Exposure-Controlled Dosing of Drugs in Children
  • Building, Verifying and Validating Pediatric PBPK Models: Vulnerabilities and Knowledge Deficits
  • ADME Issues Encountered and Addressed in Drug Discovery and Development
  • Management of MIST in a Case of Multiple Metabolic Species Differences

About ISSX

As the foremost organization representing the interests of researchers and educators in the field, the Society is engaged in multiple activities to support, promote, and advance the profession on a global scale.

ISSX Mission

ISSX advances research and education on the interplay of living systems with medicines and chemicals for the benefit of society worldwide.

ISSX Meetings

ISSX meetings bring together a network of academic and industry research scientists and future scientists in toxicology, pharmacology, molecular biology, and other disciplines related to the study of xenobiotics.


Xenobiotics measurement assay test kit Xenobiotics measurement assay test kit Xenobiotics measurement assay test kit


ISSX | Twitter | Facebook | LinkedIn | Oregon Convention Center

27th Congress of the International Society of Thrombosis and Haemostasis and 65th Annual Scientific and Standardization Committee (SSC) (ISTH 2019)

International Society Thrombosis Haemostasis International Society Thrombosis Haemostasis International Society Thrombosis Haemostasis


Diapharma will attend International Society of Thrombosis and Haemostasis (ISTH 2019). Please click here to schedule a meeting with us or email us directly. ISTH 2020 will be held in Milan, Italy.


About ISTH 2019

International Society Thrombosis Haemostasis

ISTH 2019 is the XXVII Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Melbourne, Australia, July 6-10, 2019. It is the 27th Congress overall and features the 65th annual Scientific and Standardization Committee (SSC) meeting.

​ISTH 2019 will bring together thousands of the world’s leading experts in thrombosis, hemostasis and vascular biology to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care. ​

Through an extensive lineup of educational sessions, poster and oral communications, state-of-the-art lectures, medical industry exhibits and professional networking opportunities, the Congress promotes important scientific discourse and advancement.


International Society Thrombosis Haemostasis

ISTH 2019 Plenary Schedule

  • Postpartum Hemorrhage
  • Molecular Drivers of Platelet Production
  • Thrombotic Microangiopathies
  • Safe Anticoagulants: Targeting the Contact Pathway

ISTH 2019 Topic Streams

International Society Thrombosis Haemostasis

Arterial Thrombosis

  • Atherosclerosis
  • Atrial Fibrillation
  • Cardiovascular Risk Factors
  • Myocardial Infarction
  • Stroke and Fibrinolysis
  • Antiplatelet Therapy

Bleeding

  • Hemophilia
  • FVIII/IX biology
  • Von Willebrand disease
  • Rare Bleeding Disorders

Coagulation Consults

  • TTP, HUS and Microangiopathies
  • Antiphospholipid Antibody Syndrome
  • Cancer-Associated Thrombosis
  • Disseminated Intravascular Coagulation
  • Trauma and Surgical Coagulopathies
  • ​Perioperative Management of Anticoagulation

New Technologies

  • Biomarkers of Thrombosis and Hemostasis
  • Laboratory Diagnostics
  • Epigenetics, OMICs and Bioinformatics
  • Blood Components and Cellular Therapies
  • Nanotechnology and Novel Molecules

Platelets

  • Platelet Structure and Function
  • Megakaryocyte Biology
  • Inherited Platelet Disorders
  • Immune Platelet Disorders
  • Acquired Platelet Disorders

Vascular Biology

  • Blood Vessels
  • Endothelial Biology
  • Inflammation and Sepsis
  • Innate and Adaptive Immunity
  • Contact Pathway, Factor XII

Venous Thrombosis

International Society Thrombosis Haemostasis

  • Venous Thromboembolism
  • Genetic Risk Factors of Thrombosis
  • Coagulation Factors and Inhibitors
  • Protein C pathway
  • Novel Anticoagulants
  • Heparins and Heparinoids
  • Vitamin K Antagonists

Women’s & Children’s Coagulation

  • Pregnancy and Pregnancy Complications
  • Pediatric Thrombosis and Hemorrhage

About ISTH

The International Society on Thrombosis and Hemostasis (ISTH) is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.



International Society Thrombosis Haemostasis International Society Thrombosis Haemostasis

International Society Thrombosis Haemostasis


ISTH | Twitter | Facebook | LinkedIn | YouTube | MCEC | #ISTH2019

Diapharma National Sales Meeting (May 2019)

Cambridge Health Institute’s Inaugural World Pharma Week (WPW)

pharma assay pharma assay


Diapharma is planning to attend World Pharma Week (WPW) this year. Please click here to schedule a meeting with us or email us directly.


About World Pharma Week

World Pharma Week brings together international pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.



WPW | Twitter | Facebook | LinkedIn | YouTube | Seaport Hotel & World Trade Center | #WorldPharmaWeek

1st International Workshop of the Steatohepatitis in HIV Emerging Research (SHIVER) Network

steatohepatitis HIV biomarker measurement assay test kit steatohepatitis HIV biomarker measurement assay test kit steatohepatitis HIV biomarker measurement assay test kit



Diapharma is sponsoring and attending the 1st International Workshop of the Steatohepatitis in HIV Emerging Research (SHIVER) Network this year. Please click here to schedule a meeting with us or email us directly.


SHIVER = Steatohepatitis in HIV Emerging Research


ABOUT THE SHIVER WORKSHOP

The goal of this workshop is to provide a multidisciplinary view of the current state of nonalcoholic steatohepatitis (NASH) in HIV research, treatment, and disease burden both nationally and internationally, and to establish the platform for collaborative research projects between Canada and institutions leaders on the topic. During this workshop, Canadian scientists and the members of the SHIVER (Steatohepatitis in HIV Emerging Research) Network will work together to establish research priorities in the field of NASH in HIV. This work will form the basis of research proposals to CIHR and International grant applications and conjunct publications from the Network. This workshop fills a void in existing HIV meetings. It is the only forum that brings together an international group of academics, clinicians, community members to review the latest science and foster collaborative work towards improving understanding of this major comorbidity in people living with HIV.

The SHIVER Network is an international group of academics and researchers established in December 2016. Its mandate is to evaluate clinically relevant research questions and share data with the aim of leading cutting-edge research worldwide. The overarching goal of the Network is to build research capacity, conduct innovative research, translate evidence into practice policy, and promote a global effort into an emerging, major comorbidity for PLHIV by focusing on the themes of epidemiology, diagnostics, and prevention. The Network brings together leaders in the field: 11 world-class investigators from International and Canadian institutions.

SHIVER Topics

  • Pathophysiology/metabolic syndrome
  • NAFLD/NASH: pathophysiology, histology and natural history
  • Mechanisms of liver disease in patients infected with HIV
  • Mechanisms of immune aging in chronic viral infection
  • Aging, frailty and NASH
  • Biomarkers and diagnostics
  • Update on biomarkers and other non-invasive diagnostic tools for NAFLD/NASH
  • Imaging techniques: Multicenter AIDS cohort study
  • Transient elastography and CAP to screen for NAFLD in HIV
  • MRI and biopsy: European cohort on HIV and metabolic liver disease (ECHAM)
  • Antiretroviral therapy and liver disease
  • Screening strategies in cirrhosis and practices
  • Transplant and HIV

 


steatohepatitis HIV biomarker measurement assay test kit


SHIVERMUHC

Digestive Disease Week® 2019

digestive assay measurement test kit


Diapharma is planning to attend the Digestive Disease Week® 2019 this year. Please click here to schedule a meeting with us or email us directly.


About Digestive Disease Week® 2019

digestive assay measurement test kit

The Digestive Disease Week is one of the top 50 medical meetings by HCEA in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. The congress is expected to attract worldwide gastroenterologists, clinical investigators, scientists and medical professionals related to the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Focusing on displaying and delivering the educational sessions about recent advancements in research related to gastroenterology, the meeting will come-up as a benchmark and turning point for the medical personnel.

Digestive Disease Week is sponsored by these societies:

  • American Association for the Study of Liver Diseases (AASLD)
  • American Gastroenterological Association (AGA)
  • American Society for Gastrointestinal Endoscopy (ASGE)
  • The Society for Surgery of the Alimentary Tract (SSAT)

Applied Pharmaceutical Toxicology 2019


Diapharma is planning to attend the Applied Pharmaceutical Toxicology 2019 this year. Please click here to schedule a meeting with us or email us directly.


Applied Pharmaceutical Toxicology 2019 Topics

Sessions for the 2019 Discovery Toxicology Workshop

Session I:  Machine Learning/AI/Computational Approaches in Toxicology

Session II:  Non-Clinical to Clinical Translation

Session III:  Organ on a Chip/3D Cultures/Predictive Toxicology

Session IV:  Cell and Gene therapy /New Modalities /Regulatory Interactions

Session V:   Predictive Toxicology

Session VI:  Big Data and New Technologies


About The Boston Society

The Boston Society is an international non-profit organization dedicated to bringing the best scientific ideas to industry through workshops and conferences.


APT | LinkedIn | The Boston Society

American Heart Association (AHA) Vascular Discovery: From Genes to Medicine (formerly Arteriosclerosis, Thrombosis and Vascular Biology / Peripheral Vascular Disease – ATVB/PVD) Scientific Sessions 2019

heart assay test kit heart assay test kit


heart assay test kitDiapharma is planning to attend the American Heart Association (AHA) Vascular Discovery: From Genes to Medicine Scientific Sessions 2019 this year. Please click here to schedule a meeting with us or email us directly.


About The Vascular Discovery from Genes to Medicine (formerly ATVB – Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease) 2019

This annual meeting includes diverse disciplines within the arteriosclerosis, thrombosis, vascular biology, peripheral vascular disease, vascular surgery, and functional genomics research communities that allow investigators to explore areas of cross-disciplinary interests.


AHA | Twitter | Facebook | Instagram | LinkedIn | YouTube | PinterestBoston Marriott Copley Place

Hemostasis and Thrombosis Research Society / North American Society on Thrombosis and Hemostasis Scientific Symposium (HTRS 2019)

thrombosis assay thrombosis assay thrombosis assay


Diapharma is planning to attend the Hemostasis and Thrombosis Research Society / North American Society on Thrombosis and Hemostasis Scientific Symposium (HTRS/NASTH 2019) this year. Please click here to schedule a meeting with us or email us directly.


thrombosis assay

Hemostasis and Thrombosis Research Society (HTRS) / North American Society on Thrombosis (NASTH) Scientific Symposium

This comprehensive scientific meeting is open to all healthcare professionals and basic/translational science investigators interested in the advancement of research in non-malignant hematology in both pediatric and adult medicine. HTRS/NASTH 2019 is the first symposium to be offered jointly by the Hemostasis and Thrombosis Research Society (HTRS) and the North American Society on Thrombosis and Hemostasis (NASTH).


About the HTRS

thrombosis assay

The Hemostasis and Thrombosis Research Society, Inc. (HTRS) is a North American professional medical society dedicated to advancing care for people with bleeding and thrombotic disorders through investigator-initiated research, mentoring, and continuing medical education.

HTRS was incorporated as a nonprofit, 501c3 organization in the State of Wisconsin in 1994. HTRS is a professional medical society with over 650 members from the United States and Canada.

HTRS members are physicians, researchers, nurses, nurse practitioners, pharmacists, coagulation laboratory technicians, representatives from industry, and other allied health care professionals involved in caring for pediatric and adult patients with bleeding and/or thrombotic disorders.

HTRS is governed by a volunteer board of directors comprising academic hematologists and physician researchers from the United States and Canada.


About NASTH

thrombosis assay

The North American Society on Thrombosis and Hemostasis (NASTH) is a regional professional society dedicated to the advancement of thrombosis and hemostasis research, education and clinical care.

Membership is free and open to scientists and clinicians in the field.


thrombosis assay


HTRS | NASTH | Twitter | Facebook

 

XXXII International Symposium on Technical Innovations in Laboratory Hematology (ISLH 2019)

laboratory bioassay laboratory bioassay laboratory bioassay


Diapharma is planning to attend the ISLH 2019 this year. Please click here to schedule a meeting with us or email us directly.


ISLH 2019

The International Society for Laboratory Hematology (ISLH), North American Specialized Coagulation Laboratory Association (NASCOLA), Canadian Association of Pathologists (CAP) and Canadian Hematology Society (CHS) are hosts to the ISLH 2019, the XXXII International Symposium on Technological Innovations in Laboratory Hematology.


ISLH 2019 Workshop

ISLH 2019 is offering a full day pre-meeting workshop on Wednesday, May 8, 2019 (8:00 AM – 4:00 PM). ISLH invites you to register for this pre-meeting workshop which is being held in collaboration with the NASCOLA, CHS and CAP.

This workshop will be presented by internationally recognized experts in hematology and coagulation areas. By attending this workshop, you will be exposed to up-to-date information on broad topics in hematology including: benign hematologic disorders causing cytopenias and cytosis; standardization; and current practices in flow cytometry and molecular genetic testing.

This workshop will be of benefit for trainees, medical technologists, scientists and pathologists.


About the ISLH

The International Society for Laboratory Hematology (ISLH), a non-profit organization was founded in 1992 by an international group of laboratory professionals in order to chart new directions for laboratory hematology.

ISLH had its origins back in 1984. Motivated to see laboratory hematology recognized as an independent discipline, Dr Berend Houwen organized meetings on “Technical Innovations in Laboratory Hematology” to bring together scientists, manufacturers, clinicians, and regulatory representatives to exchange ideas on Technical Innovations in Laboratory Hematology. The first meeting was held in Banff, Alberta, Canada. The meeting was an outstanding success and heralded the arrival of a new forum for dissemination of information from around the globe on laboratory hematology. The meeting became a must attend event on the calendar for hematology laboratorians culminating in the decision to form ISLH in 1992.

At the time of incorporation as a society it was decided also that a new journal be started again to provide a forum for publication of research and review articles in the broadening arena of laboratory hematology. In 2003 this journal Laboratory Hematology received acknowledgment that it had been officially indexed which again was a significant milestone for ISLH. The current journal, “The International Journal of Laboratory Hematology” is the official journal of the ISLH. The journal provides an international forum for all new developments in the research and practice of laboratory hematology and includes invited reviews, full length original articles and correspondence.

The ISLH, from those humble beginnings has now grown to the stage where it has near 900 members globally from over 50 countries. It is truly international in all aspects of its business with annual scientific meetings held in the US, Europe and Asia.

ISLH has also been instrumental in standards and guidelines development in laboratory Hematology. These include the publication in 2001 of the first flow based reference method for platelet counting and the publication in 2005 of The International Consensus Group for Hematology Review: Suggested Criteria for Action Following Automated CBC and WBC Differential Analysis. This publication gathered 20 leading hematology laboratorians from around the globe to share their views on slide review and feedback suggest it has been one of the most important laboratory hematology publications in the past 30 years.

ISLH has also expanded its repertoire of disciplines to cater for the growing needs of laboratory hematologists. Today ISLH addresses the following sub-disciplines with up-to-date symposia, research and journal reviews on:

  • Cellular Analysis
  • Flow Cytometry
  • Hemostasis and Thrombosis
  • Molecular Diagnostics
  • Hematology Informatics
  • Hemoglobinopathies
  • Anemias
  • Hematopathology
  • Point of Care Testing

laboratory bioassay


ISLHTwitter | Vancouver Convention Center

American Association for the Study of Liver Diseases / Food and Drug Administration Drug-Induced Liver Injury (AASLD/FDA DILI) Conference

dili liver assay measurement test kit dili liver assay measurement test kit dili liver assay measurement test kit


Diapharma will attend the AASLD/FDA DILI Conference this year. Please click here to schedule a meeting with us or email us directly.


dili liver assay measurement test kitAbout the AASLD/FDA DILI Conference

There are growing challenges to accurately predict drug-induced liver injury (DILI) risk tied to evolving immunotherapies and in patients with underlying chronic liver disease. This international academic-industry-government conference sponsored by the FDA and AASLD, will hear expert presentations on new treatments with hepatotoxic liability and discuss study populations of growing concern as well as many state-of-the-art scientific tools and methods that are now becoming available for the assessment of DILI risk. There will also be a robust exchange of ideas and debate towards establishing consensus among participants in the meeting as a prelude for a planned comprehensive revision of the seminal FDA guidance on the pre-marketing evaluation of DILI, issued 10 years ago.


AASLD/FDA DILI Conference Topics

Treatment of Liver Diseases

  1. When does DILI get in the way?
  2. Analysis of Hepatotoxicity connected to drugs cleared by the Liver
  • Drug development in patients with liver disease
  • Which liver diseases may predispose to hepatotoxicity
  • Blood and liver cell PK & PD measures in the treatment of liver disease
  • Altered hepatic transporters in liver disease: are these a prelude to DILI?
  • When can complications of underlying liver disease become confused with DILI?

Tools for Pre-marketing Assessment of DILI Liability

  • How good are we at predicting drugs that are hepatotoxic from chemical structure?
  • Liver cell cocultures: do these discriminate between toxic and non-toxic drugs?
  • Assessing hepatotoxicity risk profiles in drug discovery
  • New markers of ALD from NIH networks
  • In silico and in vitro simulations to predict idiosyncratic DILI

Immunotherapy and Liver Toxicity

  • What is immunotherapy and what are its unintended hepatotoxic consequences?
  • What animal models can we use to characterize risk with new agents?
  • DILI pathways that are immune-mediated: are they overlapping or drug-specific?
  • Immune-mediated hepatitis and clinical histopathology
  • Are the molecular targets associated with DILI on immune cells or liver cells?

Immunotherapy and Liver Toxicity

  • Emerging toxicity profiles in clinical trials of immune checkpoint inhibitors?
  • Immune-mediated hepatitis in a tertiary referral center – phenotypes and management
  • Will we reliably predict patient-level therapeutic and adverse responses to treatment in the future?

The FDA Guidance on the Premarketing Assessment of DILI

  • DILI guidance: goals, challenges and current status
  • Industry perspectives and initiatives to fill key gaps in the guidance
  • How should we assess deteriorated liver function in DILI patients with cirrhosis?

Further Considerations for Revising the FDA Guidance on DILI

  • Can we do better in collecting study subject data and graphic tools for analysis of DILI?
  • The value of collecting bio-samples in clinical trials
  • Assessing and managing DILI risk in trials
  • CDER perspective: DILI guidance for new patient populations and drug classes
  • Interactive structured panel discussion with audience participation


dili liver assay measurement test kit dili liver assay measurement test kit dili liver assay measurement test kit


AASLD | Twitter | Facebook | InstagramLinkedIn | YouTube | Marriott

4th International Workshop on NASH Biomarkers

NASH NAFLD biomarker ELISA assay test kit NASH NAFLD biomarker ELISA assay test kit


Diapharma will attend the 4th International Workshop on NASH Biomarkers meeting this year. Please click here to schedule a meeting with us or email us directly.


The 4th International Workshop on NASH Biomarkers will be held in Washington DC, May 5-6, 2019. The NASH Biomarkers workshop is organized by the Liver Forum.

MEETING OBJECTIVES

  • Review regulatory landscape and gaps in regulatory science related to biomarker development for NAFLD
  • Review gaps in evidence to qualify specific biomarkers for NAFLD
  • Stimulate collaborative science to accelerate biomarker development for NAFLD
  • Promote innovation in design and analytic approaches to biomarker development for NAFLD

NASH NAFLD biomarker ELISA assay test kitThe recognition of non-alcoholic steatohepatitis (NASH) as a significant cause of morbidity and mortality around the globe has generated much activity in therapeutic and diagnostic development. Histology-based assessments requiring liver biopsies remains the NASH diagnostic standard and drug developers and clinical researchers are challenged by the lack of accepted and/or validated non-invasive diagnostic, prognostic and endpoint biomarkers. Collaboration will facilitate progress to acceptance, validation and/or qualification of non-invasive biomarkers.

This public, abstract-driven workshop will focus on NASH biomarker development by bringing together individuals and organizations in the field of NASH Biomarkers. By sharing knowledge, coordinating activities, and working through the complex issues surrounding NASH, the NASH Biomarkers Workshop will continue to impact the advancement of the field.

Some topics will include:

  • Regulatory and third party payer perspectives on NASH biomarkers
  • Pathways and priorities for biomarker assessment
  • Hierarchical testing strategies for NASH
  • Pre-cirrhotic NASH and cirrhotic NASH
  • Biomarkers of therapeutic response for pre-cirrhotic NASH
  • NASH in diabetes and heart disease

 

22nd American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

gene therapy assay test kit measurement gene therapy assay test kit measurement gene therapy assay test kit measurement


Diapharma will is planning to attend the 22nd American Society of Gene and Cell Therapy (ASGCT) Annual Meeting this year. Please click here to schedule a meeting with us or email us directly.


About the 22nd American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

gene therapy assay test kit measurement

The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting provides an international forum where the latest gene and cell therapy developments are presented and critically discussed. As the leading American conference focusing solely on gene and cell therapy, ASGCT’s annual meeting brings together more than 3400 professionals including scientists, physicians, and patient advocates.


gene therapy assay test kit measurementASGCT 2019 Topics

CAR T and Related Immune Effector Cell Therapies Workshop

Clinical Long Term Follow-Up

Now that CAR T cells have been in clinical use for over 5 years, this session will focus on the clinical results and longer-term follow up of CAR T cell studies in hematologic malignancies, on the consensus grading systems that have emerged as CAR T cells enter general practice and there are more and more clinical studies, and on how clinical centers manage the administration and collection of long-term follow-up data required by regulatory bodies.

Novel Engineering and Gene Editing

This session will focus on the scientific innovation as well as the safety and regulatory aspects of next-generation genetic engineering strategies that are in development that will enable complex strategies to target novel antigens not amenable to standard autologous CAR T cell therapies or to enable allogeneic cellular products.

Beyond Autologous CAR-T Cells for Cancer

CAR T cells are in wide clinical use in B cell cancers as autologous cellular products that have been transduced to express a single transgene. This session will focus on innovations with alternative cellular products and indications, such as allogeneic NK cells, stem cells, and potential uses of engineered cell therapies on non-cancer indications.

Gene Editing Workshop

The Gene Editing workshop provides an overview of current gene editing technologies and approaches, emerging uses and applications, with sessions highlighting junior investigators and clinical gene editing programs.

Introduction to Gene Editing

NIH Genome Editing Consortium Grant Recipients

National Institutes of Health recently awarded its first grants through the Somatic Cell Genome Editing program

Corporate Reviews

A series of presentations from some of the leading companies in gene editing, describing their pre-clinical and clinical programs.

NIH Genome Editing Consortium Grant Recipients Continued

The National Institutes of Health recently awarded its first grants through the Somatic Cell Genome Editing program.

Gene editing is a dynamic area of research, attracting many new investigators.

A series of presentations from some of the leading companies in gene editing, describing their pre-clinical and clinical programs.

Pre-Approval Commercialization Workshop

The Pre-Approval Commercialization Workshop covers industry perspectives on CMC Challenges for cell and gene modified cell therapy products, updates from global regulatory bodies, manufacturing challenges in late phase development of gene therapy products, and discussions on the difficulties in commercializing AAV product candidates.

Global Regulatory Update: Outlook in 2019 – Policy Approaches and Considerations in Gene Therapy

Manufacturing Challenges During Late Phase Development of Gene Therapy Products

Hindrance to Commercializing AAV Product Candidates

Post-Approval Commercialization Workshop will include sessions on patient focused drug development; post-approval change management and overall impact on commercialization; and pricing, reimbursement, and payment models for gene therapies.

Bio Industry Symposium

Entering the Post-RAC Era Charting the Course of Cell & Gene Therapy Drug Development for the Future

Innovation in First Time in Human Study Clinical Studies

Pricing, Access, and Value of Gene Therapies

Nanoagents & Synthetic Formulations Symposium

Non-Viral Vectors and Immunity

Respiratory & GI Tract Symposium

Novel Strategies for Lung and GI Tract-directed Genetic Therapies

Adoptive T-Cell Therapy Education Session

Modalities of Genome Editing Education Session

Oncolytics Education Session

NK Cells Versus iNKT Cells Education Session

Induced Pluripotent Stem Cells Education Session

Cancer Scientific Symposium

Cancer Gene Therapies: Universal Cells, Targeted Vectors and Solid Tumor CART Efficacy

West Genome Editing Scientific Symposium

Gene Editing: From Platform Engineering to Assessing Impact of Innate and Adaptive Responses

Viral Gene Transfer Vectors Scientific Symposium

Vector Development, Clinical Implementation, and Corporate Connections

Translational Science and Product Development Scientific Symposium

Evaluating Gene & Cell Therapy Product Candidates

RNA Therapeutics Education Session

Design, Delivery, and Application of RNA Therapeutics

Cardiovascular Scientific Symposium

Beyond Cell Therapy: Extracellular vs. Multicellular Cardiovascular Regenerative Approaches

Immune Responses Scientific Symposium

Basic and Translational Aspects of Immunology and Gene and Cell Therapy

Neurologic & Ophthalmic Scientific Symposium

Genome Editing in the Retina and CNS

Translating non-viral Gene Delivery to Human Therapeutics

Genetic Modification of Stem Cells

Prophylactic and Therapeutic Antibodies against Infectious Diseases

Applications of Gene and Cell Therapy Technologies for Metabolic Diseases

Hematologic and Immunologic Scientific Symposium

Engineering Homing, Persistence and Potency in Cell Therapies

Commercializing Gene and Cell Therapies – Planning for Post-Approval Success and Pitfalls to Avoid

Gene Editing and Gene Modulation for Musculoskeletal Disease

Monroe Oligonucleotide and RNAi Therapeutics Scientific Symposium

Clinical Status of Oligonucleotide-based Drugs


About The ASGCT

The American Society of Gene & Cell Therapy (ASGCT) is a non-profit medical and professional organization that represents researchers and scientists devoted to the discovery of new genetic and cellular therapies. ASGCT was established in 1996 by Dr. George Stamatoyannopoulos, professor of medicine at the University of Washington’s School of Medicine and a group of the country’s leading researchers in gene therapy. With nearly 1,800 members in the United States and worldwide, ASGCT is the largest association of individuals involved in genetic and cellular therapeutics. ASGCT’s mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT’s strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.



 


ASGCT | ASGCT app | Facebook | Facebook Event | Twitter | Instagram | LinkedIn | YouTube | Washington Hilton

The 23rd Annual Virginia Liver Symposium & Update in Gastroenterology

liver biomarker assay measurement test


liver biomarker assay measurement test


Diapharma is sponsoring and attending The 23rd Annual Virginia Liver Symposium & Update in Gastroenterology this year. Please click here to schedule a meeting with us or email us directly.


Brochure

Overview

The Division of Gastroenterology, Hepatology and Nutrition, the Liver Transplant Program and VCU Health Continuing Medical Education are pleased to offer the 23rd Annual Virginia Liver Symposium and Update in Gastroenterology in Richmond, Virginia at the Westin Hotel. The program is designed for primary care and sub-specialty physicians, and advanced practice providers who treat patients with gastrointestinal and liver disorders.

Objectives

  • Discuss treatment strategies for the management of daily challenges in gastroenterology
  • Review recent research advances and current literature of advances in treatment of chronic liver disease
  • Review recent advances and current literature in gastroenterology and hepatology

Target Audience

  • Family Practice
  • Gastroenterology
  • General Practice
  • Hepatology
  • Internal Medicine
  • Nephrology
  • Nurse Practitioner
  • Nursing, Oncology
  • Physician Assistant

Schedule

 

22nd Annual Virginia Liver Symposium & Update in Gastroenterology

Registration and continental breakfast
7:00AM – 8:00AM
Pre-Function

Welcome and announcements
8:00AM – 8:05AM
John Kuemmerle, MD, AGAF, FACG

SESSION I: Daily Challenges in Clinical Gastroenterology

Educational Objectives:

  • To learn the updated guidelines for evaluation and medical management of NASH
  • To understand the various medical weight loss programs and expected outcomes
  • To understand the various surgical weight loss programs and expected outcomes

Update on evaluation and medical treatments of NASH
8:05AM – 8:30AM
Mohammad Shadab Siddiqui, MD

Medical weight loss
8:30AM – 8:55AM
Susan Wolver, MD, FACP

Surgical weight loss
8:55AM – 9:20AM
Guilherme M Campos, MD, PhD, FACS, FASMBS

Session I | Panel Discussion
9:20AM – 9:30AM
Richard K Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF (Moderator)
Susan Wolver, MD, FACP
Guilherme M Campos, MD, PhD, FACS, FASMBS
Mohammad Shadab Siddiqui, MD

Alvin Zfass State of the Art Lecture | Fifty years of ERCP
9:30AM – 10:15AM
Peter B Cotton, MD, FRCS, FRCP

Break with exhibitors
10:15AM – 10:35AM

SESSION II: Update on common GI diseases

Educational Objectives:

  • To understand presentation and management of IBD in the elderly
  • To understand how to manage acute pancreatitis
  • To understand best practices in managing upper GI bleeding

Update on inflammatory bowel disease in the elderly
10:35AM – 11:00AM
Jill Gaidos, MD

Update on management of acute pancreatitis
11:00AM – 11:25AM
Doumit BouHaidar, MD

Update on management of acute upper GI bleeding
11:25AM – 12:10PM
George Smallfield, MD, MSPH

Session II | Panel Discussion
12:10PM – 12:20PM
George Smallfield, MD, MSPH
Stephen Bickston, MD, PhD, FACS, FASMBS (Moderator)
Doumit BouHaidar, MD
Jill Gaidos, MD

Lunch with exhibitors

Lunch Workshop Sessions

Workshop A | Pearls for Managing viral hepatitis
12:45PM – 1:45PM
Richard K Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF
Reena Cherian, FNP
Carolyn Driscoll, PhD, NP
Shawn W Lewis, NP

Objectives:
To understand managing viral hepatitis C and B in 2019.

Workshop B | Pearls in managing decompensated cirrhosis 
12:45PM – 1:45PM
Hannah Lee, MD
Scott Matherly, MD
Richard Todd Stravitz, MD
Mohammad Shadab Siddiqui, MD

Objectives:
Understand current management of decompensated cirrhosis.

Workshop C | Diet and microbiome in IBS: Low FOD MAP, Gluten Free and Beyond 
12:45PM – 1:45PM
Ann Leggett, ACNP

Objectives:
Understand how the diet and microbiome impact IBS.

Workshop D | Tricks and tips in managing complicated IBD
12:45PM – 1:45PM
John Kuemmerle, MD, AGAF, FACG
Stephen Bickston, MD, PhD, FACS, FASMBS
Jill Gaidos, MD

Objectives:
To learn the tricks and tips on managing patients with complicated IBD.

SESSION III: Advances in Hepatology

Educational Objectives:

  • To understand the epidemiology and changing paradigm of hepatocellular carcinoma
  • To understand how we use imaging to evaluate liver lesions
  • To know how to evaluate and manage hepatocellular carcinoma

The Epidemiology of HCC in 2019: A changing paradigm
1:45PM – 2:15PM
Hashem B El-Serag, MD, MPH

Evaluation of the liver lesion: See spot, don’t run
2:15PM – 2:45PM
Ryan Clayton, MD

HCC: Management 2019
2:45PM – 3:15PM
Scott Matherly, MD

Session III | Panel Discussion
3:15PM – 3:25PM
Hashem B El-Serag, MD, MPH
Ryan Clayton, MD
Scott Matherly, MD
Richard Todd Stravitz, MD (Moderator)

Break with exhibitors
3:25PM – 3:40PM

SESSION IV: Recent Advances in Hepatology

Educational Objectives:

  • To understand how to evaluate autoimmune hepatitis
  • To understand how to manage constipation
  • To recognize and manage liver disease in pregnancy

Management of autoimmune hepatitis
3:40PM – 4:05PM
Vaishali Patel, MD

Constipation: When to going gets tough
4:05PM – 4:30PM
John Kuemmerle, MD, AGAF, FACG

Liver disease in pregnancy
4:30PM – 4:50PM
Richard K Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF

Session IV | Panel Discussion
4:50PM – 5:00PM
Richard K Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF
John Kuemmerle, MD, AGAF, FACG
Vaishali Patel, MD
Ravi Vachhani, MBBS (Moderator)

Final comments
5:00PM – 5:10PM
Richard K Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF


About the VCU Health System Division of Gastroenterology, Hepatology and Nutrition

liver biomarker assay measurement test

The Division of Gastroenterology, Hepatology and Nutrition has a long tradition of excellence in clinical practice, education and research, and remains dedicated to this pursuit of excellence. The scope of clinical operations and faculty expertise cover the entire spectrum of gastrointestinal and liver health and diseases. Special programs focus on esophageal disorders, gastrointestinal cancer, women’s health, inflammatory bowel disease, intestinal failure, obesity, pancreatic disorders, fatty liver disease, viral hepatitis and liver transplantation and are part of some of the premier services offered here at the VCU Health System.

liver biomarker assay measurement test

Along with a cutting-edge seven-room endoscopy suite offering advanced endoscopic procedures, the hepatology program remains one of the premier programs in the country. The GI Division at the Veterans Affairs Medical Center, has equally innovative clinical programs including endoscopic ultrasound, liver transplantation and inflammatory bowel disease. The GI Division has a long standing, multifaceted educational program with offerings for medical students, residents, fellows, community physicians and other gastroenterologists.

The NIH-funded academic training program is in its 40th year and has produced numerous leaders in the field of gastroenterology and hepatology. The impact of this division on the state-of-the-art of gastroenterology, hepatology and nutrition continues to be strong and can be assessed by both the quality and number of publications. In addition, numerous faculty members have research funding from the NIH and/or the Department of Veterans Affairs. Thus, the division remains strong and committed to being a fertile training ground for future leaders in gastroenterology.

liver biomarker assay measurement test


VCU | Twitter | Facebook | Westin

3rd Annual NASH Summit 2019

K18 Liver Injury NASH Biomarker Measurement Assay Test Kit K18 Liver Injury NASH Biomarker Measurement Assay Test Kit K18 Liver Injury NASH Biomarker Measurement Assay Test Kit


K18 Liver Injury NASH Biomarker Measurement Assay Test Kit

Diapharma will attend and exhibit at the 3rd Annual NASH Summit 2019 this year. Please click here to schedule a meeting with us or email us directly.

Visit Diapharma to discuss K18 assays as prescreening tools and secondary endpoints in NASH clinical trials. Learn about our panels of mechanistic biomarkers that provide insight into the biological processes occurring during liver injury. Keratin/Keratin 18 (CK18/K18) is an important biomarker of hepatocyte cell death. Explore M30/M65 ELISAs for measuring hepatocyte apoptosis/necrosis non‐invasively. Diapharma offers additional assays for liver injury, including HA, α‐GST, and Collagen IV. For research use only in the U.S. and Canada.


NASH = NON-ALCOHOLIC STEATOHEPATITIS


K18 Liver Injury NASH Biomarker Measurement Assay Test Kit

NASH Summit 2019

Accelerate the Successful Development of Your Non-Alcoholic Steatohepatitis (NASH) Therapeutic

The NASH Summit is the industry’s most comprehensive forum for advancing the development of successful NASH therapeutics. Focused on discovery through to late-stage clinical development of non-alcoholic steatohepatitis (NASH) candidate pipelines, the 3rd Annual NASH Summit Boston will bring together 300+ drug developers from 140+ organizations across 4 days of unparalleled content sharing and networking.

The 3rd Annual NASH Summit with 57 industry leaders will present actionable takeaways on the next 12 months of NASH drug development. The forum will provide you with the data, insight, and lessons needed to inform the acceleration of your NASH candidate pipeline:

Contextualize the progress of the leading candidates beyond data alone to understand patient recruitment strategies, commercialization considerations and hurdles addressed prior to success.

Understand how to build the confidence of investors and evaluate the payers’ perspective on reimbursement.

Improve drug efficacy in both early and late stage NASH by identifying and validating novel targets & drug mechanisms of action.

Be part of the leading conversations and outline the next 12 months of your R&D and commercial decisions that will accelerate the development of your NASH candidate.

As competition in the NASH space increases, find out how you can move your candidate into differentiation and identify the best mode of action to stay ahead as this field looks to overcome its current limitations.

NASH Summit 2019 Topics

K18 Liver Injury NASH Biomarker Measurement Assay Test Kit

  • Non-invasive NASH biomarkers
  • Liver fibrosis: deliniating and utilizing at complexities of fibrosis pathology
  • Stratification of NASH through data sets
  • Systems biology NASH: approaches and applications
  • Drug development strategy and regulatory intelligence in NASH
  • Biomarkers in NAFLD drug development diagnostic, prognostic and monitoring biomarkers
  • Public/private partnerships in advancing biomarkers for NAFLD
  • Finding non-invasive biomarkers for NASH (FNIH Biomarkers Consortium)
  • Cinical leaders in NASH
  • Designing clinical trials in pediatric NASH
  • Similarities and differences between pediatric and adult NASH
  • NASH trial in children from a family to physician to industry perspectives
  • Potential impact and value of NASH therapies
  • Translatability of NASH biomarkers
  • Machine learning for NASH biomarkers
  • Overview of NASH diagnostic landscape
  • Disease burden of NAFLD and NASH
  • NASH therapies reducing disease burden and mortality
  • Cost-effectiveness of NASH therapies
  • Inflammation as a driver of NASH
  • Current understanding and gaps in knowledge of NASH
  • Future of NASH
  • Targeting NASH molecular drivers
  • Bile acid modulators for the treatment of NASH
  • Metabolomics in NASH clinical trials
  • Targeting integrin αVβ1 for treatment of liver fibrosis associated with NASH
  • CSTI-100, a melanin-concentrating hormone receptor 1 (MCHR1) antagonist, for the treatment of NASH and metabolic syndrome comorbidities
  • 3D bioprinted human liver tissue to model NAFLD/NASH in vitro
  • NASH/NAFLD: does genotype connect to phenotype?
  • Analyzing, quantifying and targeting multiple NASH pathways
  • Analysis of NASH pathways by single cell sequencing
  • NASH in the context of wider liver and cardiovascular disease
  • NASH as a metabolic, non-communicable disease
  • Polypharmacological anti-NASH effects
  • Profiling NASH in the context of metabolic syndrome
  • The gap between non-invasive assessment of NASH PoC endpoints
  • Targeting multiple drivers of NASH by GSNOR inhibition
  • Regulatory guidance on NASH drug development
  • NASH cirrhosis: specifics of cirrhotic trials
  • Complexities of fibrosis pathology
  • Systems biology in NASH

Click here to view the About NASH Summit 2019 video

 


K18 Liver Injury NASH Biomarker Measurement Assay Test Kit K18 Liver Injury NASH Biomarker Measurement Assay Test Kit K18 Liver Injury NASH Biomarker Measurement Assay Test Kit


NASHSummit | Hilton Boston Logan Airport

Anticoagulation Forum 15th National Conference

anticoagulation DOAC anticoagulant measurement assay test kit anticoagulation DOAC anticoagulant measurement assay test kit anticoagulation DOAC anticoagulant measurement assay test kit

 


Diapharma will attend the Anticoagulation Forum 15th National Conference this year. Please click here to schedule a meeting with us or email us directly.

 


Anticoagulation Forum 15th National Conference

  • Top anticoagulation papers
  • New antithrombotic agents
  • Updates from ASH and ACC
  • Combined therapy – AFIB, coronary and peripheral disease
  • Anticoagulants for secondary prevention of CAD/PAD
  • What is PAD
  • Combined antithrombotic therapy
  • Optimizing anticoagulation clinics
  • State of anticoagulation management services
  • Optimizing Warfarin
  • Practical issues with transitioning to DOAC clinic
  • Controversies and challenges in VTE
  • VTE Treatment – drug, duration dose
  • Diagnostic imaging dilemmas in VTE
  • Managing VTE in cancer patients
  • New patient safety goals
  • National action plan for anticoagulant adverse drug event prevention
  • Core elements of anticoagulation stewardship
  • Improving safety and quality in anticoagulation care
  • Bridging difficult anticoagulation cases
  • Clinically important drug interactions
  • Cornucopia of issues in anticoagulation
  • DOAC reversal
  • Focused updates on antithrombotics in AFib
  • Women’s health and anticoagulation

 


anticoagulation DOAC anticoagulant measurement assay test kit

About The Anticoagulation Forum

The Anticoagulation Forum is a membership organization of physicians, pharmacists and nurses dedicated to excellence in anticoagulant therapy.

Anticoagulation Forum Mission

The Anticoagulation Forum is a nonprofit organization of multidisciplinary health care professionals improving the quality of care for patients taking antithrombotic medications. The Anticoagulation Forum strives to minimize the risk and maximize the benefit of strategies used for the prevention and treatment of thromboembolic disease.

Anticoagulation Forum Vision

The Anticoagulation Forum is the premier provider of education and the authoritative voice among anticoagulation professionals. The AC Forum offers insight and expertise to practicing clinicians. The AC Forum’s goal is to have a community where physicians, pharmacists and nurses can find the latest research, engage in educational programs, and find tools to evaluate and enhance their practice.

 


 


ACForum | ACForum Webinars | Facebook | Twitter | Diplomat Resort

European Association for the Study of the Liver (EASL) – The International Liver Congress™ (ILC 2019)

VLVbio


liver research biomarker measurement assay test kit liver research biomarker measurement assay test kit liver research biomarker measurement assay test kit

 


Diapharma will attend the EASL – The International Liver Congress™ (ILC 2019) at the Messe Wien Exhibition & Congress Center in Vienna with VLVbio this year. Please click here to schedule a meeting with us or email us directly.


About The International Liver Congress™ (ILC 2019)

liver research biomarker measurement assay test kit

Topics will include

  • Cirrhosis and complications
  • General hepatology
  • Metabolism, alcohol and toxicity
  • Liver tumors
  • Cholestasisa and autoimmune
  • Viral hepatitis
  • Liver immunology
  • Liver inflammation and immune-oncology
  • Adaptive and innate immune mechanisms
  • Viral hepatitis & cancer, cholestasis and fatty liver disease

About The International Liver Congress™

The International Liver Congress™ (ILC) is the annual EASL meeting, and the flagship event in EASL’s educational calendar.

Every year in April, scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology and radiology and imaging come together from around the world to learn about the latest in liver research.

Specialists share recent data, present studies and findings, and discuss the hottest topics on liver disease. The annual Congress attracts around 10,000 delegates and 250 media representatives from all over the world.

 


About The European Association for the Study of the Liver (EASL)

EASL hosts the annual meeting known as The International Liver Congress™ and a range of scientific events and initiatives throughout the year. EASL grants fellowships, mentorships and bursaries, lobbies at the EU commission, produces Clinical Practice Guidelines, offers online education, apps and many other initiatives.

Journal of Hepatology

The Journal of Hepatology is the official journal of EASL publishing original papers, reviews and letters to the editor concerned with clinical and basic research in the field of hepatology.

liver research biomarker measurement assay test kit

 


EASL – The International Liver Congress™ 2018 (ILC 2018) Highlights & Videos


liver research biomarker measurement assay test kit liver research biomarker measurement assay test kit liver research biomarker measurement assay test kit

 


EASL | ILC 2019 | 2018 Congress Review | Facebook | Facebook Event | Twitter | LinkedIn | YouTube

Journal of Hepatology Facebook | Twitter | YouTube

Messe Wien Exhibition & Congress Center

liver research biomarker measurement assay test kit

Society of Toxicology (SOT 2019) 58th Annual Meeting & ToxExpo 2019

toxicology measurement assay test toxicology measurement assay test


Diapharma will attend the Society of Toxicology (SOT 2019) and exhibit at ToxExpo 2019 booth 4081. Please click here to schedule a meeting with us or email us directly.

cancer research assay measurement test

View our SOT invitation postcard.


Our booth location

toxicology measurement assay test


DILI and DIKI remain as frequent causes of drug termination in clinical trials or withdrawals from the market. Visit Diapharma at our booth to discuss promising biomarkers currently being evaluated. The M30 Apoptosense® ELISA detects hepatocyte apoptosis while M65®/M65 Epideath® ELISAs detect apoptosis and necrosis, whether caused by drugs, toxins, or disease. Diapharma offers an extensive line of liver and kidney injury biomarkers, including K18, HA, α-GST, and Collagen IV. Research use only.

toxicology measurement assay test

 

Multiplate® Platelet Function Analyzer

 

toxicology measurement assay test


About The Society of Toxicology (SOT) Annual Meeting

toxicology measurement assay test

Over 80 scientific sessions, including six sessions designated as Innovations in Applied Toxicology (IAT) or Innovations in Toxicological Sciences (ITS)

 

Toxicology societies include:

  • American College of Toxicology
  • International Union of Toxicology
  • IUTOX 15th International Congress of Toxicology
  • Safety Pharmacology Society
  • Society of Toxicologic Pathology
  • Society of Toxicology
  • Teratology Society
  • The Toxicology Forum

 

Topics include:

  • Publicly Available Exposure Tools to Inform the Toxic Substances Control Act
  • Assay Development Principles and Good Research Practices for Rigor and Reproducibility in In Vitro Toxicology
  • Complex Mixtures and UVCBs: Analysis, Testing, and Risk Assessment
  • Developmental Toxicity of the Skeletal System: Interpretation of Findings in DART Studies and Implications for Risk Assessment
  • Industrial Application of Computational Toxicology in the 21st Century
  • Role of Toxicokinetics in Human Health Safety Assessments
  • Mechanistic Understanding and Quantitative Risk Assessment in Immunotoxicology
  • Applications and Review of Physiologically-Based Pharmacokinetic Modeling for Regulatory Risk Assessment
  • Basic Course on Dermal and Ocular Toxicology
  • Systematic Review in Toxicology
  • Current Dose-Response Modeling Strategies and Applications in Chemical Risk Assessment
  • Microbiome and Environmental Toxicants: From Study Design and Analysis to Regulatory Guidance
  • Structural and Functional Alterations of Mitochondria in Chemically-Induced Cytotoxicity
  • Robust Assembly of Human Tissues for Disease Modeling and Discovery
  • Advances in In Vitro to In Vivo Extrapolation
  • Alpha-Synuclein: A Good Protein Turned Bad in Chronic Brain Diseases with Toxicological Implications
  • Potential Application of Next-Generation Toxicological Tools
  • Novel Genetic-Based Tools for Evaluating Toxicity Potential, Mechanism of Action, and Population Dynamics
  • Computational Modeling to Risk Assessment of Endocrine Disruptors
  • MALDI Tissue Imaging: A New Tool for Making TK/TD Connections to Histopathology
  • Mechanisms and Effects of Diabetogenic Environmental Metals: Type II Diabetes Mellitus and Diabetic Kidney Disease
  • Pharmaceutical Investigative Toxicology: Case Studies in Optimizing Drug Discovery and Guiding Human Risk Assessment
  • Cellular Model Systems to Assess Individual Risk to Neurotoxicants
  • Electronic Waste: An Evolving Global Health Concern and Risk Assessment Challenge
  • Federal Efforts in Rapidly Assessing Hazard and Risk to Emerging Threats and Emergency Response
  • Immune-Epithelial Cell Cross Talk in Lung Toxicology and Disease
  • Patterns of Co-Exposure and Its Implications for Understanding the Health Effects of Mixtures
  • Cellular Dynamics and Models of Blood-Brain Barrier Developmental Toxicity ITS
  • Strategic Development of Read-Across within the EU-ToxRisk Project and Beyond
  • Rethinking Chemical Carcinogenicity Assessment
  • Applying Systems Biology Approaches to Understand the Joint Action of Chemical and Nonchemical Stressors
  • NextGen Renal Proximal Tubule Toxicity Screening: Novel Cellular Model and Complex Culture Platforms
  • Classification of Substances as Endocrine Disruptors Has a Public Health Benefit
  • Expanding the Definition and Understanding of Endothelial Dysfunction (ED) Due to Inhaled Toxicants
  • Stem Cells and Metals Toxicity: From Tissue Regeneration and Repair to Carcinogenesis
  • Systems Toxicology Approaches to the Science of Safety Evaluation
  • Using Zebrafish as a Model to Understand and Ultimately Prevent Neurotoxicity
  • Emergent Mechanisms of Cytochrome P450 Gene Regulation: Defining an Improved Roadmap towards 21st Century Pharmacogenomics
  • Predicting Metabolic Clearance Rates for Drug Leads and Environmental Chemical Risk Assessment
  • Shifting Currents in Predictive Toxicology and Safety Evaluation with In Vitro and Alternative Approaches
  • Strategies to Mitigate the Health Impacts of Air Pollutants in Susceptible Populations
  • Explicating the Pathogenic Environmental Factors in Nonalcoholic Fatty Liver Disease
  • Integrated ‘Omics Approaches to Toxicity Assessments
  • Scientific and Regulatory Update in the Application of the 3Rs Principle in Chemical and Drug Development
  • Innovation in Biomarker Qualification
  • Microbiota and Contributions to Neurodevelopment: Implications in Neurological Function, Behavior, and Toxicity
  • Novel Safety Biomarker Qualification
  • Perfluoroalkyl Substances (PFAS): Global and Persistent Environmental Contaminants
  • Species Relevance: Approaches to Determine the Most Relevant Species for Safety Assessment of Pharmaceutical Products
  • Humanized Mouse Models for Evaluations of Immune Function and Preclinical Immunotoxicology Studies
  • Toxicity of Natural Products Alone and in Combination with Pharmaceutical Agents
  • New Approaches Using Mode-of-Action to Predict Acute and Systemic Toxicity IAT
  • Utility of Echocardiography in Cardiac Safety Assessment
  • Effective Alternatives for Acute Oral and Inhalation Systemic Toxicity Testing
  • Improving Carcinogenicity Assessments of Human Pharmaceuticals and Pesticides
  • Dynamic RNA Modifications in Environmental Response and Disease
  • Understanding and Managing Ocular Findings in General Toxicology Studies
  • Nerve Agent Poisoning: Mechanisms of Toxicity, Recent Releases, Verification, and Innovative Treatment Approaches
  • Reproductive and Developmental Toxicity Related to Electronic Cigarettes
  • Immune System of Occupationally-Relevant Exposures to Multiwalled Carbon Nanotubes
  • Chemically Synthesized Therapeutic Peptides
  • Oxidative Stress in Health and Disease: Mechanisms, Methods of Detection, and Biomarkers
  • In Vitro Developmental Toxicity Assays and Building Integrated Testing Strategies
  • Air Pollution-Induced Cardiovascular Toxicity: Endothelial Progenitor Cells as Critical Mediators
  • Microphysiological Systems: A New Era in Neurotoxicology?
  • Risk Assessment of Consumer Products and Articles: Critical Considerations and Case Studies for Characterizing and Quantifying Consumer-Relevant Exposures to Chemicals and Nanomaterials
  • Biomarkers Unique to Dependence Toxicity in Adolescents
  • Nerve Agent and Pesticide Poisoning: Best Practice Methodologies for Assessing Long-Term Health Effects
  • Causes and Outcomes of Epigenetic Dysregulation by Carcinogenic Metals
  • Preconception Exposure to Toxicants: Assessing Gamete Quality and Reproductive Outcomes
  • Use of Adverse Outcome Pathways to Design Nonanimal Testing Strategies for Assessing Inhalation Toxicity

 


toxicology measurement assay test

About the Society of Toxicology (SOT)

Founded in 1961, the Society of Toxicology (SOT) is a professional and scholarly organization of scientists from academic institutions, government, and industry representing the great variety of scientists who practice toxicology in the US and abroad. The Society’s mission is to create a safer and healthier world by advancing the science and increasing the impact of toxicology.

The society organizes an annual meeting (usually in the early spring) and several smaller colloquia via its special interest sections and groups. It publishes the journal Toxicological Sciences, the newsletter Communiqué, as well as public position papers and guidelines on conflicts of interest in toxicology.


toxicology measurement assay test

About ToxExpo

ToxExpo is a gathering of over 300 toxicology-related companies and organizations with 6,000 attendees in the fields of regulatory & safety, general toxicology, risk assessment, and neurotoxicology. ToxExpo occurs over three days in-person and year-round online. ToxExpo is a venue which facilitates face-to-face interactions, networking and learning opportunities with a common goal of advancing scientific research.

Future meetings are planned in Hawaii 2019 (IUTOX ICTXV) and Anaheim 2020 (59th Annual Meeting).


 

 

 


SOT 2019 | Diapharma at SOT | SOT | ToxExpo 2019 | Twitter | Facebook | SOT Facebook Event | YouTube | Baltimore Convention Center

American Association for Cancer Research (AACR 2019)

cancer research biomarkers measurement assay test kit cancer research biomarkers measurement assay test kit cancer research biomarkers measurement assay test kit

 


Diapharma will attend the American Association for Cancer Research (AACR 2019) this year. Please click here to schedule a meeting with us or email us directly.


About the AACR

cancer research biomarkers measurement assay test kit

Founded in 1907, the American Association for Cancer Research (AACR) organization now has more than 34,000 members in over 90 countries. The AACR is the world’s oldest and largest professional association related to cancer research. The AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. The mission of the American Association for Cancer Research is to prevent and cure cancer through research, education, communication, and collaboration.

 

AACR sites

 

cancer research biomarkers measurement assay test kit cancer research biomarkers measurement assay test kit cancer research biomarkers measurement assay test kit cancer research biomarkers measurement assay test kit cancer research biomarkers measurement assay test kit

cancer research biomarkers measurement assay test kit cancer research biomarkers measurement assay test kit cancer research biomarkers measurement assay test kit cancer research biomarkers measurement assay test kit cancer research biomarkers measurement assay test kit

 


 

About AACR 2019

cancer research biomarkers measurement assay test kit

The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.

 

AACR 2019 Topics

  • Biomarker Studies: Study Design and Statistical Considerations
  • Genetic Predispositions to Childhood Leukemias: Implications for Pathogenesis and Screening
  • Host versus Tumor Autophagy in Cancer
  • Immune-Targeted Biomarker Incorporation into Therapeutic Decision Making
  • Intersection of Radiation and Immune Therapy
  • Modulation of the Gut Microbiome to Treat Dysbiosis and Cancer
  • Molecular Pathology for Cancer Researchers: Present and Future
  • Preleukemia and Clonal Hematopoiesis
  • Quantitative Approaches to Study Cancer Evolution and Heterogeneity
  • Controversies in Replication cfDNA Measurements
  • Defining Tumor Organ-systems with Single Cell Transcriptomics
  • Game-Changing Technologies for High Through-Put Functional Characterization of Cancer Gene Variants
  • Cancer Genomic Reference Samples: MDIC Somatic Reference Sample Collaborative Initiative
  • CAR-T Therapy State of the Art
  • Characterizing Cancer Disparities Nationally and Internationally Using Publicly Available Data: Recent Advances
  • Lead Optimization in Cancer Drug Discovery
  • Novel Chemical Tools and Leads for Unprecedented Targets
  • Unconventional Modalities to Extend the Antitumor Target Space
  • Co-evolution of Tumor and Microenvironment in Cancer Metastasis
  • CtDNA for Cancer Stratification, Monitoring, Clonal Tracking, MRD Detection, and Early Diagnosis
  • Diverse Functions of Neutrophils in Cancer
  • The Endothelium and Fluid Flows: Linking Metastasis and Immunity
  • Extracellular Vesicles and Intercellular Communication in Cancer
  • Fibroblasts in the Driver’s Seat: Impact on Tumor Progression and Therapy Resistance
  • Fluorescence Image-Guided Surgery for Improved Clinical Outcomes
  • From Cancer Genomics to the 3D Organization of the Genome
  • Functional Follow-Up of Microbiome Associations for Cancer Epidemiology Studies
  • Integrating Tumor Immunology and Molecular Epidemiology
  • How to Effectively Advocate for Cancer Research and Science-based Policy
  • Metabolic Drivers of Cancer
  • Molecular Regulation of Cancer Inflammation, Progression, and Treatment Resistance
  • Obesity: The Effects of Local and Systemic Inflammation on Cancer
  • Oncolytic Virus Therapy
  • Ordering Genomic Changes as Actionable Targets in Pediatric Cancers
  • Organoids as Model Systems in Cancer
  • Pancreatic Tumor Microenvironment
  • Personalized Circulating Tumor DNA Analysis for Minimal Residual Disease Detection
  • Resistance to Therapies and Cancer Cell Dormancy
  • Single-Cell and Spatial Genomics
  • Stromal Niches for Organ-Tropic Metastasis
  • Systems Biology Approaches to Cancer
  • Tools for Machine Learning in Cancer Image Analysis
  • Tumor Immunology and Immunotherapy for Nonimmunologists: Roundtable Discussions
  • Tumor Immunology and Immunotherapy for Nonimmunologists: Standard Cancer Therapies are Ultimately Immunotherapies
  • Update on Young Women’s Breast Cancer
  • Vascular-Immune Cell Cross-Talk: Implications for Cancer Immunotherapy
  • BRCA1 Variants of Unknown Significance (VUS): New Vistas in the Assessment of Cancer Risk
  • The ABCs of Doing Cancer Clinical Trials
  • Biomarker-Directed Clinical Trials
  • Deciphering and Targeting Lysosomes in Cancer
  • Designing Biomarker Studies to Achieve Desired Clinical Applications
  • Methods for Utilizing the Microbiome in Cancer Epidemiology Research
  • Methods to Study Metabolism for Cancer Research
  • Modeling Tumor Dormancy
  • Novel Imaging Strategies in the Metastatic Niche
  • Sample Size and Power Workshop for Basic, Translational, and Clinical Studies

 

AACR Future Meetings

  • AACR 2020, April 24-29, 2020, San Diego, California
  • AACR 2021, April 10-14, 2021, Washington, D.C.
  • AACR 2022, April 9-13, 2022, New Orleans, Louisiana

 


 


AACR | AACR 2019 | Twitter | Facebook | LinkedIn | YouTube | Georgia World Congress Center

Society for Laboratory Automation and Screening (SLAS) 2019

Society for Laboratory Automation and Screening assay measurement test Society for Laboratory Automation and Screening assay measurement test Society for Laboratory Automation and Screening assay measurement test

 


 

Laboratory

 

Diapharma will attend the Society for Laboratory Automation and Screening (SLAS) 2019 this year. Please click here to schedule a meeting with us or email us directly.


About SLAS

Society for Laboratory Automation and Screening assay measurement test

The Society for Laboratory Automation and Screening (SLAS) is a global community focused on advancing life sciences discovery and technology.


About SLAS 2019

SLAS2019 will provide a unique combination of education, access to innovative technologies and intelligent peer networking, delivering unmatched value for professionals and students looking to discover the latest life sciences technologies and how they can be applied to drive research objectives.

SLAS2019 will offer a world-class scientific program that showcases top laboratory science and technology podium presentations from industry leaders around the globe. Each podium presentation is hand selected by the SLAS2019 Scientific Program Committee from hundreds of vigorously reviewed abstract submissions. Presentations offer SLAS2019 participants compelling content and fresh perspectives on emerging laboratory technologies from a broad range of industries, including drug discovery and development, informatics, clinical diagnostics, food and agricultural sciences, forensics and security sciences, petrochemicals and energy, and consumer products.

SLAS 2019 Topics

  • Advances in Bioanalytics and Biomarkers
  • Assay Development and Screening
  • Automation and High-Throughput Technologies
  • Biologics Discovery
  • Cellular Technologies
  • Data Analysis and Informatics
  • Drug Target Strategies
  • High-Definition Biotechnology
  • Micro- and Nanotechnologies
  • Molecular Libraries
  • Podium and Poster Presentations

SLAS 2019 Conference Preview

 


 

 

 

 


SLAS | Facebook | Twitter | LinkedIn | YouTube | Events DC | Walter E Washington Convention Center

Diapharma National Sales Meeting (December 2018)

Help reduce screen failures in NASH clinical trials using K18 Biomarkers. Visit us at The Liver Meeting® to learn more.

New Biomarkers for Liver and Kidney Toxicity Studies

 

New Biomarkers for Liver and Kidney Toxicity Studies

 

Panels of Biomarkers for

NAFLD, NASH, AH, and DILI Research Featuring K18

 

 

Visit us at Booth 601

Diapharma invites you to stop by booth 601 while attending The Liver Meeting® 2018 in San Francisco, CA, November 9 – 13.

 

Visit Diapharma to discuss K18 assays as prescreening tools and secondary endpoints in NASH clinical trials.

Learn about our panels of mechanistic biomarkers that provide insight into the biological process occurring during liver injury.

  • M30 Apoptosense®
  • M65 EpiDeath®
  • M65® ELISA

Research use only in the U.S. and Canada

New Biomarkers for Liver and Kidney Toxicity Studies

Diapharma Group, Inc., 8948 Beckett Rd., West Chester, OH 45069

ML-00-00392Rev01

The Liver Meeting® 2018 – The 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

liver biomarker assay test kit ELISA liver biomarker assay test kit ELISA


Diapharma will attend and exhibit at The Liver Forum and The Liver Meeting (AASLD) this year. Booth 601. Please click here to schedule a meeting with us or email us directly.


About The Liver Meeting

The Liver Meeting® provides a forum for the exchange of basic, translational and clinical research in diseases of the liver and biliary tract, and in liver transplantation. The Liver Meeting® creates an arena for the presentation and interchange of opinions on state-of-the-art care and management of the full spectrum of patients with liver disease.

Topics

  • AASLD / ILTS Transplant Course
  • Liver Transplant Oncology
  • Cholestatic and Autoimmune Liver Diseases
  • Associated Liver Disease
  • Pediatric Liver Disorders
  • HCV
  • AASLD / ASGE Endoscopy Course
  • Precision Medicine in Hepatology
  • AASLD / NASPGHAN Pediatric Symposium
  • Liver Disease in the Perinatal Period
  • Herbal and Dietary Supplement Induced Liver Injury
  • Genetics and Epigenetics in NAFLD
  • ACLF (Acute on Chronic Liver Failure)
  • Liver Cell Biology in Hepatic Diseases
  • Surgery and Liver Transplant Committee and Liver Transplantation and Surgery
  • Matrix Biology and the Liver
  • Cell Death Pathways and Mediators in Liver Disease
  • Alcoholic Liver Disease
  • Hepatobiliary Neoplasia
  • Clinical Hepatology

 



liver biomarker assay test kit ELISA

About the AASLD

The mission of the American Association for the Study of Liver Diseases (AASLD) is to advance the science of hepatology and to promote liver health.

AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment options for millions of liver disease patients. AASLD advances the science and practice of hepatology through meetings such as The Liver Meeting®, educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.

 


Postcard | AASLD | FacebookTwitter | LinkedIn | YouTube | InstagramMoscone Center

World Thrombosis Day

October 13 is World Thrombosis Day.


World Thrombosis Day


World Thrombosis Day (WTD) focuses attention on the often overlooked and misunderstood disease of thrombosis. With hundreds of educational events in countries around the world, WTD and its partners such as Diapharma, place a global spotlight on thrombosis as an urgent and growing health problem. WTD seeks to increase global awareness of thrombosis, including its causes, risk factors, signs/symptoms and evidence-based prevention and treatment. Ultimately, we strive to reduce death and disability caused by the disease.

thrombosis hemostasis measurement assay test kit

The International Society on Thrombosis and Haemostasis (ISTH) and the Centers for Disease Control and Prevention (CDC) will co-host a World Thrombosis Day 2018 Webinar — Hospital-Associated Venous Thromboembolism: What You Need to Know, Thursday, October 11, 2018 from 10-11am EST.

You must be registered to participate!



World Thrombosis Day


Thrombosis refers to abnormal, life-threatening blood clots that form in the artery or vein. A clot in the vein (usually in the leg or pelvis) is known as a deep vein thrombosis (DVT) and a clot that breaks off and travels to the lungs is known as a pulmonary embolism (PE). Together, DVT and PE make up venous thromboembolism (VTE).


WTD | Facebook | Twitter | YouTube | Pinterest | Instagram | #WTDAY16, #KNOWTHROMBOSIS

Xtalks Blog – Managing the Screen Failure Rate in NASH Clinical Trials: The Use of Cytokeratin 18 Assays as a Prescreening Tool

Non‐Alcoholic Fatty Liver Disease (NAFLD) is a growing global epidemic and the most common cause of liver disease in all Western countries. NAFLD refers to a spectrum of conditions and it is defined as the excessive accumulation of fat in the liver not caused by heavy alcohol consumption. Patients with Non‐Alcoholic Steatohepatitis (NASH), a more advanced form of NAFLD, are at an increased risk for liver-related mortality and cardiovascular disease. NAFLD affects a considerable share of today’s global population: the prevalence of NAFLD worldwide is estimated to be 20‐35% and of those 10–30% have NASH. There are currently no approved drug therapies for NAFLD or NASH, and many clinical trials are underway to address this unmet need for pharmacologic treatment options.

One of the biggest challenges facing pharmaceutical companies involved in NASH clinical trials is the cost‐effective and timely enrollment of study subjects. This is partly due to the large number of trials that are actively recruiting subjects. Adding to this is the difficulty of finding patients with confirmed NASH. Despite the high prevalence of NAFLD, there is an overall low awareness of this disease – among both providers and patients. Patients are often asymptomatic and even those with a high likelihood of NAFLD are rarely referred to a specialist for a formal evaluation to confirm the diagnosis. Furthermore, once patients have been recruited to participate in a treatment trial, there are additional hurdles to identify those that meet the requirements for study enrollment.

Subjects enrolling in NASH clinical trials are frequently required to have a NAFLD Activity Score (NAS) of ≥4 and a fibrosis stage of F1‐F3, as assessed by liver biopsy. Up to 50% of screened subjects will not meet these eligibility criteria. This high screen failure rate has been reported by several of the published NASH studies, including PIVENS, FLINT, GOLDEN, and CENTAUR. The large number of ineffective biopsies adds significantly to the cost and duration of clinical trials. Consequently, strategies to reduce the screen failure rate are a high priority for clinical research organizations (CROs) and the companies developing NASH drugs. One approach is to prescreen recruited subjects with serum biomarkers or imaging tests prior to performing a biopsy, with the goal to enrich the study population that meets the required features for enrollment, ie. NAS ≥4 and F1‐F3.

The NAS was developed as a tool to measure changes in NAFLD during therapeutic trials. It is based on the histological analysis of a liver biopsy sample and it is the cumulative score of three components: Steatosis (0‐3, based on the percentage of surface area affected by steatosis), lobular inflammation (0‐3, based on the number of inflammatory foci), and hepatocyte ballooning (0‐2, based on the number of ballooned cells). A ballooning score of ≥1 is one of the inclusion parameters for most NASH clinical trials. However, previous studies have reported that 20‐40% of the NAFLD population do not display any ballooning (ballooning score 0) by biopsy, which makes these individuals ineligible for enrollment. Therefore, in the context of NASH clinical trials, identifying and eliminating subjects that will likely have no ballooning prior to performing a biopsy would decrease the number of unproductive procedures. Ballooning is a form of liver cell injury that is characterized by the swelling of hepatocytes as a result of damage to the cytoskeleton. Ballooned hepatocytes can be identified by the loss of immunostaining of the intermediate filaments cytokeratin 8 (CK8) and cytokeratin 18 (CK18) in their cytoplasm. In addition, ballooning is associated with elevated levels of caspase‐cleaved fragments of CK18 (cCK18) in serum. Circulating cCK18 may thus be useful as a non‐invasive marker for hepatocyte ballooning. Serum levels of both CK18 and cCK18 have also been shown to correlate with steatosis and inflammation in NASH. Finally, several studies have reported that both forms of CK18 are markedly higher in serum samples from patients having NASH than those without NASH.

In addition to its use for prescreening subjects, CK18 is currently included as an endpoint in over 60 clinical trials with a NAFLD/NASH indication. An AASLD‐FDA Joint Workshop has recommended a decrease in markers of hepatic injury or cell death, such as CK18, as a secondary endpoint for early phase NASH trials. These early phase studies are generally of limited duration (12‐18 months), and histological endpoints may be difficult to meet in this timeframe. CK18 may therefore be useful as a surrogate marker to demonstrate response to treatment, and serum cCK18 levels have been shown to correlate with improvement in histology in at least two published phase 2b trials.

In summary, in NASH clinical studies CK18 assays could be valuable tools for qualifying subjects recruited to participate in a treatment trial. Prescreening study subjects with CK18 assays may therefore result in time and cost savings. Furthermore, CK18 may be useful as a surrogate endpoint to show efficacy of treatment in NASH drug studies, especially in early phase trials where histological assessments are not feasible.

 

ML-00-00380 Rev01

60th American Society of Hematology (ASH 2018) Annual Meeting & Exposition

 


Diapharma is planning to attend the 60th American Society of Hematology (ASH) Annual Meeting & Exposition this year. Please click here to schedule a meeting with us or email us directly.


ASH 60

The 60th ASH Annual Meeting and Exposition will be the world’s most comprehensive hematology event of 2018. The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. More than 25,000 hematology professionals from every subspecialty will attend.



hematology assay test kit chromogenic ELISAAbout ASH

The American Society of Hematology (ASH) is the world’s largest professional society concerned with understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. ASH is dedicated to helping hematologists conquer blood diseases.

The field of hematology has experienced a recent surge in progress thanks to novel technologies, mechanistic insights, and cutting-edge therapeutic strategies that have driven significant and meaningful advances in the quality of care. These foundational insights are reframing modern research with the continued goal of improving outcomes and discovering cures for the most challenging hematologic diseases.

Whereas certain blood disorders have benefited from the tremendous progress in clinical research and development of new therapies, other areas have continuing challenges such as disease heterogeneity and the complex combinations of genetic drivers that have evaded effective treatment to date. A wide variety of blood-related diseases – from malignancies such as lymphoma and leukemia, to non-malignant diseases including hemoglobinopathies, blood platelet, and coagulation disorders, including orphan diseases of the hematopoietic system – continue to be associated hematology assay test kitwith significant morbidity and mortality and demand attention to reduce their burden and improve the quality of care worldwide.

Today, the research community looks to emerging technologies and tools in the areas of genetics and epigenetics, gene therapies, and regenerative medicine to identify areas that have strong potential to make a dramatic impact on patient care across a range of diseases.

The ASH agenda serves as a roadmap for the prioritization of research support across the hematology community, including recommendations for dedicated resources from funding agencies and foundations that will equip researchers today and in the future to make truly practice-changing discoveries. These specific and critically important research questions must be answered to gain the insights that will launch the field into the next generation of care for hematologic conditions.

ASH publishes BloodThe HematologistASH Clinical NewsASH Self-Assessment Program, and the Hematology ASH Education Program.


ASH | Facebook | Twitter | LinkedInYouTube

American Association of Pharmaceutical Scientists Annual Meeting and Exposition (AAPS PharmSci 360)

Pharmaceutical Science Assays, test kits, bioreagents, controls, calibrators, antibodies Pharmaceutical Science Assays, test kits, bioreagents, controls, calibrators, antibodies


Diapharma is planning to attend the American Association of Pharmaceutical Scientists Annual Meeting and Exposition (AAPS PharmSci 360) this year. Please click here to schedule a meeting with us or email us directly.


Pharmaceutical Science Assays, test kits, bioreagents, controls, calibrators, antibodies

AAPS PharmSci 360

AAPS PharmSci 360 will cover all aspects of the pharmaceutical sciences. Each track will be split equally between chemical and biomolecule areas, resulting in 10 sub-tracks that will cover many of the areas making the biggest headlines in the pharmaceutical sciences today.

  • Preclinical Development
  • Bioanalytics
  • Clinical Pharmacology
  • Manufacturing and Bioprocessing
  • Formulation and Quality


Pharmaceutical Science Assays, test kits, bioreagents, controls, calibrators, antibodiesAbout the AAPS

AAPS advances the capacity of pharmaceutical scientists to develop products and therapies that improve global health.

Our members primarily come from a pharmaceutics, biopharmaceutics, or pharmacy field of study. AAPS members also represent those scientists from complimentary disciplines, such as chemistry, biology, engineering, and medicine, involved in the discovery, development, and manufacture of pharmaceutical products and therapies.

To learn more about our members, take a look at our member video series featured below, “I am AAPS.

Members of the American Association of Pharmaceutical Scientists (AAPS) gathered during the 2013 AAPS Annual Meeting and Exposition to discuss why they chose a career in pharmaceutical sciences and how AAPS has helped foster their journey. The I Am AAPS video series displays the diversity of AAPS membership while exhibiting one common goal: to impact global health.


AAPSFacebook | Twitter | LinkedIn | YouTube | DC Convention Center

Society of Environmental Toxicology and Chemistry (SETAC) North America 39th Annual Meeting

toxicology assay test kit ELISA


SETAC ecotox ELISA assay test kit

Diapharma will attend the Society of Environmental Toxicology and Chemistry (SETAC) North America 39th Annual Meeting this year. Please click here to schedule a meeting with us or email us directly. Diapharma supplies TECO® Vitellogenin ELISAs for testing on over 25 different fish species. These assays have the ability to detect VTG protein in serum, WBH or epidermal mucus samples. Visit us at booth 427 to discuss these assays as well as new ecotox assays in development. Research use only.


About SETAC North America

toxicology assay test kit ELISA

Bridging Divides Between Environmental Stewardship and Economic Development

The SETAC North America meeting will explore the link between sustainable economic development and environmental stewardship. The SETAC North America meeting offers connections between desired ecosystem goods and services, stable flourishing societies and sustainable economies.

Aquatic Toxicology, Ecology and Stress Response

Explores ecology, ecotoxicolgy and response to stress of all aquatic systems, including lentic and lotic freshwater systems, estuaries, coastal and marine environments

Terrestrial Toxicology, Ecology and Stress Response

Covers all life forms (avian and mammalian wildlife and other organisms) living in areas from the deserts to the tropics and everything in between

Environmental Risk Assessment

Aquatic and terrestrial environments, and all potential stressors (physical, chemical, biological and biotechnological) with human and ecological endpoints towards the goal of integrated holistic assessment

Chemistry and Exposure Assessment

Chemical analysis, monitoring, fate and modeling, green chemistry and alternative chemical assessment

Predictive and Statistical Toxicology

In silico and in vitro tools and methods involving adverse outcome pathway (AOP), mode of action, molecular toxicology, OMICs, animal alternative testing, quantitative structural activity relationship (QSARs), high-throughput techniques and emerging approaches for statistical toxicology

 



toxicology assay test kit ELISA

About SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology.

SETAC publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


Postcard | SETAC | SETAC-NA | Facebook | Twitter | LinkedIn | YouTube | flickr

American College of Toxicology (ACT) 39th Annual Meeting

toxicology assay test kit ELISA toxicology assay test kit ELISA toxicology assay test kit ELISA


Diapharma is planning to attend the American College of Toxicology 39th Annual Meeting this year. Please click here to schedule a meeting with us or email us directly.

toxicology assay test kit ELISA


About The American College of Toxicology

The American College of Toxicology (ACT) is a professional international organization of around 1000 research and regulatory scientists dedicated to a safer global community. These Toxicologists are experts in the science of toxicology (the study of detrimental effects of substances on biological systems) who work in pharmaceutical and biotech companies, contract research organizations, and regulatory agencies. ACT promotes information on applied toxicology and safety assessment through year‑round education, an annual American College of Toxicology meeting, and its peer‑reviewed scientific journal, International Journal of Toxicology.


ACT | Palm Beach Convention Center

Mayo Clinical Labs – Clinical and Laboratory Update in Thrombosis and Anticoagulation 2018

diapharma anticoagulation assay test kits


Diapharma is planning to attend the Mayo Clinical Labs – Clinical and Laboratory Update in Thrombosis and Anticoagulation 2018 meeing this year. Please click here to schedule a meeting with us or email us directly.


diapharma anticoagulation assay test kitsMayo Medical Laboratories is a global reference laboratory operating within Mayo Clinic’s Department of Laboratory Medicine and Pathology. Mayo Medical Laboratories offers more than 3,000 tests across the full spectrum of health care sub-specialties. Mayo Medical Laboratories works side by side with hospitals to ensure that physicians and providers have knowledge of, and access to, the latest testing and treatment guidance through our services and tools.

Mayo Medical Laboratories enables health care institutions to collaborate with 160 Mayo Clinic physicians and scientists and 3,000 laboratory professionals.


Mayo Clinical Labs | FacebookTwitter | Google+ | YouTube | InstagramLinkedIn

45th Canadian Ecotoxicity Workshop (CEW)

ecotoxicology biomarker endocrine disruptor assay test kit ecotoxicology biomarker endocrine disruptor assay test kit


Diapharma will attend the 45th Canadian Ecotoxicity Workshop (CEW) this year. Please click here to schedule a meeting with us or email us directly.


About the 45th CEW

Topics

  • Contaminants and Ecosystem Health
  • General Aquatic Toxicology
  • Pesticides
  • Toxicity of Metals and Metal Mixtures
  • Sediment and Soil Ecotoxicity
  • Wildlife Ecotoxicology and Disease
  • Behavioural Toxicology
  • Multi-Generational Toxicology and Epigenetics
  • Municipal Wastewaters and Water Treatment
  • Environmental Effects Monitoring
  • Aquaculture
  • Bioassays and Test Methods
  • Omics (genomics, proteomics, metabolomics)
  • Estuarine toxicology
  • Marine bioassay development and advances
  • Chemical product testing

ecotoxicology biomarker endocrine disruptor assay test kitAbout the CEW

CEW was formerly known as the Aquatic Toxicity Workshop (ATW) in the 1970s. Workshops expanded from chemical lethality tests on fish and invertebrates to impacts by chemical, physical and biological agents on the integrity of aquatic ecosystems. Links to wildlife ecotoxicology, sediment/soil toxicity issues and ecosystem science emerged as the field of aquatic toxicology evolved.

The Canadian Ecotoxicity Workshop (CEW) is Canada’s annual meeting in ecological toxicology. Members of CEW share information on contaminants in aquatic and terrestrial ecosystems. Participants include students, academics, government scientists and regulators, environmental consultants and industry representatives.

CEW is held annually in a different region of Canada to draw interest among a wider group of ecotoxicologists.


Canadian Ecotoxicity Workshop | Facebook | Twitter | LinkedInSheraton Vancouver Wall Centre

Cambridge Healthtech Institute (CHI) Discovery on Target – NASH & Fibrosis Conference

NASH marker ELISA assay test kit NASH marker ELISA assay test kit


Diapharma is planning to attend the NASH & Fibrosis Conference this year. Please click here to schedule a meeting with us or email us directly.


NASH marker ELISA assay test kit

NASH marker ELISA assay test kitThe NASH and Fibrosis is organized by the Cambridge Healthtech Institute.

Non-alcoholic Steatohepatitis (NASH) is a disease of the liver that starts with an accumulation of fat and proceeds to inflammation and scarring of the liver. The scarring begins as fibrosis, but can worsen to cirrhosis and eventual liver failure. The global incidence of NASH is rapidly rising. NASH drug development is a growing area of activity in the pharmaceutical industry. CHI’s NASH and Fibrosis conference convenes discovery scientists in academics, biotech and pharma who work in the area of fibrosis, inflammation or liver disease to share insights, tools and stay abreast of this emerging and rapidly progressing field.

Topics

  • ACC Inhibitor for NASH
  • Animal models for NASH and fibrosis
  • Combating liver fibrosis
  • Combining FXR and CCV for potential NASH treatments
  • CSTI-100, a Melanin-Concentrating Hormone Receptor 1 (MCHR1) antagonist, for the treatment of NASH
  • Galectin 3 Inhibitor for NASH cirrhosis
  • NASH drug candidates
  • NASH basic science overview
  • Thyroid hormone receptor agonists for treating NASH


Cambridge Health Institute | Facebook | Twitter | YouTube

Hemostasis Gordon Research Conference (GRC): Defining the Interactions Between Blood, Cells, and Vessels in Hemostasis and Disease

hemostasis thrombosis chromogenic clotting assay test kit hemostasis thrombosis chromogenic clotting assay test kit hemostasis thrombosis chromogenic clotting assay test kit


Diapharma is planning to attend the Hemostasis Gordon Research Conference (GRC): Defining the Interactions Between Blood, Cells, and Vessels in Hemostasis and Disease meeting this year. Please click here to schedule a meeting with us or email us directly.


hemostasis thrombosis chromogenic clotting assay test kitAbout the GRC

The Hemostasis Gordon Research Conference (GRC) is a small scientific meeting on the topics of blood coagulation, platelet biology, anticoagulant pathways, and associated diseases. The Hemostasis GRC includes scientists interested in the biology, biochemistry, and genetics of platelets and coagulation proteins; physicians involved in the treatment of bleeding and thrombotic diseases; and investigators from small and large pharmaceutical/biotechnology companies developing new therapeutics and diagnostics for disorders of the hemostatic system. Topics at the Hemostasis GRC include novel and emerging aspects of hemostasis and thrombosis, as well as newly-identified roles for coagulation proteins, cells, and biophysical mechanisms in human disease.

GRC Topics

  • Initiating Events in Hemostasis and Thrombosis
  • Initiation of Contact Activation
  • Mechanisms of Platelet Alpha and Dense Granule Biogenesis
  • Contact Pathway Activation and Polyphosphate
  • Contributions from the Blood and Vasculature
  • Regulation of Endothelial Exocytosis
  • Fibrin/GPVI Interactions in Thrombosis and Hemostasis
  • Combining Immunohematology and Biophysics to Better Understand Immune-Mediated Blood Cell Disorders: Lessons Learned from HIT
  • A Chromosome 5 Cis-Regulatory Element Regulates Mouse Platelet PAI-1 Expression
  • Molecular Interactions Between Blood and Platelets
  • Genomic Approaches to von Willebrand Disease
  • Emerging Concepts in Immune-Mediated Thrombotic Thrombocytopenic Purpura
  • Platelet/Fibrin Interactions During Thrombosis
  • Cellular Contributions to Hemostasis and Thrombosis
  • Alterations in von Willebrand Factor and Redox State in Sickle Cell Disease
  • Zymogen Factor XII and Neutrophil Functions
  • The Dynamics of Protease Activated Receptor (PAR) Activation and Signaling
  • Role of VWF Glycans in Regulating Clearance
  • Mechanisms of Altered Platelet Production During Inflammation
  • Advanced Models of Coagulation
  • Insights into the Pathophysiology of Thrombosis Using Mice with Impaired Anticoagulation
  • Regulating Intra-Clot Thrombin and Fibrin Production Under Flow
  • Mathematical Models of Coagulation
  • Oral Therapy for Hemophilia
  • Novel Anticoagulants Through Allosteric Regulation of Coagulation Proteases
  • Targeting FXa with Aptamer-Small Molecule Active Site Inhibitor Pairs for Potent and Reversible AnticoagulationAssessing the Benefit of Emicizumab for the Treatment of Hemophilia A: From Lab to Label
  • Platelet-Like Particles for Hemostasis and Wound Repair
  • Coagulation Mechanisms Beyond Hemostasis
  • Mechanisms Coupling Hemostatic Factors to Tumorigenesis
  • The Role of Factor XIII-A in Energy Metabolism
  • Coagulation in Sickle Cell Disease
  • Role of Coagulation in Liver Injury and Repair
  • Gut Microbial Choline Metabolite TMAO Enhances Platelet Hyper-Reactivity and Thrombosis Risk
  • Hemostasis and Thrombosis: Bench to Bedside
  • Antithrombotic Therapy
  • Cellular Targets in Thrombosis

GRC | Facebook | Twitter | Instagram | Waterville Valley Resort Conference Center

70th American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo

chemistry biomarker assay test kit chemistry biomarker assay test kit chemistry biomarker assay test kit


Diapharma is planning to attend the 70th American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo this year. Please click here to schedule a meeting with us or email us directly.


chemistry biomarker assay test kit

About the AACC Meeting 2018

The 70th AACC Annual Scientific Meeting & Clinical Lab Expo is the largest global scientific conference and trade show in the field of laboratory medicine. At this meeting, you’ll have the opportunity to connect with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine.

At the 70th AACC meeting, you’ll learn about cutting edge technology, vital research and changes in the field of laboratory medicine. The AACC Clinical Lab Expo has more than 200 new product introductions, educational and scientific sessions.

Session Types

  • Allergies Immunology
  • Antibodies
  • Antibodies – Government / Regulatory
  • Antibodies – Immunology
  • Biomarkers – Cancer / Tumors
  • Biomarkers Lipids / Lipoproteins
  • Biomarkers Technology
  • Bone and Mineral Metabolism
  • Cancer
  • Cancer / Tumors
  • Cancer – Patient Safety
  • Cancer Personalized Medicine & Cancer Genetics
  • Cardiovascular Disease – Genomics
  • Cardiovascular Disease – Kidney Disease
  • Cardiovascular Disease – Lipids / Lipoproteins
  • Coagulation Allergies
  • Coagulation Markers
  • Coagulation Pulmonary Disease
  • Coagulation
  • Critical Care – Cardiovascular Disease
  • Critical Care – Toxicology
  • Delivery Methods – Immunology – Transplantation
  • Endocrinology Biomarkers
  • Endocrinology Harmonization
  • Endocrinology – Kidney Disease – Bone and Mineral Metabolism
  • Endocrinology – Maternal-Fetal – Thyroid Disease
  • Endocrinology – Testing Methods
  • Endocrinology – Toxicology
  • Factors Affecting Test Results – Antibodies
  • Factors Affecting Test Results – Endocrinology Biomarkers – Diabetes – Thyroid Disease
  • Factors Affecting Test Results – Endocrinology – Ethics
  • Factors Affecting Test Results – Endocrinology Tumor Markers
  • Factors Affecting Test Results – Harmonization Biomarkers – Diabetes
  • Factors Affecting Test Results – Hematology
  • Factors Affecting Test Results – Immunoassay
  • Factors Affecting Test Results – Testing Methods
  • Genomics
  • Guidelines – Cancer
  • Harmonization – Immunology
  • Hematology – Coagulation
  • Hematology – Coagulation – Patient Types
  • Hematology – Particles
  • Hematology – Testing Methods – Proteins
  • Hematology – Tumor
  • History
  • Immunoassay
  • Immunology – Multiplex Lab Test
  • Lipids / Lipoproteins
  • Liver Disease
  • Markers – Emerging Technology – Multiplex Lab Test
  • Mass Spectrometry
  • Mass Spectrometry – Cancer – Proteins
  • Mass Spectrometry – Emerging Technology
  • Mass Spectrometry – Endocrinology
  • Mass Spectrometry – Proteomics
  • Mass Spectrometry – Proteomics – Proteins
  • Mass Spectrometry – Quality Assurance – Testing Methods
  • Mass Spectrometry Testing Methods
  • Mass Spectrometry – Toxicology – Testing Methods
  • Maternal-Fetal – Diabetes
  • Maternal-Fetal – Metabolites
  • Maternal-Fetal – Thyroid Disease
  • Molecular Diagnostics
  • Neurological Diseases – Tumor
  • Neurological Diseases – Tumor – Antibodies
  • Nutrition – Hematology
  • Testing Methods
  • Testing Methods – Bone and Mineral Metabolism
  • Testing Methods – Cancer – Molecular Diagnostics
  • Testing Methods – Electrolytes
  • Testing Methods – Flow Cytometry
  • Testing Methods – Genomics -Molecular Diagnostics
  • Testing Methods – Immunoassay
  • Testing Methods – Immunology – Proteins
  • Testing Methods – Kidney Disease
  • Testing Methods – Proteins
  • Toxicology – Delivery Methods
  • Toxicology – Legal Issues – Integrated Diagnostics
  • Toxicology – Pediatrics
  • Toxicology – TDM
  • Toxicology – Urinalysis

chemistry biomarker assay test kitAbout the AACC

The American Association for Clinical Chemistry (AACC) is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. The AACC advocates education and collaboration to aid lab professionals.

AACC’s strategy

  1. Member Community
  2. Science & Innovation
  3. Content & Education
  4. Advocacy & Influence
  5. Resources & Capacity

AACC’s Vision

Better health and healthcare through laboratory medicine.

AACC’s Mission

AACC provides global leadership in advancing the practice and profession of clinical laboratory science and medicine.

Collaboration Proves Key to a Quick Diagnosis

After a patient’s unusual, gelled blood sample raises red flags, a lab expert and the patient’s doctor discover that a rare cancer is behind the patient’s vague symptoms. #Laborastories

Posted by American Association for Clinical Chemistry (AACC) on Monday, April 2, 2018

AACC Principles

Laboratory medicine evolves as a result of biomedical discoveries, innovations in technology, and the changing healthcare environment. The shift toward outcomes-based payment models has already begun and laboratory medicine professionals are a critical component in the delivery of high-quality, cost-effective healthcare. With an ever-growing array of new diagnostic discoveries and technologies, individuals with deep and specialized knowledge of laboratory tests are crucial to ensuring the right testing paradigm is applied and the results interpreted accurately.

AACC is the home of cutting-edge research and comprehensive education in the field. AACC brings together clinical laboratory professionals and provides collaborative networking. In representing laboratory medicine to policymakers and other stakeholders, AACC strives to enhance general awareness and understanding of the unique expertise its members bring to the healthcare team and to pursue policies that enhance the ability of laboratory medicine professionals to thrive and improve patient care.


AACC | Facebook | Twitter | YouTube | LinkedIn | McCormick Place

International Society on Thrombosis and Haemostasis (ISTH) 64th Annual Scientific and Standardization Committee (SSC) Meeting

thrombosis hemostasis biomarker ELISA chromogenic assay measurement test kit


Diapharma is planning to attend the International Society on Thrombosis and Haemostasis (ISTH) 64th Annual Scientific and Standardization Committee (SSC) Meeting this year. Please click here to schedule a meeting with us or email us directly.


About the SSC 2018

ISTH SSC 2018 is a scientific event in the field of thrombosis and hemostasis that brings together the world’s leading experts. SSC meetings are a platform for scientific and clinical working groups. SSC 2018 will facilitate a discourse about current diagnostic and therapeutic challenges, discussing novel approaches and standards.


thrombosis hemostasis biomarker ELISA chromogenic assay measurement test kitAbout the SSC

The Scientific and Standardization Committee (SSC) is a permanent committee of the International Society of Thrombosis and Hemostasis (ISTH). The SSC has independent authority over its scientific program and reports to the ISTH Council. It is made up of 20 subcommittees in addition to one standing committees and the executive committee.

SSC Subcommittees

  • Animal, Cellular And Molecular Models
  • Biorheology
  • Coagulation Standards Standing Committee
  • Control Of Anticoagulation
  • Disseminated Intravascular Coagulation
  • Factor VIII, Factor IX & Rare Coagulation Disorder
  • Factor XI And The Contact System
  • Factor XIII And Fibrinogen
  • Fibrinolysis
  • Genomics In Thrombosis And Hemostasis
  • Hemostasis & Malignancy
  • Lupus Anticoagulant / Antiphospholipid Antibodies
  • Pediatric/Neonatal Thrombosis And Hemostasis
  • Perioperative And Critical Care Thrombosis And Hemostasis
  • Plasma Coagulation Inhibitors
  • Platelet Immunology
  • Platelet Physiology
  • Predictive/Diagnostic Variables
  • SSC Executive Committee
  • Vascular Biology
  • Von Willebrand Factor
  • Women’s Health Issues In Thrombosis and Hemostasis

Standards, Nomenclature, Registries and Databases

thrombosis hemostasis biomarker ELISA chromogenic assay measurement test kit

The SSC supports the ISTH’s mission through developing and recommending standards relevant to the fields of thrombosis and hemostasis. Many of the standards developed by the SSC are adopted by the World Health Organization (WHO) as International Standards.

The SSC began as the authoritative body which first standardized the naming of blood clotting factors. Its subcommittees act as expert bodies in the standardization of nomenclature to support the blood clotting community. Its recommendations and classifications are published in the Society’s official journal, the Journal of Thrombosis and Haemostasis (JTH).

The SSC supports numerous registries and databases where information is collected, updated and shared with the scientific community for greater understanding on the underlying causes of hemorrhagic and thrombotic disorders. SSC structure and function can be found in the SSC Rules and Guidelines.

Networking, Education and Annual Meetings

The SSC draws its strength and credibility from the hundreds of physicians and scientists who volunteer to lead and participate in its activities.

The SSC organizes annual meetings where subcommittee members and experts present their ongoing work in public sessions. These sessions discuss the latest research on bleeding and thrombotic disorders and provide information that attendees can use to improve their ability to diagnose and treat the various disorders of hemostasis.

 


thrombosis hemostasis biomarker ELISA chromogenic assay measurement test kitAbout the ISTH

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals. The ISTH promotes education and outreach initiatives, research activities, scientific meetings, peer-reviewed publications, expert committees and the development of standards allowing a common language and approach to basic and clinical science all over the world.

ISTH History

In the 1950s, a group of investigators used seed money from the National Heart, Lung and Blood Institute (NHLBI) to form the International Committee on Thrombosis and Haemostasis (ICTH). In the 1960s, the ICTH grew larger and became the International Society on Thrombosis and Haemostasis (ISTH). The ICTH focused on blood coagulation and hemorrhagic disorders while the ISTH expanded to include platelet function and regulation, the mechanisms of thrombosis, fibrinolysis and thrombolysis, and problems of thromboembolic disorders.

Today, the ISTH is the leading thrombosis and hemostasis professional organization in the world with more than 4000 members in almost 100 countries.


ISTH | SSC | Facebook | Twitter | LinkedIn | YouTube | Instagram | Convention Centre Dublin

thrombosis hemostasis biomarker ELISA chromogenic assay measurement test kit thrombosis hemostasis biomarker ELISA chromogenic assay measurement test kit thrombosis hemostasis biomarker ELISA chromogenic assay measurement test kit

22nd North American International Society for Study of Xenobiotics (ISSX) Meeting

Xenobiotics assay test kit biomarker Xenobiotics assay test kit biomarker


Diapharma is planning to attend the 22nd North American International Society for Study of Xenobiotics (ISSX) Meeting this year. Please click here to schedule a meeting with us or email us directly.


Xenobiotics assay test kit biomarker

About the ISSX

Xenobiotics assay test kit biomarker

ISSX is a scientific organization for researchers interested in the metabolism and disposition of xenobiotics. ISSX works to advance research and education on the interplay of living systems with medicines and chemicals. Including members from both academia and industry, ISSX provides a home for like-minded research scientists and future scientists in toxicology, pharmacology, molecular biology, and other disciplines related to the study of xenobiotics.

The ISSX hosts an international xenobiotics meeting, offers short courses, symposia, lectures and other events. Those involved at any level in the metabolism and disposition of drugs and other chemicals will benefit from attendance. The meeting allows for dialogue and exchange of scientific expertise among the world’s leading experts in drug/xenobiotic research.


ISSX | ISSX 2018Facebook | Twitter | LinkedInPalais des congrès de Montréal

American Association for the Study of Liver Diseases / European Association for the Study of the Liver (AASLD/EASL) Nonalcoholic Fatty Liver Disease (NAFLD) Endpoints Conference

NAFLD biomarker assay test kit NAFLD biomarker assay test kit


Diapharma is planning to attend the American Association for the Study of Liver Diseases / European Association for the Study of the Liver (AASLD/EASL) Nonalcoholic Fatty Liver Disease (NAFLD) Endpoints Conference this year. Please click here to schedule a meeting with us or email us directly.


About the NAFLD Endpoints Conference

The NAFLD Endpoints Conference will bring together academic, regulatory and pharmaceutical sectors to discuss therapeutic endpoints, trial designs and appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of NAFLD. This meeting will bring relevant parties to the table to discuss the next generation of therapeutic agents to affected individuals with NAFLD. AASLD and EASL possess the expertise in NAFLD to bridge knowledge gaps that regulatory and pharmaceutical industry have identified to development of novel therapeutic agents for NAFLD.

Objectives

  • Understand how lessons learned from completed NASH trials may influence future clinical trial design and endpoints.
  • Identify potential approaches to phenotyping adult and pediatric patients with NASH.
  • Discuss available methods to study clinical outcomes and their limitations in the context of NASH clinical trials.
  • Understand the strengths and limitations of currently available biomarkers to stage disease and assess dynamic change.

Sessions

  1. Session I: Current Landscape and Lessons Learned from Recently Completed Trials
  2. Session II: Placebo Arm and Lifestyle Management in Clinical Trials
  3. Session III: Segmenting the Population – Phenotyping for Clinical Trials
  4. Session IV: Clinical Events and Patient-Related Outcomes
  5. Session V: Endpoints – Defining Response to Treatment
  6. Session VI: What Will the NAFLD Landscape Look Like In 2025?NAFLD biomarker assay test kit

 About the AASLD

The American Association for the Study of Liver Diseases (AASLD) is a scientific organization which attempts promote liver health and prevent and cure liver disease through hepatology.

The organization publishes podcasts, newsletters and the journals HEPATOLOGYClinical Liver Disease (CLD), and Liver Transplantation.


About EASL

Founded in 1996, the European Association for the Study of the Liver (EASL) has grown from a small organisation that played host to 70 hepatologists at its first meeting, to becoming the leading lassociation dedicated to the liver and liver disease in Europe.

EASL has 4000+ worldwide members provides The International Liver Congress™ for 11,000 liver experts to meet and discuss latest scientific liver research. EASL has given rise to many international clinical trials and research collaborations to the benefit of patients all over the world. EASL aims to be the home of hepatology to cure and prevent liver disease.

EASL promotes research in the science of liver disease (Hepatology) and fosters public awareness of liver diseases and management.


AASLD | AASLD Facebook | AASLD Twitter | AASLD LinkedIn | AASLD YouTube | AASLD Instagram | EASL | EASL Facebook | EASL Twitter | EASL LinkedIn | EASL YouTube | The Westin Alexandria

Diapharma National Sales Meeting (June 2018)

International Association for Great Lakes Research 61st Annual Conference on Great Lakes Research (IGLAR) – Great Science for Tomorrow’s Solutions

watershed toxicology vitellogenin ELISA assay test kit watershed toxicology vitellogenin ELISA assay test kit watershed toxicology vitellogenin ELISA assay test kit


Diapharma is planning to attend the International Association for Great Lakes Research 61st Annual Conference on Great Lakes Research (IGLAR) – Great Science for Tomorrow’s Solutions meeting this year. Please click here to schedule a meeting with us or email us directly.


watershed toxicology vitellogenin ELISA assay test kitThe International Association for Great Lakes Research (IAGLR) is a member-run, professional scientific organization made up of researchers studying the Laurentian Great Lakes, other large lakes of the world, and their watersheds. IAGLR members encompass all scientific disciplines with a common interest in the management of large lake ecosystems.

IAGLR holds an annual Conference on Great Lakes Research, publishes the Journal of Great Lakes Research, and also gives awards and scholarships.


IGLAR | Facebook | Twitter | UTSC

Kinin 2018 CLE

kinin products assay test kits kinin products assay test kits kinin products assay test kits


Diapharma is planning to attend and exhibit at the Kinin 2018 CLE meeting this year. Please click here to schedule a meeting with us or email us directly.


About Kinin 2018 CLE

Kinin 2018 CLE is organized by Case Western Reserve University School of Medicine (CWRU) and would be held during Jun 17 – 20, 2018 at Cleveland, Ohio, United States of America.


CWRU SOM | Facebook | Twitter | YouTube | Instagram

American College of Veterinary Internal Medicine (ACVIM) Forum 2018

veterinary biomarker assay test kit veterinary biomarker assay test kit veterinary biomarker assay test kit


Diapharma is planning to attend the American College of Veterinary Internal Medicine (ACVIM) Forum 2018. Please click here to schedule a meeting with us or email us directly.



About the ACVIM Forum

The first ACVIM Forum was held in 1983 in New Orleans with just 350 attendees. The purpose of the meeting was to bring state of the art information to veterinarians, and through the Forum, the ACVIM grew by 600 members between 1981 and 1993. With only four sessions at the first meeting, the ACVIM Forum has now grown to attract more than 3,000 attendees with more than 460 hours of CE credit. Whether this is your first time exploring the ACVIM Forum or you have been a regular attendee, you can expect outstanding educational opportunities and time spent with both new and familiar colleagues.

veterinary biomarker assay test kit


ACVIM | Facebook | Twitter | LinkedIn | YouTube | WSCC

Laurentian Society of Environmental Toxicology and Chemistry (SETAC) 23rd Annual General Meeting & Conference

toxicology assay test kit ELISA toxicology assay test kit ELISA toxicology assay test kit ELISA


Diapharma is planning to attend the Laurentian SETAC 23rd Annual General Meeting & Conference this year. Please click here to schedule a meeting with us or email us directly.


toxicology assay test kit ELISA

About the Laurentian Chapter of SETAC

The Laurentian Chapter of SETAC is the Ontario regional Chapter of the Society of Environmental Toxicology and Chemistry (SETAC) and is comprised of students, academics, and people from private business, government, and industry.

The Laurentian Chapter of SETAC’s mission is to promote communication and education in environmental toxicology and chemistry among academia, government, business, and industry.


About SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology.

SETAC publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


SETAC | Laurentian SETAC | Facebook | Twitter | Queen’s University

25th International Fibrinogen & 3rd International Factor XIII Workshop

fibrinogen coagulation factor xiii measurement assay test kit fibrinogen coagulation factor xiii measurement assay test kit fibrinogen coagulation factor xiii measurement assay test kit


Diapharma is planning to attend the 25th International Fibrinogen & 3rd International Factor XIII Workshop this year. Please click here to schedule a meeting with us or email us directly.


fibrinogen coagulation factor xiii measurement assay test kit

The 25th International Fibrinogen Workshop will be held jointly with the 3rd International Factor XIII Workshop at the Graylyn International Conference Center of Wake Forest University in Winston-Salem. The latest advances in basic, clinical and bioengineering research relating to Fibrinogen and Factor XIII will be presented.

Topics:

  • Genetics & Fibrinogen variants
  • Biomechanics, Structure and Polymerization
  • Fibrin clot properties
  • Fibrinolysis
  • Fibrinogen-cell Interactions
  • Inflammation & Disease
  • Clinical Aspects
  • Biomedical and Tissue Engineering
  • Several Factor XIII sessions

https://www.youtube.com/watch?v=K4WSaxz5WFs

 


IFRSECAT | Graylyn Center | Wake Forest

Digestive Disease Week® 2018 Monumental Developments in Science & Medicine

digestive disorder biomarker assay test kit

digestive disorder biomarker assay test kit digestive disorder biomarker assay test kit digestive disorder biomarker assay test kit


Diapharma is planning to attend the Digestive Disease Week® 2018 Monumental Developments in Science & Medicine meeting this year. Please click here to schedule a meeting with us or email us directly.


The theme of the Digestive Disease Week® 2018 will be ‘Monumental Developments in Science and Medicine’. Gastroenterologist, hepatologists, doctors and professionals specializing in endoscopy and gastrointestinal surgery are all part of the Digestive Disease Week.

Posted by Digestive Disease Week® (DDW®) on Friday, December 1, 2017

 

 


DDW | DDW blogFacebook | Twitter | YouTube | InstagramWalter E. Washington Convention Center | Washington.org

American Society of Clinical Oncology (ASCO) 2018

oncology products ELISA assay test kits


Diapharma is planning to attend the American Society of Clinical Oncology (ASCO) meeting this year. Please click here to schedule a meeting with us or email us directly.


oncology products ELISA assay test kitsThe American Society of Clinical Oncology (ASCO) Annual Meeting is organized by American Society of Clinical Oncology (ASCO) and would be held during Jun 01 – 05, 2018 at Chicago, Illinois, United States of America. The Annual Meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. The ASCO Annual Meeting offers informative educational and scientific sessions that highlight the latest in cancer care treatments. The Sessions at a Glance Grid provides a detailed look at all Clinical Science Symposia, Education Sessions, Extended Education Sessions, Meet the Professor Sessions, and Clinical Problems in Oncology Sessions organized by primary track, as well as by date and time.


ASCO-2018.org | ASCO18.org | McCormick Place Convention Center

Thank you for visiting us at THSNA 2018!


Thank you for stopping by our booth at THSNA 2018. We enjoyed the chance to speak with you about the products Diapharma offers. Check out our website for detailed product info and contact information for your Territory Manager.


Chromogenic Factor VIII and FIX Assays

for Hemophilia Studies

 

FDA cleared chromogenic FVIII kits from Diapharma:

COAMATIC® FVIII (K822585)
COATEST® SP FVIII (K824086)
COATEST® SP4 FVIII (K824094)

Contains bovine factor reagents

 

ROX Factor IX* (900020)

Bringing chromogenic Factor IX determination into the next era

*Research use only in the U.S. and Canada

 

Visit diapharma.com for our complete line of chromogenic substrates, inhibitors, assay kits, proteins, enzymes, and more.


Questions? Over 20 years of scientific expertise and customer support just a click or phone call away.

THSNA Chromogenic Factor VIII FIX Measurement Assay Test Hemophilia Study


THSNA Chromogenic Factor VIII FIX Measurement Assay Test Hemophilia Study


8948 Beckett Rd 45069 West Chester US
ML-00-00339Rev01

3rd International Workshop on NASH Biomarkers

NASH NAFLD biomarker ELISA assay test kit NASH NAFLD biomarker ELISA assay test kit NASH NAFLD biomarker ELISA assay test kit


Diapharma will be attending the 3rd International Workshop on NASH Biomarkers meeting this year. Please click here to schedule a meeting with us or email us directly.


NASH NAFLD biomarker ELISA assay test kitThe 3rd International Workshop on NASH Biomarkers will be held in Washington DC, May 18-19, 2018. The NASH Biomarkers workshop is co-organized by the Liver Forum and Expert Medical Events.

MEETING OBJECTIVES

  • Review regulatory landscape and gaps in regulatory science related to biomarker development for NAFLD
  • Review gaps in evidence to qualify specific biomarkers for NAFLD
  • Stimulate collaborative science to accelerate biomarker development for NAFLD
  • Promote innovation in design and analytic approaches to biomarker development for NAFLD

NASH NAFLD biomarker ELISA assay test kitThe recognition of non-alcoholic steatohepatitis (NASH) as a significant cause of morbidity and mortality around the globe has generated much activity in therapeutic and diagnostic development. Histology-based assessments requiring liver biopsies remains the NASH diagnostic standard and drug developers and clinical researchers are challenged by the lack of accepted and/or validated non-invasive diagnostic, prognostic and endpoint biomarkers. Collaboration will facilitate progress to acceptance, validation and/or qualification of non-invasive biomarkers.

This public, abstract-driven workshop will focus on NASH biomarker development by bringing together individuals and organizations in the field of NASH Biomarkers. By sharing knowledge, coordinating activities, and working through the complex issues surrounding NASH, the NASH Biomarkers Workshop will continue to impact the advancement of the field.

Some topics will include:

  • Regulatory and third party payer perspectives on NASH biomarkers
  • Pathways and priorities for biomarker assessment
  • Hierarchical testing strategies for NASH
  • Pre-cirrhotic NASH and cirrhotic NASH
  • Biomarkers of therapeutic response for pre-cirrhotic NASH
  • NASH in diabetes and heart disease

Expert Medical Events | The Westin Alexandria

Applied Pharmaceutical Toxicology 2018

toxicology products ELISAs assay test kits


Diapharma is planning to attend the Applied Pharmaceutical Toxicology 2018 meeting this year. Please click here to schedule a meeting with us or email us directly.


 

Applied Pharmaceutical Toxicology 2018

Agenda

  • Discovery Toxicology
  • Discovery and Development Toxicology
  • Development Toxicology

Discovery Toxicology Workshop

  • Impactful Investigative Toxicology Case Studies
  • Acute Anaphylactoid Reactions
  • Hot Topics in Discovery Toxicology
  • Proposed Sessions for the Development Toxicology Workshop
  • Impurities and Occupational Exposure Limits / Health Hazard Categorization
  • Regulatory Guidance Development and Updates
  • Key Learning from Recent Clinical Trial Experiences

toxicology products ELISAs assay test kitsAbout The Boston Society

The Boston Society is a non-profit organization involved in education, training, discussion, and scientific activities in support of drug discovery and development. The Boston Society was originally founded as ‘Society for Advanced Therapeutics Inc. and did business as ‘BSAT’.

The founders of The Boston Society organize meetings that are industry-focused, while maintaining non-profit status.

Membership in the Boston Society includes scientists involved in every area of research and development from academic, industrial, and governmental laboratories. Their interests include advancement of techniques and instrumentation, synthesis, and the full spectrum of activities necessary to discover and develop novel entities and technologies.


APT | Boston SocietyLinkedIn

Ozark-Prairie Society of Environmental Toxicology and Chemistry (OPSETAC)


Diapharma is planning to attend the Ozark-Prairie Society of Environmental Toxicology and Chemistry (OPSETAC) meeting this year. Please click here to schedule a meeting with us or email us directly!


About the Ozark-Prairie Regional Chapter of the Society of Environmental Toxicology and Chemistry (OPSETAC)

SETAC ecotox endocrine disruption vtg vitellogenin ELISA Assay Test Kit

toxicology assay test kit

The Ozark-Prairie Regional Chapter of the Society of Environmental Toxicology and Chemistry (OPSETAC) provides a forum for scientists and students in the fields of Environmental Toxicology and Environmental Chemistry to exchange information pertinent to the Ozark-Prairie region and offers assistance and support to students entering these professions.

The Ozark-Prairie region consists of large portions of the central United States, including much of the Ozark Plateau, the “Corn Belt” and Great Plains. In recent years, chapter membership has included residents of Missouri, Iowa, Illinois, Oklahoma, Nebraska and the Dakotas.

The theme for 2018 is “Celebrating 30 years of OP-SETAC.”


About SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology.

SETAC publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


SETAC | OPSETAC | Facebook | Watershed Center

Society of Environmental Toxicology and Chemistry (SETAC) Mid-South

 


Diapharma is planning to attend the Society of Environmental Toxicology and Chemistry (SETAC) Mid-South meeting this year. Please click here to schedule a meeting with us or email us directly.


About SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology.

SETAC publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).

Carolinas Society of Environmental Toxicology and Chemistry (SETAC)

toxicology products assay test kits


Diapharma is planning to attend the Carolinas Society of Environmental Toxicology and Chemistry (SETAC) meeting this year. Please click here to schedule a meeting with us or email us directly.


toxicology products assay test kitsAbout Carolinas SETAC

Carolinas SETAC is a non-profit regional chapter of the international Society of Environmental Toxicology and Chemistry (SETAC).  The chapter is an independently administered entity intended to meet local needs of SETAC members and chapter members and to promote the goals of its parent society.

Members of Carolinas SETAC come from a variety of disciplines from the Carolinas and surrounding states. The Chapter encourages student membership, and many aspects of the chapter are focused on student participation and benefits.

The regional meetings provide students with an excellent forum for research presentations and an opportunity to interact with other scientists and prospective employers.  Students are also encouraged to take on leadership roles by serving on the Carolinas SETAC Board of Directors and committees.


About SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology.

SETAC publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


SETAC | Carolinas SETAC | FacebookTwitter

Hudson-Delaware Regional Chapter of the Society of Environmental Toxicology and Chemistry (HDC-SETAC)

ecotoxicology vitellogenin ELISA assay test fish swab kit


ecotoxicology assay test kit

Diapharma is planning to attend and exhibit at the Hudson-Delaware Chapter of the Society of Environmental Toxicology and Chemistry (HDC-SETAC) meeting thisyear. Please click here to schedule a meeting with us or email us directly.

Non-invasive, non-destructive ecotoxicology assays. Environmental impact matters. Use Teco® Mucus Collection Swabs to assess testing endpoints in fish species for:


About HDC-SETAC

ecotoxicology vitellogenin ELISA assay test fish swab kit

The Hudson-Delaware Chapter of the Society of Environmental Toxicology and Chemistry (HDC-SETAC) is a professional society for environmental scientists, engineers and related disciplines concerned with environmental science and health located in the Hudson River and Delaware River metropolitan area.

HDC-SETAC is a regional chapter of SETAC, a national scientific non-profit organization of about 4,000 members and was founded in 1984, making it one of the first established regional chapters within North America. The Hudson-Delaware chapter attracts scientists and students from academia, consulting, government, and industry and offers an informative and educational Annual Spring Meeting and Fall Workshop for environmental sciences.

HDC-SETAC is all about environmental scientists and students of our region and our meetings and workshops are designed to educate attendees about current issues and topics of the Hudson/Delaware region.


About SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology.

SETAC publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


HDC-SETAC | Marriott | Rowan University

Chesapeake Potomac Regional Chapter (CPRC) of the Society of Environmental Toxicology and Chemistry (SETAC) Annual Spring Meeting

toxicology products assay test kits toxicology products assay test kits toxicology products assay test kits


Diapharma is planning to attend and exhibit at the Chesapeake and Potomac Regional Chapter (CPRC) of the Society of Environmental Toxicology and Chemistry (SETAC) meeting this year. Please click here to schedule a meeting with us or email us directly.

ecotoxicology vitellogenin ELISA assay fish test swab kit

Non-invasive, non-destructive ecotoxicology assays. Environmental impact matters. Use Teco® Mucus Collection Swabs to assess testing endpoints in fish species for:


toxicology products assay test kitsAbout CPRC SETAC

The Chesapeake and Potomac Regional Chapter (CPRC) of the Society of Environmental Toxicology and Chemistry (SETAC) is a regional chapter of SETAC-North America (NA) serving the Chesapeake-Potomac Region (Maryland, DC, Virginia, and West Virginia). CPRC SETAC is a mixture of members within government, industry, consultants and academia.

CPRC SETAC studies and attempts to provide solutions for environmental problems and management and regulation of natural resources.

CPRC SETAC promotes student activities by providing opportunities to find jobs, graduate schools, internships, and volunteer opportunities. CPRC SETAC provides students a forum to present research papers and posters.

The CPRC SETAC publishes 2 newsletters per year and has 2 annual meetings:

  1. Annual Spring meeting (Mini-SETAC) with poster presentations and invited and submitted speakers
  2. Autumn/Winter Dinner meeting, informal dinner-style, with usually one invited speaker

About SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology. SETAC has many regional sub-chapters.

SETAC publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


SETAC | CPRC | Faceboook | Instagram | University of Mary Washington | Jepson Alumni Executive Center

2nd Annual Nonalcoholic Steatohepatitis (NASH) Summit

NASH NAFLD biomarker ELISA assay test kit


Diapharma is planning to attend the 2nd Annual Nonalcoholic Steatohepatitis (NASH) Summit this year. Please click here to schedule a meeting with us or email us directly.


NASH NAFLD biomarker ELISA assay test kit

About The Annual NASH Summit 

The 2nd Annual NASH Summit will include drug developers and organizations in a forum to focus on late stage clinical development of non-alcoholic steatohepatitis (NASH) candidates.

The NASH Summit will present data and lessons learned that will enable you to:

  • Understand how to progress your candidate towards a combinational NASH treatment
  • Define clinical primary and secondary endpoints and understand the status of the biopsy at the time current NASH candidates will enter market to map out your clinical trials
  • Utilize metabolomic and inflammatory biomarkers in NASH preclinical development models to more robustly diagnose and track NASH disease progression
  • Improve drug efficacy in both early and late stage NASH by identifying and validating novel targets & drug mechanisms of action

 

The NASH summit’s agenda will include:

  • Latest Advancements in NASH Drug Development
  • Early stage clinical compounds being evaluated for NASH
  • Regulatory guidance on development of NASH therapeutics
  • Latest Regulatory Requirements for Developing NASH Therapeutics
  • Developing animal models with relevant NASH biology
  • Characterization of NASH animal models
  • Steatosis and inflammation, fibrosis, markers of stellate cells, as well as serum biomarkers
  • Novel Animal Models & Combination Therapies to Combat NASH
  • 2 new diet-induced NASH models in mice
  • Novel preclinical findings on NASH-reducing capabilities of combining FXR and GLP-1R agonists
  • Fructose Metabolism for NASH – KHK Inhibitor
  • Treatment with a KHK-inhibitor reverses metabolic dysfunction in several rodent models of NAFLD-NASH
  • Critical pathophysiologic drivers of NASH
  • Novel targets for NASH and metabolic rare diseases using an in vitro platform
  • Targeting Pyruvate Metabolism to Treat NASH
  • Difficulties in Effectively Utilizing Available Patients in NASH Clinical Trials
  • Genetics in defining NASH pathology from fatty liver to cirrhosis
  • Metabolic drivers of NASH and metabolomic identification of NASH patient subtypes
  • Fibrosis resulting from other pathologies as a substitute for NASH fibrosis during drug development
  • Diabetes and cardiovasular patients as candidate for NASH clinical trials
  • Drug Repurposing Strategies in NASH Clinical Trials
  • Thyroid hormone receptor beta agonist in the NASH liver reduces lipotoxicity through multiple pathways
  • Risk Mitigation of Drug Induced Liver Injury in NASH Drug Development
  • Next Generation NASH Therapeutics
  • NASH Pathology
  • Genes Modulating Risk for NASH Development
  • Human Gluco & Liporegulatory Physiology & Pathophysiology as Drivers of Novel NASH Therapies
  • Human physiological and pathophysiological basis of commonalities and differences in NASH and related metabolic diseases
  • Diabetes therapies to treat NASH and where to seek additional pharmacology
  • New NASH serum biomarkers
  • Cyp 7b1 as a new target for drug development to combat NAFLD
  • Oxysterol metabolites to NASH and insulin resistance
  • New Technologies to Identify & Validate Novel Targets in NASH
  • Oxidative stress as an important factor in the transition from NAFLD to NASH
  • Key enzymes believed to be responsible for oxidative stress in NASH
  • Noninvasive diagnostic markers is necessary to effectively track and treat NASH.
  • 3D bioprinted human tissues to model liver diseases such as NASH and fibrosis
  • Serum and imaging biomarkers as traceable representatives of NASH pathology
  • Combinational Therapies in the Treatment of NASH
  • Liver injury in NASH
  • Immunological & Molecular Pathways of NASH Pathology
  • MetAP2 Inhibitors in the Treatment of NASH
  • Bile acid receptors to treat NASH
  • TGR5 and FXR agonists approaches to NASH
  • Inflammation in NASH driven fibrosis
  • Signaling pathways and miRNA biomarkers in NASH
  • Relationship of NASH with Other Diseases
  • Clinical Trials & Endpoints in NASH Cirrhosis
  • Pre-cirrhotic and cirrhotic NASH including pathphysiology, clinical complications, progression, and prognosis
  • Regulatory endpoints in NASH cirrhosis clinical trials
  • NASH Heterogeneity & Relationships as a Sequel of CVM Disease
  • NASH & Diabetes Preclinical Animal Models
  • Preclinical pharmacology results in diabetes and NASH animal models
  • Novel biologics for the treatment of diabetes and NASH
  • Metabolic Syndrome as a Driver of NAFLD & NASH
  • Preclinical and clinical evidence of entero-hepatic targeting as a therapeutic intervention for NASH
  • Cardiometabolic implications in NASH treatment goals
  • Preclinical Biomarker Developments in NASH for Better Translation into the Clinic
  • Molecular MR Imaging of Oxidized Collagen to Monitor Active Fibrogenesis in Preclinical Models of NASH
  • Molecular MR imaging of oxidized collagen decreases after anti-fibrotic treatment in preclinical models of NASH
  • Increasing public understanding and appreciation of relevance, scope and impact of NASH
  • Improving physician education and appreciation of NASH diagnosis and management from primary care through specialists
  • Retrospective data analysis to design and optimize NAFLD/NASH study inclusion criteria
  • FGF21 Pathway in NASH
  • GLP1 Agonists for the Treatment of NASH

Pre-Conference workshops

Discovery Stream – Workshop A

  • Comprehensively Evaluate the Predictions & Understanding of the Microbiome in Nonalcoholic Steatohepatitis.
  • Reviewing Preclinical Models In-Depth as a Comparison of Traditional & Next Generation Advantages & Disadvantages
  • Reviewing Preclinical Models In-Depth as a Comparison of Traditional & Next Generation Advantages & Disadvantages

Discovery Stream – Workshop B

  • Enhance the Understanding of Liver Cell-to-Cell Interactions in the Pathogenesis of NASH & Evaluate the Opportunity for Next Generation Therapeutic Targets
  • Exploring the Translatability of Non-Invasive Biomarkers in NASH
  • Overcoming NASH as the Next Big Global Epidemic & Evaluating the Challenges of Bringing a NASH Drug to Market

NASH Summit | Revere Boston Common

Experimental Biology (EB) / American Society for Biochemistry and Molecular Biology (ASBMB) 2018

biological assay test kits reagents


Diapharma is planning to attend the Experimental Biology (EB) / ASBMB 2018 meeting this year. Please click here to schedule a meeting with us or email us directly.


biological assay test kits reagents

About Experimental Biology (EB)

Experimental Biology (EB) is an annual meeting of more than 14,000 scientists, 5 host societies and 25 guest societies. The 5 host societies:

  • American Association of Anatomists (AAA)
  • The American Physiological Society (APS)
  • American Society for Biochemistry and Molecular Biology (ASBMB)
  • American Society for Investigative Pathology (ASIP)
  • American Society for Pharmacology & Experimental Therapeutics (ASPET)

This multidisciplinary, scientific meeting features plenary and award lectures, pre-meeting workshops, oral and posters sessions, on-site career services and exhibits of an array of equipment, supplies and publications required for research labs and experimental study.

General fields of study include anatomy, biochemistry and molecular biology, investigative pathology, nutrition, pharmacology, and physiology. EB is open to all members of the sponsoring and guest societies and nonmembers with interest in research and life sciences. The majority of scientists represent university and academic institutions as well as government agencies, non-profit organizations and private corporations.

The Experimental Biology 2018 meeting will have over 50 sessions open to all attendees, 300 companies exhibiting, more than 5000 posters and over 400 oral sessions including:

  • Anatomy
  • Biochemistry and Molecular Biology
  • Pathology
  • Pharmacology
  • Physiology
  • Cancer and Therapy
  • Cardiovascular
  • Education
  • Emerging Technologies
  • Inflammation/Immunity
  • Metabolism and Metabolic Disease
  • Microbiome
  • Neuroscience
  • Nutrition/Obesity
  • Professional Development
  • Public Engagement/Science Policy
  • Regenerative Medicine (Stem Cells, Tissue Regeneration, Biomaterials)

biological assay test kits reagents

About The American Society for Biochemistry and Molecular Biology (ASBMB)

diapharma chromogenic clotting elisa assay test kit

The American Society for Biochemistry and Molecular Biology (ASBMB) was founded in 1906. The roots of the society were in the American Physiological Society, which had been formed 20 years earlier.

ASBMB was originally called the American Society of Biological Chemists, before obtaining its current name in 1987. ASBMB’s mission is to advance the science of biochemistry and molecular biology through publication of scientific and educational journals, the organization of scientific meetings, advocacy for funding of basic research and education, support of science education at all levels, and by promoting the diversity of individuals entering the scientific workforce. The organization currently has over 12,000 members.

The American Society for Biochemistry and Molecular Biology publishes The Journal of Biological Chemistry, Molecular & Cellular Proteomics, and The Journal of Lipid Research and the monthly magazine ASBMB Today. ASBMB journals are peer-reviewed and cover research in the fields of microbiology, molecular genetics, RNA-related research, proteomics, genomics, transcription, peptides, cell signaling, lipidomics, and systems biology.

ASBMB hosts and sponsors numerous meetings each year. The annual meeting is held each April in conjunction with the Experimental Biology meeting. Additionally, themed special symposia are organized throughout the year.

ASBMB Sessions will include:

  • Biochemical Communication Between the Microbiome and the Host
  • Intrinsically Disordered Proteins and their Regulation and Functions
  • Lipid Signaling and Metabolism
  • Novel Enzymology
  • RNA Form and Function
  • Discussion Panel: Strategically Building Your CV at Every Career Stage
  • Synthetic Biology
  • Adapting Proteostasis to Ameliorate Neurodegenerative Diseases
  • Communicating Scientific Ideas to Novice Audiences
  • Environmental Health, Biomarkers and Precision Medicine
  • Glycobiology and Functional Glycomics
  • New Insights into the Links Between Metabolism and Disease
  • Regenerative Medicine presented by the Society for Experimental Biology and Medicine
  • RNA in Human Disease
  • Systems Biology and Proteomics
  • Molecular Visualization
  • Advances in Single Cell Omics
  • Biochemistry of Autophagy and Organelle Trafficking
  • Novel Antibiotics and Alternatives
  • Signal Transduction, Pathogenesis and Disease
  • RNA-mediated Epigenetics
  • Structural Biology
  • Biochemical Basis for Epigenetics and Chromatin Remodeling
  • Enzyme Dynamics in Catalysis, Spectroscopy and Theory
  • Metabolomics and Lipidomics
  • Metals in Biology

http://facebook.com/expbio/videos/1665942490092837/


ASBMB | ASBMB Facebook | ASBMB Twitter | ASBMB Youtube | ASBMB LinkedInEB | EB Facebook | EB Twitter | EB Youtube | San Diego Convention Center

Ohio Valley Chapter (OVC) of the Society for Environmental Toxicology and Chemistry (SETAC) Regional Meeting – New Tools and Technologies: Human Health and Ecological Risk Assessment

toxicology measurement assay test kit toxicology measurement assay test kit


Diapharma is planning to attend the Ohio Valley Chapter (OVC) of the Society for Environmental Toxicology and Chemistry (SETAC) Regional Meeting this year. Please click here to schedule a meeting with us or email us directly.


About the Ohio Valley SETAC Meeting

The Ohio Valley Chapter of the Society for Environmental Toxicology and Chemistry (SETAC) regional meeting will be held April 20, 2018, at the Ohio State University Museum of Biological Diversity, 1315 Kinnear Rd, in Columbus, OH. Ohio Valley SETAC is a regional professional meeting of toxicologists, chemists, environmental engineers, and risk assessors and policy experts.


Society for Risk Analysis Ecological Risk Assessment Specialty Group

In 2018, Ohio Valley SETAC will partner with the Society for Risk Analysis Ecological Risk Assessment Specialty Group to focus on recent innovations that have broader toxicological and risk assessment implications. This joint regional meeting will feature plenary sessions in the morning, followed by an afternoon poster session and student poster competition.

“New Tools and Technologies: Human Health and Ecological Risk Assessment” is the meeting theme. Presentations on all topics in environmental toxicology and chemistry, including environmental policy will be considered.


About the Ohio Valley SETAC

toxicology measurement assay test kit

The Ohio Valley Chapter (OVC) is a regional chapter of the Society for Environmental Toxicology and Chemistry (SETAC) North America and consists of a group of volunteers dedicated to improving regional network of scientists, regulators and educators. Founded in 1984 originally as the Indiana/Kentucky/Ohio (IKO) SETAC chapter, OVC SETAC organizes small regional scientific conferences for us to meet our neighbors and potential collaborators, become familiar with advances in many environmental fields, and give opportunities (and sometimes money!) to students to present their work and meet new mentors.

OVC SETAC has grown close to 100 members from Ohio, Kentucky, Indiana, Michigan and West Virginia including several corporate affiliates, and it is now offering professional development workshops along with discussions of topics that are timely and of both regional and national interest. Services to students in the region have expanded providing an outlet for presentation of student research.


toxicology assay test kitAbout SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a not-for-profit, global professional organization comprised of some 6,000 individual members and institutions from academia, business and government. Since 1979, the Society has provided a forum where scientists, managers and other professionals exchange information and ideas on the study, analysis and solution of environmental problems, the management and regulation of natural resources, research and development, and environmental education.

SETAC’s founding principles are:

  • Multidisciplinary approaches to solving environmental problems
  • Tripartite balance among academia, business and government
  • Science-based objectivity

SETAC | Ohio Valley SETACFacebook | Twitter | OSU MBD

Society of Environmental Toxicology and Chemistry (SETAC) Rocky Mountain Regional Chapter

toxicology measurement assay test kit toxicology measurement assay test kit toxicology measurement assay test kit


toxicology measurement assay test kit

Diapharma will be attending the Society of Environmental Toxicology and Chemistry (SETAC) Rock Mountain Regional Chapter meeting this year. Please click here to schedule a meeting with us or email us directly.


About RM SETAC

Rocky Mountain SETAC is a non-profit regional chapter of the Society of Environmental Toxicology and Chemistry (SETAC). RM SETAC serves the Rocky Mountain region states of Colorado, Montana, Utah, and Wyoming.


About SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology.

SETAC publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


SETACSETAC Rocky Mountain | Fort Collins Science Center

University of North Carolina at Chapel Hill Center for Thrombosis and Hemostasis 9th Symposium on Hemostasis

Thrombosis and Hemostasis Thrombosis and Hemostasis Thrombosis and Hemostasis


Diapharma is planning to attend the University of North Carolina at Chapel Hill Center for Thrombosis and Hemostasis 9th Symposium on Hemostasis meeting this year. Please click here to schedule a meeting with us or email us directly.


The UNC Hemophilia and Thrombosis Center is committed to education, research, health, and quality of life of people with bleeding and clotting disorders as well as Hereditary Hemorrhagic Telangiectasia. Over the past seventy years, the department has made numerous contributions to the understanding and treatment of hemophilia and thrombosis. The Center has its roots in the 1940s when Drs Brinkhous, Wagner, Landell, Graham and others began their pioneering investigations in hemophilia. The Center is currently recognized as an International Hemophilia Training Center by the World Federation of Hemophilia. It is one of 16 Centers funded by the National Heart, Lung, and Blood Institute as part of a Hemostasis-Transfusion Medicine Network. It is one of 5 thrombosis centers piloted by the Centers for Disease Control to find out how to best provide treatment and preventative care to people with thrombosis or thrombophilia.

Thrombosis and Hemostasis   Thrombosis and Hemostasis


UNC | SOM | Hemophilia and Thrombosis Center

European Association for the Study of the Liver (EASL) International Liver Forum and Congress™ (ILC 2018)

hepatology liver biomarker assay test kit


Diapharma is planning to attend the European Association for the Study of the Liver (EASL) International Liver Forum and Congress™ (ILC 2018) this year. Please click here to schedule a meeting with us or email us directly!


About EASL

In 1996, the European Association for the Study of the Liver (EASL) began as a group of hepatologists from European countries who came together to share information. EASL evolved into a major European Association with international influence dedicated to the liver and liver disease. EASL has members from all over the world and provides an annual platform, The International Liver Congress™ for  liver experts to meet and discuss latest scientific research. EASL has given rise to many international clinical trials and research collaborations.

EASL’s mission is to beat liver disease by being the home of hepatology so that all who are involved with liver disease can realize their full potential to cure and prevent it.

EASL promotes research in the science of liver disease (Hepatology), provides state-of-the-art education for physicians and scientists, fosters public awareness of liver diseases and their management, acts as an advisor to European Health authorities, facilitates scientific exchanges and catalyzes European multi-center controlled trials, supports young investigators to ensure that the liver remains at the forefront of research.

EASL hosts the annual International Liver Congress™, a range of other scientific events, grants fellowships, mentorships and bursaries, lobbies at the EU commission, produces Clinical Practice Guidelines, offers online education, apps and many other initiatives. EASL members are entitled to reduced registration fees to the annual EASL meeting, The International Liver Congress™ and all EASL meetings throughout the year.


About the ILC

The International Liver Congress™ (ILC) is the annual EASL meeting, and the flagship event in EASL’s educational calendar.

Every year in April, scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology and radiology and imaging come together from around the world to learn about the latest in liver research.

Specialists share recent data, present studies and findings, and discuss the hottest topics on liver disease. The annual Congress attracts around 10,000 delegates and 250 media representatives from all over the world making this a truly international networking opportunity!

The International Liver Congress™ 2018 will take place 11-15 April 2018 at the Paris expo Porte de Versailles – Pavillon 7, Paris, France.


EASL | ILC | Facebook | Twitter | YouTube | LinkedIn

Society of Environmental Toxicology and Chemistry Midwest Chapter (26th Annual Midwest SETAC) – Sustaining Ecosystem Services

toxicology measurement assay test kit toxicology measurement assay test kit


Diapharma is planning to attend the Society of Environmental Toxicology and Chemistry Midwest Chapter (26th Annual Midwest SETAC) – Sustaining Ecosystem Services meeting this year. Please click here to schedule a meeting with us or email us directly.


The 26th Annual Meeting of the Midwest Chapter of the Society of Environmental Toxicology and Chemistry (MWSETAC) will take place April 9, 2018 with the theme of “Sustaining Ecosystem Services.” Presentations will occur in sciences relevant to Midwest SETAC (see below). Membership in the society is not required to attend or present.

Sustaining Ecosystem Services Topics

  • Analytical chemistry of contaminants
  • Behavioral toxicology
  • Biomarkers
  • Climate assessments
  • Cumulative risk assessment & management
  • Ecological risk assessment and field studies
  • Ecological studies of contaminants
  • Effects of pollutants on population growth & biological integrity
  • Effluent toxicity
  • Emerging contaminants of concern
  • Endocrine disruptors
  • Environmental modeling case studies
  • Fate and transport of contaminants
  • Health risks from air pollution
  • Linking human health to environmental pollution
  • Measuring vs. modeling of contaminants
  • Molecular/cellular toxicology
  • Monitoring of pollutants in air, water, sediment
  • Nanotoxicity
  • Persistent & bioaccumulative chemicals
  • Regional sustainability
  • Sediment toxicology
  • Toxicity testing
  • Wildlife toxicology

toxicology measurement assay test kit

About Midwest SETAC

Midwest SETAC is a non-profit (organization dedicated to the use of multidisciplinary approaches to examine the impacts of chemicals and technology on the environment. The chapter is operated as an independent affiliate of the international SETAC organization.

Midwest SETAC promotes research, education, training and development of the environmental sciences and encourages scientists to disseminate information on environmental toxicology and chemistry. Midwest SETAC sponsors scientific and educational programs to provide a forum for communication among professionals in government, business, academia and other segments of the environmental science community involved in the use, protection and management of the environment.

Protecting water resources from overuse and impairment presents a major challenge for meeting human, environmental, economic, and social needs for sustainable development. This year’s meeting theme highlights the diversity of challenges associated with water resources in urban, peri-urban, and rural settings. Presentations (platform or poster) are welcome in all areas of science applicable or relevant to Midwest SETAC, and we especially encourage topics that speak to the overall meeting theme.

SETAC’s mission is to:

  • Promote research, education, training and development of the environmental sciences.
  • Encourage interactions among environmental scientists and disseminate information on environmental toxicology and chemistry.
  • Sponsor scientific and educations programs and provide a forum for communication among professionals in government, business, academia and other segments of the environmental science community involved in the use, protection and management of the environment

SETAC | Midwest SETAC | Facebook | Loyola University Chicago

Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease

NAFLD M30 Apoptosis Necrosis ELISA Assay Test Kit NAFLD M30 Apoptosis Necrosis ELISA Assay Test Kit NAFLD M30 Apoptosis Necrosis ELISA Assay Test Kit

Diapharma is planning to attend the Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease meeting this year. Please click here to schedule a meeting with us or email us directly.

Emerging Trends Conference Emerging Trends in Non Alcoholic Fatty Liver Disease

liver assay test kit


ABOUT AASLD

The American Association for the Study of Liver Diseases (AASLD) is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists to bring together those who had contributed to the field of hepatology.


ABOUT NAFLD

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of chronic liver disease requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which however may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality.

There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design.


AASLD | Emerging Trends in Non-Alcoholic Fatty Liver Disease | Facebook | Twitter | YouTube | Instagram | Hyatt Regency Washington on Capitol 

Society of Toxicology (SOT) 57th Annual Meeting and ToxExpo

Toxicology Assay Measurement Test Kit Toxicology Assay Measurement Test Kit


Toxicology Assay Measurement Test Kit

Diapharma is planning to attend the Society of Toxicology (SOT) 57th Annual Meeting and ToxExpo meeting this year. Please click here to schedule a meeting with us or email us directly.


Toxicology Assay Measurement Test KitThe SOT 57th Annual Meeting and ToxExpo will be held in San Antonio, Texas in 2018. Joining you are more than 6,500 toxicologists from around the world who will be sharing the latest research in the field, making connections and renewing friendships, and arranging collaborations with organizations and individuals.

SOT is continually evolving the meeting to ensure that participants can discover all of the advances in toxicology from the past year and can forge relationships to progress the field in the coming years. One of the enhancements to this year’s meeting is the introduction of all-day Poster Sessions. The posters will be on display all day, and the poster presenters will be available during one of four time blocks to discuss their work; the author attended times for each Poster Session are listed throughout the Poster Session information in the SOT Program, in the SOT Mobile Event App, and on the SOT Annual Meeting website.

Thank you for joining SOT for this exploration of cutting-edge research and experiences in toxicology.


Toxicology Assay Measurement Test KitAbout SOT

Founded in 1961, the Society of Toxicology (SOT) is a professional and scholarly organization of scientists from academic institutions, government, and industry representing the great variety of scientists who practice toxicology in the US and abroad. The Society’s mission is to create a safer and healthier world by advancing the science and increasing the impact of toxicology.

The society organizes an annual meeting (usually in the early spring) and several smaller colloquia via its special interest sections and groups. It publishes the journal Toxicological Sciences, the newsletter Communiqué, as well as public position papers and guidelines on conflicts of interest in toxicology.


SOT | Facebook | TwitterHenry B González Convention Center | San Antonio

4th Biennial Summit of the Thrombosis and Hemostasis Societies of North America (THSNA) 2018

 


Diapharma will be attending and exhibiting at the Thrombosis and Hemostasis Societies of North America (THSNA) 2018 meeting this year. Please click here to schedule a meeting with us or email us directly.


THSNA will hold its 4th comprehensive scientific meeting dedicated to thrombosis and hemostasis issues in San Diego, California from March 8-10, 2018 including a Pre-Summit Workshop Day on March 7. This summit is a collaboration of the fifteen leading non-profit organizations in both fields. THSNA 2018 will provide a focused forum for over 1,500 attendees with an interest in bleeding and clotting disorders to network, learn, and share across disciplines and disease states.


About THSNA

Thrombosis and Hemostasis Societies of North America (THSNA the “Societies”), came into existence in 2013. THSNA is the parent organization for the biannual THSNA Summit. THSNA the Societies is a federation of 15 of the leading non-profit organizations in hemostasis and thrombosis in the US, Canada and Mexico. THSNA is becoming a premier forum for hemostasis and thrombosis in North America.

In addition to directing biennial THSNA educational summits, the THSNA mission is to advance the prevention, early diagnosis, management, and cure of bleeding and clotting disorders. THSNA advocates for federal, pharmaceutical and private funding for clinical and basic research in hemostasis and thrombosis, educational programs, working with health care policy makers and government agencies to promote public health policies, promoting publications, and nurturing and mentoring of the next generation of hematologists, nurses, pharmacists, laboratory investigators, basic scientists and other specialists in the field of thrombosis and hemostasis.


THSNA | Twitter | Marriot MarquisSan Diego Gaslamp Quarter

Thank You for Visiting Us at SETAC

THANK YOU!

We enjoyed speaking with you at SETAC 2017    

Thank you for taking a few minutes to discuss with us the features of the TECO vitellogenin ELISA with mucus collection set as well as the related cortisol and HA assays.

These ecotox ELISAs are unique in that they allow you to sample fish using a validated epidermal mucus collection set, enabling you to more easily collect samples in the field or perform time course studies.

Read more here or contact your Territory Manager for pricing and ordering info.

 


Ecotox ELISAs Available from Diapharma

Vitellogenin Protein

  • mucus, blood or homogenate

Endocrine disruptor analysis

 

Cortisol Protein

  • mucus

Environmental stress analysis

vitellogenin ELISA measurement assay test

Hyaluronic Acid (HA)

  • mucus

Liver toxicity analysis

 

For research use only in the U.S. and Canada

vitellogenin ELISA measurement assay testThank you for making us your trusted resource for 20 years!

Watch the video

 

 

 


ML-00-00328Rev01

American Association for the Study of Liver Disease (AASLD) – Industry Colloquium: Novel Targets and Therapies in Liver Disease

 


Diapharma is planning to attend the American Association for the Study of Liver Disease (AASLD) Industry Colloquium: Novel Targets and Therapies in Liver Disease meeting this year. Please click here to schedule a meeting with us or email us directly.


This conference will focus on therapeutic developments from the perspective of clinical and translational investigators and regulatory professionals. Participants will gain insight into novel therapies and the regulatory landscape for a variety of liver diseases with robust therapeutic pipelines. In addition, attendees will have opportunities to discuss the latest on biomarkers and the design of treatment studies for these diseases.

  • Therapeutic developments from the perspective of clinical and translational investigators and regulatory professionals
  • Novel therapies and the regulatory landscape for a variety of liver diseases with robust therapeutic pipelines
  • The latest in biomarkers and the design of treatment studies for these diseases

 

  • Session I: NASH
  • Session II: Cholestatic Liver Diseases
  • Session III: Portal HTN
  • Session IV: Cirrhosis
  • Session V: Hepatocellular Carcinoma
  • Session VI: Hepatitis B

AASLD | FacebookTwitter | LinkedIn | YouTube | Instagram | Bethesda North Marriott

Thank You for Visiting Us at The Liver Meeting

THANK YOU!

We enjoyed speaking with you at The Liver Meeting®

 

liver meeting cytokeratin 18 biomarker ELISA Thank you for taking a few minutes to discuss with us the latest news on M30/cytokeratin 18 (CK18) and other serum liver biomarkers.

These mechanistic biomarkers can provide important insights into the biologic processes in liver diseases and liver injury. Discover the K18 hepatocyte biomarker used in drug development research.

Read more here or contact your Territory Manager for pricing and ordering info.


liver meeting cytokeratin 18 biomarker ELISA

 

Biomarkers Available from Diapharma

 

Caspase – Cleaved Keratin 18

(ccK18: M30 ELISA)

Hepatocyte apoptosis

 

Keratin 18

(cleaved and uncleaved: M65 ELISA)

Hepatocyte apoptosis and necrosis

 

Hyaluronic Acid (HA)

Liver fibrosis and loss of liver function

 

α-GST

Drug Development

– Acute kidney and liver injury

– Highly sensitive & specific biomarker

 

Collagen IV

Liver & kidney injury biomarker

Complimentary to α-GST & π-GST

 

Adiponectin, Proinsulin, & Leptin

Diabetes, metabolic syndrome,

endocrine factors

 

For research use only in the U.S. and Canada

 

Thank you for making us your trusted resource for 20 years!

Watch the video

liver meeting cytokeratin 18 biomarker ELISA

 

liver meeting cytokeratin 18 biomarker ELISA


 

8948 Beckett Rd 45069 West Chester US

ML-00-00323Rev01

A Comprehensive Endocrine Disruptor Screening Program: A VTG ELISA that Preserves the Fish

Vitellogenin Fish ELISAs

Diapharma invites you to join our webinar:

A Comprehensive Endocrine Disruptor Screening Program:
A VTG ELISA that Preserves the Fish

Webinar Details

Date: Wednesday, December 13, 2017
Time: 11am EST (NA) / 4pm GMT (UK) / 5pm CET (EU-Central)
Duration: 60 minutes
Featured Speaker

Vitellogenin Fish ELISAsVitellogenin (VTG) in fish is an estrogen-induced yolk precursor protein mainly synthesized in the liver, prior to deposition in the maturing oocytes, where it is split into the yolk proteins lipovitellin 1, lipovitellin 2 and phosvitin. These proteins provide nourishment for developing embryos.

Due to its estrogen-dependent synthesis, vitellogenin is considered to be a hallmark “female protein”. Since male and juvenile fish do not produce much estrogen, their vitellogenin levels are quite low, and non-physiological induction of vitellogenin in these fish is thought to indicate estrogen mediated endocrine disruption. Therefore, vitellogenin determination is one of the core endpoints in screening and testing for endocrine disrupting chemicals standardized in the OECD Guidelines for the testing of chemicals for estrogenic activity.

Historically, vitellogenin measurement has been limited to blood or whole body homogenate (WBH) samples – both of which are sample types that require invasive and destructive treatment of fish. Recent studies, however, have shown that vitellogenin can also be detected in the epidermal mucus of fish, though the VTG concentration there can be significantly lower compared to that in blood or WBH. Thus, suitable methods for mucus collection and vitellogenin determination in mucus are required.

The TECO Vitellogenin System is unique in that it includes a validated mucus collection set for gentle and effective mucus sampling adapted to a highly sensitive laboratory ELISA test. The assay offers the following advantages:

  • A simple, standardized sampling technique
  • A non-invasive and non-destructive sampling procedure
  • A defined sample matrix free of protease contamination from non-target tissues or lymphatic fluid
  • An optimal procedure for obtaining vitellogenin samples during field testing

This webinar will describe the background associated with the development of this assay, how it can be used as a part of a comprehensive endocrine disruptor screening program and future directions utilizing fish mucus samples to measure related endpoint proteins.

Keywords: ELISA, Environmental Toxicology, Environmental Monitoring

Our Speaker

Vitellogenin Fish ELISAs


Reinhard Möller, PhD, Sales & Marketing Manager, TECOmedical AG

Dr. Möller received his PhD from the University of Goettingen/Germany where he studied agriculture and worked on developing different ELISA assays related to animal endocrinology. He has extensive cell culture and immunology experience as well as in-depth knowledge of assay development and scale-up. He currently works to promote the implementation and use of the TECO Vitellogenin Fish ELISAs which are ideal assays for labs researching endocrine disruptor chemicals (EDCs), performing REACH chemical testing or assessing EDCs as a part of a regulatory framework. He has experience working with large reference labs, government agencies, research labs and industry labs.

This program is intended for:

  • Research scientists working in the fields of ecotoxicology or endocrine disruptor chemicals research
  • Industry representatives evaluating environmental toxicology effects of workplace chemicals or pesticides
  • Laboratory professionals at waste-water treatment facility testing plants
  • Technologists and supervisors at reference laboratories performing environmental monitoring studies
  • Government and regulatory personnel establishing and enforcing environmental protections policies

Register here:

http://xtalks.com/Endocrine-Disruptor-Screening-Program-VTG-ELISA.html or at diapharma.com

Our Partners

Vitellogenin Fish ELISAs

TECOmedical is a Swiss-based company with subsidiaries throughout Europe. They are a leading provider of CE-marked in vitro specialty assays in the areas of medical and veterinary diagnostics, pharmaceutical biosafety, and environmental testing. They also develop and evaluate new test systems in collaboration with thought leaders or as a service to pharmaceutical, CRO or research organizations.

Vitellogenin Fish ELISAs

Diapharma is a US-based distributor of specialty diagnostic and research assays for the fields of hemostasis & thrombosis, platelet function testing, toxicology and environmental monitoring. With a team of dedicated technical and scientific product managers, Diapharma is able to bring leading assays from the EU to US market. They specifically partner with TECOmedical to provide the full portfolio of vitellogenin ELISA assays to US and Canadian customers.

Products from TECOmedical are for research use only in U.S. & Canada

ML-00-00324Rev01

59th American Society of Hematology (ASH 2017) Annual Meeting & Exposition

hematology hemostasis assay test kit


Diapharma will be attending ASH this year. Please click here to schedule a meeting with us or email us directly.hematology assay test kit


About ASH 2017

The American Society of Hematology (ASH) invites you to its 59th annual meeting. The ASH Annual Meeting is the world’s premier event in malignant and non-malignant hematology. The meeting provides an invaluable educational experience and an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field, as well as a global community of more than 20,000 hematology professionals from every subspecialty.




About ASH

hematology assay test kit

The American Society of Hematology (ASH) is the world’s largest professional society concerned with understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. ASH is dedicated to helping hematologists conquer blood diseases.

The field of hematology has experienced a recent surge in progress thanks to novel technologies, mechanistic insights, and cutting-edge therapeutic strategies that have driven significant and meaningful advances in the quality of care. These foundational insights are reframing modern research with the continued goal of improving outcomes and discovering cures for the most challenging hematologic diseases.

Whereas certain blood disorders have benefited from the tremendous progress in clinical research and development of new therapies, other areas have continuing challenges such as disease heterogeneity and the complex combinations of genetic drivers that have evaded effective treatment to date. A wide variety of blood-related diseases – from malignancies such as lymphoma and leukemia, to non-malignant diseases including hemoglobinopathies, blood platelet, and coagulation disorders, including orphan diseases of the hematopoietic system – continue to be associated hematology assay test kitwith significant morbidity and mortality and demand attention to reduce their burden and improve the quality of care worldwide.

Today, the research community looks to emerging technologies and tools in the areas of genetics and epigenetics, gene therapies, and regenerative medicine to identify areas that have strong potential to make a dramatic impact on patient care across a range of diseases.

The ASH agenda serves as a roadmap for the prioritization of research support across the hematology community, including recommendations for dedicated resources from funding agencies and foundations that will equip researchers today and in the future to make truly practice-changing discoveries. These specific and critically important research questions must be answered to gain the insights that will launch the field into the next generation of care for hematologic conditions.

ASH publishes Blood, The Hematologist, ASH Clinical News, ASH Self-Assessment Program, and the Hematology ASH Education Program.


ASH | ASH2017 | Twitter | Facebook | YouTube

2018 NASH-TAG Conference


NASH ELISA assay test kit


Diapharma will be attending the 2018 NASH-TAG Conference this year. Please click here to schedule a meeting with us or email us directly.


NASH-TAGFacebook | Twitter | LinkedIn | The Chateaux Deer Valley

Diapharma National Sales Meeting (November 2017)

Society of Environmental Toxicology and Chemistry (SETAC) North America 38th Annual Meeting

toxicology assay test kit toxicology assay test kit toxicology assay test kit


Diapharma will be attending and exhibiting at the Society of Environmental Toxicology and Chemistry (SETAC) North America 38th Annual Meeting this year. Please click here to schedule a meeting with us or email us directly.

toxicology assay test kit


toxicology assay test kitAbout SETAC

The Society of Environmental Toxicology and Chemistry (SETAC) is a not-for-profit, global professional organization comprised of some 6,000 individual members and institutions from academia, business and government. Since 1979, the Society has provided a forum where scientists, managers and other professionals exchange information and ideas on the study, analysis and solution of environmental problems, the management and regulation of natural resources, research and development, and environmental education.

SETAC’s founding principles are:

  • Multidisciplinary approaches to solving environmental problems
  • Tripartite balance among academia, business and government
  • Science-based objectivity


SETAC Postcard | SETAC | SETAC 2017Twitter | Facebook | YouTube | Minneapolis Convention Center

The Liver Meeting® 2017 – The 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

 liver biomarker CK18 apoptosis assay test kit


Diapharma will be attending and exhibiting at The Liver Meeting 2017.  See what’s new in CK18 biomarkers for NASH and AH research at Booth 543. CK18 plays a role in cell death. Explore M30/M65 ELISAs for measuring hepatocyte apoptosis and cell death non-invasively. Diapharma offers an extensive line of liver injury biomarkers, including K18, HA, α-GST, and Collagen IV. Research use only. Please click here to schedule a meeting with us or email us directly.


liver assay test kitThe The Liver Meeting® brings together scientists and healthcare professionals involved or interested in preventing and curing liver disease. During The Liver Meeting® 2017, more than 9500 hepatologists and hepatology health professionals from across the nation and around the world will gather in Washington, DC, to exchange the latest liver disease research, discuss treatment outcomes, and interact with colleagues at the annual, must-attend event in the science and practice of hepatology.

The The Liver Meeting® 2017 – The 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) covers topics such as:

  • Clinical Liver Transplantation and Liver Surgery
  • Clinical Hepatobiliary Neoplasia and Liver Imaging
  • Human Cholestatic and Autoimmune Liver Diseases
  • Portal Hypertension and Other Complications of Cirrhosis
  • Hepatotoxicity
  • Steatosis and Steatohepatitis
  • Viral Hepatitis C
  • Metabolic and Genetic Disease
  • Inflammation and Immunobiology
  • Hepatitis B
  • Pediatric Hepatology
  • Acute Liver Failure and Artificial Liver Support
  • Liver Fibrogenesis and Non-Parenchymal Cell Biology
  • Experimental Liver Transplantation and Liver Surgery
  • Cell and Molecular Biology
  • Experimental Hepatobiliary Neoplasia
  • Biliary Physiology, Transport, Cholangiocyte Biology, Experimental Cholestasis

 


Invitation Postcard | Liver Meeting | AASLD | Twitter | Facebook | YouTube | Walter E. Washington Convention Center | Washington.org

44th Canadian Ecotoxicity Workshop (CEW 2017)


Diapharma will be attending Canadian Ecotoxicity Workshop (CEW 2017). Please click here to schedule a meeting with us or email us directly.

Formerly known as the Aquatic Toxicity Workshop (ATW), CEW is Canada’s predominant annual meeting in the field of ecological toxicology and related disciplines. It provides the opportunity to share information on current and emerging topics of regional, national and international importance related to contaminants in ecosystems, both aquatic and terrestrial. Participants include students, academics, government scientists and regulators, environmental consultants and industry representatives.

The Aquatic Toxicity Workshop (ATW) became a registered Canadian corporation in 1984. In 2014, the Board of Directors voted to modify the operating name to Canadian Ecotoxicity Workshop (CEW) to reflect the broader scope of ecological toxicology issues addressed at the annual workshop. The corporate name remains as The Canadian National Aquatic Toxicity Workshop.

CEW is held annually in a different region of Canada to draw interest among a wider group of ecotoxicologists and to gain a national perspective of current and emerging issues. These three-day workshops are traditionally held in the fall, where 200-400 participants take in more than 150 platform and poster presentations.

 

19th Mayo Bleeding and Thrombosing Diseases Conference

bleed thrombosing assay test kit bleed thrombosing assay test kit


bleed thrombosing assay test kitDiapharma will be attending Mayo Bleeding and Thrombosing Diseases Conference 2017. Please click here to schedule a meeting with us or email us directly. The conference will include presentations from several faculty at Mayo Clinic from the Division of Hematology, Department of Internal Medicine and the Division of Hematopathology, Department of Laboratory Medicine and Pathology.



Mayo | Mayo Civic Center | Twitter | Facebook | YouTube

XXVI International Society of Thrombosis and Hemostasis (ISTH) Congress 2017 and 63rd Annual Scientific and Standardization Committee (SSC)

thrombosis hemostasis assay test kit

Diapharma will be attending and exhibiting at ISTH 2017. Please click here to schedule a meeting with us or email us directly.


ISTH 2017

Through an extensive lineup of educational sessions, poster and oral communications, state-of-the-art lectures, medical industry exhibits and professional networking opportunities, the Congress promotes important scientific discourse and advancement.

The ISTH 2017 Congress will be the foremost global meeting in thrombosis, hemostasis and vascular biology, and will be attended by thousands of the world’s experts. You will gain insights into the most recent scientific advances, exchange the latest research and discuss how clinical applications can be best applied to improve the lives of patients around the world.  Join Diapharma at ISTH 2017 and together, we will transcend scientific boundaries!

thrombosis hemostasis assay test kit

Areas in thrombosis and hemostasis at the ISTH 2017 meeting will include:

Atherothrombosis & Stroke

  • Atherothrombosis & Stroke
  • Atherosclerosis
  • Cardiovascular Risk Factors
  • Ischemia-reperfusion Injury
  • Myocardial Infarction
  • Peripheral Vascular Disease
  • Stroke

Coagulant & Anticoagulant Mechanisms

  • Animal Models in Thrombosis & Hemostasis
  • Coagulation Factors and Inhibitors
  • Coagulation Proteins Beyond Hemostasis
  • Contact Pathway
  • FVIII/IX
  • Protein C Pathway
  • Regulation of Coagulation
  • Tissue Factor Pathway

Coagulation Signaling & Immunity

  • Complement and Hemostatic System
  • Hemostatic Signaling
  • Infection & Hemostatic Factors
  • Inflammation and Sepsis
  • Innate & Adaptive Immunity
  • Platelets & Inflammation
  • Protease Activated Receptors

Diagnostics and OMICs

  • Bioinformatics & Systems Biology
  • Biomarkers of Thrombosis & Haemostasis
  • Epigenetics
  • Laboratory Diagnostic
  • Nanotechnology
  • OMICs

Fibrinolysis & Proteolysis

  • Cellular & Tumor Proteases
  • Coagulation and Cancer
  • Fibrinogen and Factor XIII
  • Fibrinolytic Factors and Inhibitors
  • Thrombolytic Therapy

Hemorrhagic Disorders, Hemophilia

  • Acquired Hemorrhagic Coagulation Disorders
  • Disseminated Intravascular Coagulation
  • Hemophilia – Basic
  • Hemophilia – Clinical
  • Hemophilia Gene Therapy
  • Hemorrhagic Disorders, Pediatric Aspects
  • Management of Bleeding & Trauma
  • Novel Biotherapeutics in Hemophilia
  • Rare Bleeding Disorders
  • VWF and von Willebrand Disease

Management of Thromboembolism

  • Arterial Fibrillation
  • DOACs
  • Heparins & Heparinoids
  • Novel Anticoagulants
  • Post-thrombotic Syndrome
  • Pregnancy Complications
  • Thromboembolism, Pediatric Aspects
  • Vitamin K Antagonists

Pathogenesis of Thromboembolism

  • Antiphospholipid Syndrome
  • Cancer-Associated Thrombosis
  • Genetic Risk Factors of Thrombosis
  • Hemostasis & Organ Dysfunction
  • Microparticles
  • Thrombophilia

Pediatrics

  • Diagnosis and management of inherited bleeding disorders in children
  • Diagnosis and management of acquired bleeding disorders in children
  • Epidemiology of pediatric thrombosis
  • Diagnosis of pediatric thrombosis
  • Anticoagulant prophylaxis and treatment in children

Platelets – Basic

  • Megakaryotes & Thrombopoiesis
  • Platelet Antagonists
  • Platelets Beyond Hemostasis
  • Platelet Function and Interactions
  • Platelet Proteomics and Genomics
  • Platelet Receptors
  • Platelet Signaling

Platelets – Clinical

  • ADAMTS13/TTP
  • Antiplatelet Therapy
  • HIT and ITP
  • HUS/Thrombotic Microangiopathies
  • Platelet Disorders, Acquired
  • Platelet Disorders, Inherited
  • Platelets, Pediatric Aspects

Transfusion & Biotherapeutics

  • Blood Components, Production and Substitution
  • Cellular Therapies & Blood Cell Farming
  • Novel Biomolecules
  • Patient Blood Management
  • Safety & Inactivation of Blood Components

Vascular Biology & Angiogenesis

  • Angiogenesis & Vasculogenesis
  • Blood Cells and Vessel Wall
  • Endothelial Cell Signaling
  • Non-coding RNAs
  • Vascular Progenitor and Stem Cells

ISTHthrombosis hemostasis assay test kit

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live. The ISTH initiates and promotes education and outreach initiatives, research activities, scientific meetings, peer-reviewed publications, expert committees and the development of standards allowing a common language and approach to basic and clinical science all over the world.


ISTH History

In 1954, a small group of investigators used seed money from the National Heart, Lung and Blood Institute (NHLBI) to form the International Committee on Thrombosis and Haemostasis (ICTH).

The members were well-known for their contributions to the fields of blood coagulation and hemorrhagic disorders, so news about their group spread quickly within the scientific community.

Interest grew, and the ICTH began to consider expanding the scope of its mission. The number of scientists who wanted to attend its meetings increased each year, but because of its small size, the Committee could only accommodate a few attendees..


thrombosis hemostasis assay test kit



ISTH | ISTH 2017 | Twitter | FacebookYouTube

Diapharma National Sales Meeting (June 2017)

Biotechnology Innovation Organization (BIO) International Convention

biotech assay kit


Diapharma will be attending the Biotechnology Innovation Organization (BIO) International Convention this year. Please click here to schedule a meeting with us or email us directly.

BIO2017


BIO2About BIO

Biotechnology Innovation Organization (BIO) is the world’s largest trade association representing more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.



About the BIO International ConventionBIO

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO).

The first BIO International Convention was held in 1993 and attracted approximately 1,400 attendees. The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities. Past speakers include President George W. Bush, President Bill Clinton, Former Prime Minister of Great Britain and Northern Ireland Tony Blair, Michael J. Fox, Sir Elton John, Her Majesty Queen Noor of Jordan, and General Colin Powell, among many others. The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world’s largest biotechnology exhibition – the BIO Exhibition.The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.

BIO represents academic centers, state and regional biotech associations and service providers to the industry, including financial and consulting firms.


BIO | BIO2017 | Schedule | Twitter#BIO2017 | BIOtechNow | YouTubeSan Diego Convention Center

16th Annual World Preclinical Congress (WPC) 2017

WPC


Diapharma will be attending the 16th Annual World Preclinical Congress (WPC). Please click here to schedule a meeting with us or email us directly.


oncology assay kit oncology assay kit


WPC will feature conferences, symposia, short courses and a training seminar covering various topics in preclinical research.



WPC | Twitter | Westin Copley Place

International Society for Hyaluronan Sciences (ISHAS) 11th International Meeting

diapharma chromogenic clotting elisa assay test kit diapharma chromogenic clotting elisa assay test kit diapharma chromogenic clotting elisa assay test kit


Diapharma will be attending the International Society for Hyaluronan Sciences (ISHAS) 11th International Meeting. Please click here to schedule a meeting with us or email us directly!

diapharma chromogenic clotting elisa assay test kit

The ISHAS Hyaluronan 2017 Conference will honor the discoveries on the pathological regulation of hyaluronan metabolism, especially pertaining to cancer development. Hyaluronan 2017 will consist of 10 sessions, starting with a translational focus on the applications of hyaluronan and hyaluronidase in medicine and continue with topics on structure and metabolism, development and signal transduction, chronic inflammatory diseases, and cancer.


diapharma chromogenic clotting elisa assay test kitAbout ISHAS

The ISHAS mission

  • Advance knowledge on the structure, function and therapeutic application of hyaluronan and its role in the structure and function of the extracellular matrix and cells
  • Support scientific research on the hyaluronan molecule encompassing all 3 branches of medical sciences: basic, clinical and applied
  • Initiate, organize and administer meetings for scientific communication and cooperation on national, regional and international levels
  • Participate in organizing conferences, or organizing meetings, symposia and lectures that advance the objectives of the Society
  • Arrange for publication of scientific and other reports and other printed material for the dissemination of knowledge in its field of interest and make these available for the public
  • Arrange for cooperation between various individuals, groups and organizations to further the advancement of its fields of interest
  • Seek cooperation with other national and international organizations having similar objectives
  • Seek financial aid and support from individuals, organizations, corporations, national and international governments and governmental agencies and other organizations interested in the Society’s objectives and the support of its goals

ISHAS | InterContinental Cleveland

FDA Drug-Induced Liver Injury Annual Conference XVII

DILI drug induced liver injury biomarker ELISA assay test kit DILI drug induced liver injury biomarker ELISA assay test kit DILI drug induced liver injury biomarker ELISA assay test kit


Diapharma will be attending FDA Drug-Induced Liver Injury Annual Conference XVII. Please click here to schedule a meeting with us or email us directly!


University of Maryland | College Park Marriott

American Society of Clinical Oncology (ASCO) Annual Meeting 2017

 


Diapharma will be attending the American Society of Clinical Oncology (ASCO) 2017 meeting this year. Please click here to schedule a meeting with us or email us directly.


ASCO 2017

The Annual American Society of Clinical Oncology (ASCO) Meeting brings together over 30,000 oncology professionals from around the world. Educational sessions featured world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Science sessions presented the latest ground-breaking research in oral and poster format. The ASCO Annual Meeting is one of the largest educational and scientific events in the oncology community. The five-day event provides a venue for physicians and scientists to present research results to a global audience of oncology professionals. Clinical trial results and updates presented at ASCO’s Annual Meeting represent the extent of progress made each year in the fight against cancer.


ASCO

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. As the world’s leading organization of its kind, ASCO’s mission is to conquer cancer through research, education, and promotion of the highest quality patient care. ASCO’s vision is a world where cancer is prevented or cured, and every survivor is healthy.

Over five decades, ASCO and its members have established and advanced the field of modern clinical oncology. ASCO’s memberstogether with patients with cancer, patient advocates, and the policymakers, government agencies, and philanthropic organizations like the Conquer Cancer Foundation that have invested in vital research, have enabled and delivered these advances.


oncology assay kitJournal of Clinical Oncology

The Journal of Clinical Oncology is a peer-reviewed medical journal published 3 times a month by the American Society of Clinical Oncology. It covers research on all aspects of clinical oncology. All articles older than one year are freely available online.


ASCO offers several other educational resources for cancer physicians and other health care professionals in the field of clinical oncology. These resources include scientific meetings, educational conferences, professional workshops, and special symposia on issues of particular relevance and importance to clinical oncologists and researchers.

ASCO publishes numerous journals, books, newsletters, and online and multimedia resources including the Journal of Oncology Practice (JOP), the online-only open access Journal of Global Oncology (JGO), JCO Clinical Cancer Informatics and JCO Precision Oncology.



ASCO | ASCO2017 | ASCO Connection | Cancer.netTwitter | Facebook | YouTube

Ozark-Prairie Society of Environmental Toxicology and Chemistry (SETAC)

SETAC ecotox endocrine disruption vtg vitellogenin ELISA Assay Test Kit SETAC ecotox endocrine disruption vtg vitellogenin ELISA Assay Test Kit SETAC ecotox endocrine disruption vtg vitellogenin ELISA Assay Test Kit


Diapharma will be attending Ozark-Prairie Society of Environmental Toxicology and Chemistry (SETAC) this year. Please click here to schedule a meeting with us or email us directly!


SETAC ecotox endocrine disruption vtg vitellogenin ELISA Assay Test Kit

The Ozark-Prairie Regional Chapter of the Society of Environmental Toxicology and Chemistry (SETAC) provides a forum for scientists and students in the broad fields of Environmental Toxicology and Environmental Chemistry to exchange information pertinent to the Ozark-Prairie region and offers assistance and support to students entering these professions.

SETAC ecotox endocrine disruption vtg vitellogenin ELISA Assay Test KitSETAC ecotox endocrine disruption vtg vitellogenin ELISA Assay Test Kit

The Ozark-Prairie region consists of large portions of the central United States, including much of the Ozark Plateau, the “Corn Belt” and Great Plains. In recent years, chapter membership has included residents of Missouri, Iowa, Illinois, Oklahoma, Nebraska and the Dakotas.


OPRC | Google Site | SETACUSGS

27th Society of Environmental Toxicology and Chemistry (SETAC) Europe Annual Meeting

 


Diapharma will be attending the 27th SETAC Europe Annual Meeting this year. Please click here to schedule a meeting with us or email us directly.

toxicology assay test kit

Vitellogenin, Cortisol, Hyaluronic Acid 11-Ketotestosterone fish ELISA assay test kit

The TECOmedical team will be at the SETAC meeting in Brussels to present our unique TECO Mucus Detection System. We would like to invite you to visit our booth No.16 to discuss with us the opportunities this system may offer to your laboratory research.

The TECO Mucus Collection Set allows for non-invasive collection of multiple samples from individual fish. This in combination with validated TECO ELISA kits offers many advantages:

  • Animal friendly sampling procedure following the “Three R’s principle”
  • Method of choice for monitoring and ecotox testing
  • Additional sample matrix in fish to extend the test panel
  • Less labor intensive; easier to perform
  • Establishing individual profiles for Vitellogenin, Cortisol, Hyaluronic Acid and 11-Ketotestosterone in fish
  • Looking forward to meeting you at the SETAC Congress in Brussels at booth No.16!

 

Vitellogenin, Cortisol, Hyaluronic Acid 11-Ketotestosterone fish ELISA assay test kit

SETAC Europe Brussels is a 5-day event featuring a variety of training, networking and learning opportunities. You cannot miss this event if you are interested in emerging research, regulatory developments and the latest methodologies in environmental toxicology and chemistry. Between 2,000 and 2,500 scientists, assessors, regulators and managers from academia, business and government, representing an average of 60 countries, provides a unique networking opportunity and a chance for cross-collaboration long after the closing session.

SETAC Europe is a geographic unit (GU) of the Society of Environmental Toxicology and Chemistry (SETAC), established to promote and undertake activities of SETAC in Europe, and to support activities of SETAC in the Middle East and in Africa, SETAC’s newest GU.

SETAC Europe (SE) adheres to the mission and goals of the global Society of Environmental Toxicology and Chemistry and is dedicated to support the development of principles and practices for protection, enhancement and management of sustainable environmental quality and ecosystem integrity.



SETAC | SETAC 2017Twitter | Facebook | YouTube

Digestive Disease Week® (DDW) 2017

assay test kit


Diapharma will be attending the Digestive Disease Week® 2017 meeting this year. Please click here to schedule a meeting with us or email us directly.


assay test kit assay test kit


assay test kitAbout DDW 2017

Digestive Disease Week (DDW 2017) brings together researchers and physicians in the fields of hepatology, gastroenterology, gastrointestinal surgery and endoscopy. DDW 2017 will cover topics such as:

  • Liver disease
  • Diagnosis and treatment of gastrointestinal tract and liver disorders
  • Diseases and functions of the alimentary tract
  • Gastrointestinal Endoscopy


assay test kit

DDW | BlogTwitter | #DDW17 | Facebook | YouTube | McCormick Place

2nd International Workshop on NASH Biomarkers

NASH liver Biomarker ELISA assay test kit NASH liver Biomarker ELISA assay test kit


Diapharma will be attending the 2nd International Workshop on NASH Biomarkers this year. Please click here to schedule a meeting with us or email us directly.


About The International Workshop on NASH Biomarkers

NASH biomarker ELISA apoptosis necrosis cytokeratin 18

Following the success of the previous NASH Biomarker workshop, this abstract-driven workshop will provide a forum for in-depth discussion of the latest research results on biomarkers for NASH. The nature of the program will be interactive, stimulating international and cross-disciplinary interchange and debate.

The NASH Biomarkers workshop is co-organized by the Liver Forum and Expert Medical Events.

MEETING OBJECTIVES

  • Review the current regulatory landscape and gaps in regulatory science related to biomarker development for NAFLD
  • Review the gaps in evidence needed to qualify specific biomarkers for NAFLD
  • Stimulate collaborative science to accelerate biomarker development for NAFLD
  • Promote innovation in design and analytic approaches to biomarker development for NAFLD

NASH biomarker ELISA apoptosis necrosis cytokeratin 18


About NASH

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America and a growing contributor to liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which however may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality.

NASH diagnosis currently requires liver biopsy but there are no FDA-approved therapies for NASH. Therefore, there is need to develop better diagnostic and therapeutic strategies for subjects with NASH, targeting both those with early-stage disease as well as those with advanced liver fibrosis.

The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. In particular methods to identify the patients at risk for disease progression and the validation of endpoints that reflect meaningful changes in health status in this population are needed.


Expert Medical Events / NASH Biomarkers 2017 | Marriott Georgetown

Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2017

diapharma chromogenic clotting elisa assay test kit diapharma chromogenic clotting elisa assay test kit


Diapharma will be attending and exhibiting at Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2017. Please click here to schedule a meeting with us or email us directly!


About ATVB|PVD

In collaboration with the Council on Arteriosclerosis, Thrombosis and Vascular Biology, the Council on Peripheral Vascular Disease, and the Council on Functional Genomics and Translational Biology, the ATVB|PVD annual meeting includes diverse disciplines within the arteriosclerosis, thrombosis, vascular biology, peripheral vascular disease, vascular surgery, and functional genomics research communities that allow investigators to explore areas of cross-disciplinary interests.

The conference will especially appeal to scientists and clinicians in:

  • Cardiovascular Medicine
  • Cardiovascular Research
  • Cardiovascular Surgery
  • Clinical Cardiology
  • Endocrinology
  • Functional Genomics
  • Genetics
  • Hematology
  • Immunology
  • Molecular/cellular Biology
  • Physiology
  • Thrombosis Research
  • Vascular Biology
  • Vascular Medicine
  • Vascular Surgery

ATVB | PVDHyatt Regency Minneapolis

XXXth International Symposium on Technical Innovations in Laboratory Hematology (ISLH)

Hawaii_Convention_Center2


Diapharma will be attending the XXXth International Symposium on Technical Innovations in Laboratory Hematology (ISLH) this year. Please click here to schedule a meeting with us or email us directly.


ISLH 2017

The International Society for Laboratory Hematology (ISLH) and the North American Specialized Coagulation Laboratory Association (NASCOLA) cordially invite you to attend ISLH 2017, the XXXth International Symposium on Technological Innovations in Laboratory Hematology. Please join your laboratory hematology colleagues in Honolulu, Hawaii from May 4-6, 2017.



ISLH

ISLH

The International Society for Laboratory Hematology (ISLH), a non-profit organisation, was founded in 1992 by an international group of laboratory professionals in order to chart new directions for laboratory hematology.

ISLH had its origins back in 1984. Motivated to see laboratory hematology recognized as an independent discipline, Dr Berend Houwen organized meetings to bring together scientists, manufacturers, clinicians, and regulatory representatives to exchange ideas on technical innovations in laboratory hematology. The first meeting was an outstanding success and heralded the arrival of a new forum for dissemination of information from around the globe on laboratory hematology. The meeting became a must attend event on the calendar for hematology laboratorians culminating in the decision to form ISLH in 1992. ISLH now has near 900 members globally from over 50 countries.

ISLH has also been instrumental in standards and guidelines development in laboratory hematology. These include the publication in 2001 of the first flow based reference method for platelet counting and the publication in 2005 of The International Consensus Group for Hematology Review: Suggested Criteria for Action Following Automated CBC and WBC Differential Analysis. This publication gathered 20 leading hematology laboratorians from around the globe to share their views on slide review and feedback suggest it has been one of the most important laboratory hematology publications in the past 30 years.

ISLH has also expanded its repertoire of disciplines to cater for the growing needs of laboratory hematologists. Today ISLH addresses the following sub-disciplines with up-to-date symposia, research and journal reviews on:

  • Cellular Analysisijlh
  • Flow Cytometry
  • Hemostasis and Thrombosis
  • Molecular Diagnostics
  • Hematology Informatics
  • Hemoglobinopathies
  • Hemolytic Anemias
  • Point of Care Testing
  • Standards and Guidelines

IJLH

ISLH publishes “The International Journal of Laboratory Hematology” (IJLH). The journal provides an international forum for all new developments in the research and practice of laboratory hematology and includes invited reviews, full length original articles and correspondence.


ISLH | ISLH2017 | IJLHHawaii Convention Center

American Society for Apheresis (ASFA) 2017 Annual Meeting

Westin7


Diapharma will be attending the American Society for Apheresis (ASFA) 2017 Annual Meeting. Please click here to schedule a meeting with us or email us directly.


ASFA2017


Apheresis assay test kitAbout ASFA

The American Society for Apheresis (ASFA) is an organization of physicians, scientists, nurses, and allied health professionals whose mission is to advance apheresis medicine for patients, donors and practitioners through education, evidence-based practice, research and advocacy. ASFA represents a broad range of health care professionals involved in apheresis medicine including those practicing pathology, transplantation, hematology, oncology, neurology, rheumatology, nephrology, hepatology, gastroenterology, cardiology, and ophthamology. These health care providers are involved in the performance of therapeutic apheresis procedures including plasma exchange, red cell exchange, leukocytapheresis, plateletapheresis, photopheresis, LDL apheresis, and hematopoietic progenitor cell collection. ASFA also represents those physicians and allied health professionals involved in the collection of blood products from blood donors using apheresis instruments.

The major activities of ASFA are member driven and educational, including publication of the Journal of Clinical Apheresis Special Issue: Clinical Applications of Therapeutic Apheresis: An Evidence Based Approach, publication of Principles of Apheresis Technology Textbook, publication of Therapeutic Apheresis: A Physician’s Handbook, monthly apheresis educational webinar program and developing programming for the ASFA Annual Meeting.

ASFA was formed in 1982. It grew from the merger of two organizations, the Society of Hemapheresis Specialists (SHS) and the original ASFA. The SHS was formed by nursing and allied health personnel, who were responsible for performing the donor and therapeutic procedures and operating the various blood cell separators. It was formed provide educational and networking opportunities in the field of apheresis medicine that were not available and which were needed by the original members in order to advance the field. SHS became a national forum for the exchange of views and best practices and was the forerunner of the efforts directed toward apheresis practitioner certification.

The original ASFA developed from a physician-scientist symposia. It was originally developed for the purpose to present scientific research on donor and therapeutic apheresis topics. The first apheresis symposium was held in Chicago in 1979, and was the first of annual symposia. The subsequent symposia were named the ASFA Symposia. Most of the initial Officers and Board of Directors of ASFA presented at these symposia, from which the structure of the organization grew.

In addition to providing education in apheresis medicine for healthcare professionals, ASFA also now seeks to provide education to patients undergoing apheresis treatment.


ASFA | ASFA 2017 | FacebookWestin Beach Resort & Spa

2017 BioOhio Annual Conference and 30th Anniversary Celebration

 


Diapharma will be attending the BioOhio Annual Conference and 30th Anniversary Celebration this year. Please click here to schedule a meeting with us or email us directly.


About BioOhio

diapharma chromogenic clotting elisa assay test kit

BioOhio is a member-guided service that connects and supports Ohio’s bioscience community through networking, advocacy, events, talent, information, and cost savings. BioOhio represents over 330 members that employ over 100,000 Ohioans – from Ohio’s largest employers to emerging start-ups, schools & universities, research institutions, students, and individuals.

BioOhio is the lead organization for the bioscience community and the Ohio affiliate for global bioscience associations.

diapharma chromogenic clotting elisa assay test kit

Since 1988, BioOhio has held an Annual Conference to spotlight trends in Ohio’s growing bioscience industry.

The 2017 BioOhio Annual Conference will be a celebration of statewide growth in all areas of bioscience, from medical devices, pharmaceuticals, lab equipment, and regenerative medicine, to agricultural compounds, alternative fuels, wellness products, clinical research, digital health, and wearables.


BioOhio | Facebook | TwitterGreat Lakes Science Center

Experimental Biology (EB) / ASBMB

diapharma chromogenic clotting elisa assay test kit


Diapharma will be attending the Experimental Biology (EB) / ASBMB this year. Please click here to schedule a meeting with us or email us directly.

diapharma chromogenic clotting elisa assay test kit

diapharma chromogenic clotting elisa assay test kit


About Experimental Biology (EB)

Experimental Biology (EB) is an annual meeting comprised of over 14,000 scientists and exhibitors representing six sponsoring societies and multiple guest societies. The six host societies are:

  • American Association of Anatomists (AAA)
  • The American Physiological Society (APS)
  • American Society for Biochemistry and Molecular Biology (ASBMB)
  • American Society for Investigative Pathology (ASIP)
  • American Society for Nutrition (ASN)
  • American Society for Pharmacology & Experimental Therapeutics (ASPET)

This multidisciplinary, scientific meeting features plenary and award lectures, pre-meeting workshops, oral and posters sessions, on-site career services and exhibits of an array of equipment, supplies and publications required for research labs and experimental study.

General fields of study include anatomy, biochemistry and molecular biology, investigative pathology, nutrition, pharmacology, and physiology. EB is open to all members of the sponsoring and guest societies and nonmembers with interest in research and life sciences. The majority of scientists represent university and academic institutions as well as government agencies, non-profit organizations and private corporations.


diapharma chromogenic clotting elisa assay test kit

About The American Society for Biochemistry and Molecular Biology (ASBMB)

The American Society for Biochemistry and Molecular Biology (ASBMB) was founded in 1906. The roots of the society were in the American Physiological Society, which had been formed 20 years earlier.

ASBMB was originally called the American Society of Biological Chemists, before obtaining its current name in 1987. ASBMB’s mission is to advance the science of biochemistry and molecular biology through publication of scientific and educational journals, the organization of scientific meetings, advocacy for funding of basic research and education, support of science education at all levels, and by promoting the diversity of individuals entering the scientific workforce. The organization currently has over 12,000 members.

The American Society for Biochemistry and Molecular Biology publishes The Journal of Biological Chemistry, Molecular & Cellular Proteomics, and The Journal of Lipid Research and the monthly magazine ASBMB Today. ASBMB journals are peer-reviewed and cover research in the fields of microbiology, molecular genetics, RNA-related research, proteomics, genomics, transcription, peptides, cell signaling, lipidomics, and systems biology.

ASBMB hosts and sponsors numerous meetings each year. The annual meeting is held each April in conjunction with the Experimental Biology meeting. Additionally, themed special symposia are organized throughout the year.



ASBMB | ASBMB Facebook | ASBMB Twitter | ASBMB Youtube | EBEB Facebook | EB Twitter | EB Youtube | McCormick Place

Anticoagulation Forum 14th National Conference on Anticoagulation Therapy

anticoagulation assay test kit


Diapharma will be attending the AC Forum this year. Please click here to schedule a meeting with us or email us directly.


AC Forum 2017

With an expected attendance of over 900 professionals, our forum provides the largest venue for open discussion and education on advances in anticoagulant therapy and improved patient care.

The 3-day meeting offers attendees the unique opportunity to meet colleagues from around the world with wide-ranging research interests and expertise in the diagnosis and treatment of thrombotic disorders. Special lectures focusing on recent advances and important issues in anticoagulation therapy are featured, as well as small master classes, a “meet the experts” breakfast, poster presentations of original research, and exhibitors.

The conference is open to anyone in the medical field. Past attendees have been pharmacists, physicians and nurses who provide direct care in the field of anticoagulation. Since patients with anticoagulation needs interact with doctors in many fields, medical professionals from all disciplines are welcome and can benefit from the discussions and research presented.


anticoagulation assay test kitAC Forum

Evidence that the use of and indications for oral anticoagulation therapy were rapidly expanding; that oral anticoagulation therapy was not always well managed; and that serious adverse events were commonplace, caused the founding of the AC Forum. Evidence accumulated that the systematic, coordinated care provided by anticoagulation services, resulted in improved safety and efficacy of therapy leading to better patient outcomes.

In order to promote coordinated management of oral anticoagulant therapy, the Anticoagulation Forum was established as a community of physicians, nurses and pharmacists involved in the therapeutic modality of oral anticoagulation therapy and the management of thrombotic disorders. Through the process of information exchange, medical education and scientific investigation, the Anticoagulation Forum promotes professional development and strives to enhance the quality of anticoagulation care.

As the premier provider of education and an authoritative voice among anticoagulation professionals, it is the mission of the AC Forum to offer insight and expertise to those of you on the front lines. The goal of the AC Forum is to have a community where physicians, pharmacists and nurses can come to find the latest research, engage in educational programs, and find tools to evaluate and enhance their practice.

Founded 25 years ago, the Anticoagulation Forum is the largest peer organization of anticoagulant service providers in North America. AC Forum membership includes more than 9,500 physicians, nurses, and pharmacists representing over 2,800 anticoagulation services (clinics). AC Forum members directly support over 900,000 patients annually. As the premier provider of education and the authoritative voice among anticoagulation professionals, the AC Forum offers insight and expertise to those on the front lines.

The AC Forum Board of Directors is regularly relied upon for their expert opinion. Their contributions to research and guideline development have influenced the new landscape of anticoagulation therapy. The AC Forum flagship program, the Anticoagulation Centers of Excellence, embodies their commitment to the clinical application of evidence-based practices and improved patient outcomes.

The Anticoagulation Forum is a multidisciplinary nonprofit organization of health care professionals that will improve the quality of care for patients taking antithrombotic medications. The Anticoagulation Forum attempts to minimize the risk and maximize the benefit of strategies used for the prevention and treatment of thromboembolic disease.

The AC Forum has been an advocate for improved patient care through its endorsement of the use of an International Normalized Ratio (INR) to report prothrombin time results and with its strong support of point-of-care prothrombin time monitoring and the concept of patient self-testing and patient self-management. The AC Forum has been a supporter of home treatment of venous thromboembolism with low molecular weight heparin using anticoagulation clinics as the base for overseeing home treatment programs.



AC Forum | AC2017 | Twitter | JW Marriot LA

International Liver Congress™ 2017 (ILC 2017), the 52nd Annual Meeting of the European Association for the Study of the Liver (EASL)

International Liver Congress elisa assay test kit liver biomarker apoptosis diapharma chromogenic clotting elisa assay test kit liver biomarker


Diapharma will be attending The International Liver Congress™ 2017 (EASL 2017). Please click here to schedule a meeting with us or email us directly!


About ILC

The International Liver Congress™ (ILC) is the annual EASL meeting, and the flagship event in EASL’s educational calendar.


About EASL

diapharma chromogenic clotting elisa assay test kit liver biomarker

EASL 2017 is expecting approximately 10000 participants and is going to cover categories like hepatology, hepatologymedical, hiver, pancreas and pharmaceutical. We look forward to seeing you at EASL in 2017.

EASL (European Association for the Study of the Liver) started in 1966 as a small group of 70 hepatologists from 15 European countries who came together to share best medical practices. EASL is now the leading liver association in Europe and has evolved into a major European Association with international influence dedicated to the liver and liver disease. EASL has over 4,000 members from all over the world and provides an annual platform, The International Liver Congress™, for 11,000 liver experts to meet and discuss latest scientific research. EASL has given rise to many international clinical trials and research collaborations to the benefit of patients all over the world.

 

EASL aims to be the home of hepatology so that all who are involved with liver disease can realize their full potential to cure and prevent it. EASL goals:

  • Promote research in the science of liver disease (Hepatology)
  • Provides state-of-the-art education for physicians and scientists
  • Foster public awareness of liver diseases and management


EASL | EASL Facebook | ILC FacebookTwitter | Youtube

Rocky Mountain SETAC

diapharma chromogenic clotting elisa assay test kit diapharma chromogenic clotting elisa assay test kit diapharma chromogenic clotting elisa assay test kit


Diapharma will be attending Rocky Mountain SETAC. Please click here to schedule a meeting with us or email us directly!


diapharma chromogenic clotting elisa assay test kit

About RM SETAC

diapharma chromogenic clotting elisa assay test kitRocky Mountain SETAC is a non-profit regional chapter of the Society of Environmental Toxicology and Chemistry (SETAC).  RM SETAC serves the Rocky Mountain region states of Colorado, Montana, Utah, and Wyoming.

About SETAC

The Society of Environmental Toxicology (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology.

It publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


RMSETAC | SETAC | American Mountaineering Center

Design of Medical Device (DMD) Conference

toxicology assay test kit


Diapharma will be attending the Design of Medical Device (DMD) Conference this year. Please click here to schedule a meeting with us or email us directly.


Design of Medical Devices Conference

The University of Minnesota Medical Devices Center (part of the Institute for Engineering in Medicine), the College of Science and Engineering and the Department of Mechanical Engineering presents the 16th Annual Design of Medical Devices Conference, April 10, 11-13, 2017. The world’s largest medical device conference will be held at The Commons Hotel & McNamara Alumni Center, located on the University of Minnesota Twin Cities Campus.

Conference Goals

  • Provide a national forum to bring together world-class medical device designers, researchers, manufacturers, and the public sector to share perspectives and innovations in medical device design
  • Showcase the University of Minnesota as a leader in the medical device community
  • Raise funds from corporate sponsorships to support medical device education at the University of Minnesota

The 2017 conference consists of four-days of workshops, symposiums, scientific poster sessions and technical/scientific sessions, with topics such as:

  • Advances in Medical Devices
  • Becoming a MedTech Innovator
  • Cardiovascular Engineering
  • Clinical Trials
  • Cybersecurity
  • Drug Delivery Devices
  • Emerging Technology Forum
  • Global Harmonization
  • Human Factors
  • LIVE CLINICAL CASES
  • Micro Fluidic Medical Devices
  • Neuroengineering
  • Rehab Technology
  • Surgical Robotics
  • Three-in-Five Competition
  • Valuation Competition
  • Wearable Medical Devices
  • Wheelchair Technology


Twitter | Facebook | Google+YouTube

Hemostasis & Thrombosis Research Society (HTRS) Scientific Symposium 2017

hemostasis thrombosis assay test kit


Diapharma will be attending HTRS this year. Please click here to schedule a meeting with us or email us directly.


Hemostasis Thrombosis Research


The tenth professional HTRS meeting offers a dynamic range of topics in hemostasis and thrombosis in both pediatrics and adult medicine to best fit the needs and requests of diverse audience of residents and fellows; junior faculty members and well established coagulationists; hematologists, general internists, cardiologists, and pulmonologists; hemophilia and thrombosis nurses, representatives from industry, and all professionals caring for patients with disorders of bleeding and thrombosis.


hemostasis thrombosis assay test kitAbout HTRS

HTRS is a North American professional medical society with over 500 members from the U.S. and Canada. They are a nonprofit, 501(c)(3) organization incorporated in the State of Wisconsin in 1994. Their members are physicians, researchers, nurses, nurse practitioners, pharmacists, representatives from industry, and any health care professionals involved in caring for pediatric and adult patients with bleeding and/or thrombotic disorders.


HTRS offers

  • Grants and awards for fellows, junior faculty/junior attending, and experienced academic researchers in benign hematology.
  • Continuing education for physicians, nurses, and pharmacists at biennial HTRS Scientific Symposia.
  • Career development networks for fellows and junior faculty/junior attending.
  • Trainee Workshops prior to national meetings to foster the next generation of academic hematologists.

HTRS 2017 Educational Objective

  • Describe new diagnostic techniques in the diagnosis and management of thrombotic and bleeding disorders
  • Describe new therapies for the treatment of thrombotic and bleeding disorders
  • Identify knowledge gaps in thrombotic and bleeding disorders that can be incorporated into future research

HTRS 2017 Target Audience

Physicians, nurses, pharmacists, and other allied health professionals involved in the management, treatment or referral of pediatric and/or adult patients with bleeding and thrombotic disorders.


HTRS | HTRS 2017 | DoubleTree Scottsdale

NASH Summit 2017

NASH M30 Apoptosis Necrosis ELISA assay test kit NASH M30 Apoptosis Necrosis ELISA assay test kit


Diapharma will be attending NASH Summit 2017. Please click here to schedule a meeting with us or email us directly!


NASH M30 Apoptosis Necrosis ELISA assay test kit

Focused on Non-Alcoholic Steatohepatitis, this inaugural Summit will bring together drug developers to solve the challenges they face from drug discovery to late stage clinical development. Investment is pouring into NASH (non-alcoholic steatohepatitis) drug development spurred on by changes in the regulatory environment and the need for multiple drugs to be approved to treat this complex disease.

Attend this summit to learn the latest insight to identify and validate novel targets, better recapitulate human NASH disease.

  • Optimize recapitulation of NASH in vivo and effectively translate into the clinic
  • Validate non-invasive biomarker approaches and technologies to more robustly diagnose and track disease progression
  • Improve drug efficacy in both early and late stage NASH by identifying and validating novel targets & drug mechanisms of action
  • Define clinical primary and secondary endpoints and road-map your regulatory path to approval
  • Overcome the challenges that are preventing you from accelerating the development of your NASH candidate

NASH Summit | Sheraton Boston |

American Association of Cancer Research (AACR) Annual Meeting 2017

 


Diapharma will be attending AACR this year. Please click here to schedule a meeting with us or email us directly.


The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year’s theme, “Delivering Cures Through Cancer Science,” reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients.


About the AACR

American Association for Cancer Research (AACR)


The AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.

The AACR publishes Cancer Discovery, Cancer Research, Clinical Cancer Research, Cancer Immunology Research,Molecular Cancer Therapeutics, Molecular Cancer Research, Cancer Prevention Research and Cancer Epidemiology, Biomarkers & Prevention, Cancer Reviews Online, the Cancer Prevention Journals Portal and Cancer Today.


AACR | Twitter | #AACR17Facebook | YouTube

25th Annual Midwest SETAC (MWSETAC) Meeting

SETAC ecotox endocrine disruption vtg vitellogenin ELISA Assay Test Kit


Diapharma will be attending the 25th Annual Midwest SETAC (MWSETAC) Meeting “Sustainable Water Resource Management: From Urban to Rural” this year. Please click here to schedule a meeting with us or email us directly.


SETAC ecotox endocrine disruption vtg vitellogenin ELISA Assay Test Kit

Midwest SETAC is a non-profit (organization dedicated to the use of multidisciplinary approaches to examine the impacts of chemicals and technology on the environment. The chapter is operated as an independent affiliate of the international SETAC organization.

Midwest SETAC promotes research, education, training and development of the environmental sciences and encourages scientists to disseminate information on environmental toxicology and chemistry. Midwest SETAC sponsors scientific and educational programs to provide a forum for communication among professionals in government, business, academia and other segments of the environmental science community involved in the use, protection and management of the environment.

Protecting water resources from overuse and impairment presents a major challenge for meeting human, environmental, economic, and social needs for sustainable development. This year’s meeting theme highlights the diversity of challenges associated with water resources in urban, peri-urban, and rural settings. Presentations (platform or poster) are welcome in all areas of science applicable or relevant to Midwest SETAC, and we especially encourage topics that speak to the overall meeting theme.

Topics for Presentations/Posters

  • Analytical Chemistry of Contaminants
  • Behavioral Toxicology
  • Biomarkers
  • Chemical Risks from Air Pollution
  • Climate Assessment
  • Cumulative Risk Assessment
  • Ecological Risk Assessment and Field Studies
  • Ecological Studies
  • Effects of Population Growth on Biological Integrity
  • Effluent Toxicity
  • Emerging Contaminants of Concern
  • Endocrine Disruptors
  • Environmental Modeling Case Studies
  • Fate and Transport
  • Linking Human Health to Environmental Pollution
  • Measuring vs. Modeling
  • Molecular/Cellular Toxicology
  • Monitoring Air, Water, Sediment
  • Nanotechnology
  • Persistent and Bioaccumulative Chemicals
  • Regional Sustainability
  • Risk Characterization and Management
  • Sediment Toxicology
  • Toxicity Testing
  • Wildlife Toxicology
  • Other topics as appropriate and relevant

 

SETAC ecotox endocrine disruption vtg vitellogenin ELISA Assay Test Kit


Midwest SETACFacebook | University of St. Thomas | Hampton Inn Minneapolis

Emerging Trends in Non-Alcoholic Fatty Liver Disease

NAFLD M30 Apoptosis Necrosis ELISA Assay Test Kit NAFLD M30 Apoptosis Necrosis ELISA Assay Test Kit NAFLD M30 Apoptosis Necrosis ELISA Assay Test Kit


Diapharma will be attending the Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease this year. Please click here to schedule a meeting with us or email us directly.


ABOUT THE EMERGING TRENDS CONFERENCE

The 2017 Emerging Trends Conference will spearhead a development strategy to disseminate new knowledge in NAFLD. Major advances in the epidemiology, natural history, pathogenesis and diagnostic modalities have been uncovered. By facilitating new and exciting translational and therapeutic research in NAFLD, collaborations among clinicians, industry, academic institutions, and public health agencies will be well equipped to deal with this epidemic.liver assay test kit


ABOUT AASLD

The American Association for the Study of Liver Diseases (AASLD) is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists to bring together those who had contributed to the field of hepatology.


ABOUT NAFLD

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of chronic liver disease requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which however may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality.

There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design.


Emerging Trends Conference | AASLD | Twitter | Facebook | YouTube | Hyatt Regency Washington on Capitol Hill | Reservations

Society of Toxicology (SOT) 56th Annual Meeting and ToxExpo

toxicology assay test kit


Diapharma will be attending and exhibiting at the Society of Toxicology 56th Annual Meeting and ToxExpo. SOT promises stimulating lectures and presentations on scientific breakthroughs, important education and professional training opportunities, and time to connect with friends and create new collaborations.

DILI and DIKI remain as frequent causes of drug termination in clinical trials or withdrawals from the market. Visit Diapharma at Booth 2564 to discuss promising biomarkers currently being evaluated. The M30 Apoptosense® ELISA detects hepatocyte apoptosis in blood while M65®/M65 Epideath® ELISAs detect both apoptosis and necrosis, whether caused by drugs, toxins, or disease. Diapharma offers an extensive line of liver and kidney injury biomarkers, including K18, HA, α-GST, and Collagen IV. Research use only.

 



About SOTtoxicology assay test kit

Founded in 1961, the Society of Toxicology (SOT) is a professional and scholarly organization of scientists from academic institutions, government, and industry representing the great variety of scientists who practice toxicology in the US and abroad. The Society’s mission is to create a safer and healthier world by advancing the science and increasing the impact of toxicology.

The society organizes an annual meeting (usually in the early spring) and several smaller colloquia via its special interest sections and groups. It publishes the journal Toxicological Sciences, the newsletter Communiqué, as well as public position papers and guidelines on conflicts of interest in toxicology.



About ToxExpo
toxicology assay test kit

ToxExpo unites more than 350 toxicology-related companies and organizations with the more than 6,500 attendees of the SOT Annual Meeting & ToxExpo. During the meeting, exhibitors debut the latest products and services in toxicology to scientists, executives, and industry leaders. Attendees include research scientists from industry, academia, and regulatory agencies, as well as top executives from CROs, pharma, consulting firms, technology and equipment providers, and many non-profit organizations.


toxicology assay test kit


Diapharma ToxExpo Invitation Postcard

SOT | ToxExpo | Twitter Facebook YouTube Baltimore | Baltimore Convention Center

NASH-TAG Conference 2017

NASH M30 Apoptosis Necrosis ELISA Assay Test Kit NASH M30 Apoptosis Necrosis ELISA Assay Test Kit


Diapharma will be attending the 1st Annual NASH-TAG Conference this year. Please click here to schedule a meeting with us or email us directly.


ABOUT NASH-TAG

NASH M30 Apoptosis Necrosis ELISA Assay Test Kit

Learn from world-changing thinkers and innovators in NASH (non-alcoholic steatohepatitis) and Fibrosis at NASH-TAG 2017

The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in NASH and liver fibrosis. NASH-TAG 2017 will take place over two days providing attendees an understanding of current and future directions in procedures, prospects and challenges in drug discovery and development for both NASH and liver fibrosis. Internationally renowned faculty will assist in the development of the educational content and will serve as faculty at the conference.

NASH M30 Apoptosis Necrosis ELISA Assay Test Kit NASH M30 Apoptosis Necrosis ELISA Assay Test Kit NASH M30 Apoptosis Necrosis ELISA Assay Test Kit


ABOUT NASH

Non-alcoholic fatty liver disease (NAFLD) is one of the types of fatty liver which occurs when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. NAFLD is the most common liver disorder in developed countries and is related to insulin resistance and metabolic syndrome.

Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD, and is regarded as a major cause of cirrhosis of the liver of unknown cause.


NASH-TAG | Agenda | Twitter | Facebook  | Park City Marriott

The Liver Meeting® 2016 – The 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

 


The Liver Meeting® will host nearly 10,000 hepatologists and hepatology health professionals from around the world to exchange the latest liver diseases research, discuss treatment outcomes, and interact with colleagues at the annual must-attend even in the science and practice of hepatology.


Diapharma Peviva Liver Product Presentation “The Dead Cells Still Count! Keratin 18 Cell Death Products”



aasld2About the AASLD

The American Association for the Study of Liver Diseases (AASLD) is a scientific organization which attempts promote liver health and prevent and cure liver disease through hepatology.

The organization publishes podcasts, newsletters and the journals HEPATOLOGY, Clinical Liver Disease (CLD), and Liver Transplantation.


Invitation PostcardThe Liver Meeting®, AASLD, Twitter, Facebook, YouTube

7th SETAC World Congress / SETAC North America 37th Annual Meeting

diapharma chromogenic clotting elisa assay test kit


View our SETAC Postcard, Promotion, and Flyer.


Society of Environmental Toxicology (SETAC) Orlando is a 5-day event featuring a variety of training, networking and learning opportunities. You cannot miss this event if you are interested in emerging research, regulatory developments and the latest methodologies in environmental toxicology and chemistry. More than 2,500 scientists, assessors, regulators and managers from academia, business and government, representing 40 plus countries, provides a unique networking opportunity and a chance for cross-collaboration long after the closing session.


Society of Environmental Toxicology and Chemistry (SETAC)About SETAC

The Society of Environmental Toxicology (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology.

It publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


SETAC, Twitter, Facebook, YouTube, Rosen Shingle Creek

16th Biennial Midwest Platelet Conference

platelet function analyzer

platelet function analyzer


The Midwest Platelet Conference is a biennial meeting of 100-150 scientists and clinicians from the greater Midwest region of the United States and Canada. The purpose of this meeting is for attendees to share current knowledge about platelet biology, to establish productive scientific collaborations between scientists and clinicians, and to work towards the application of this knowledge to improvements in drug development and patient care. The entire conference is focused on platelet biology and regulation in physiologic and pathophysiologic conditions. The 2016 conference is hosted by the University of Tennessee Health Science Center.


OBJECTIVES

  • Describe platelet activation pathways
  • Discuss platelet adhesion and aggregation
  • Describe the role of platelets in infammation
  • Update new approaches to regulate coagulation and anticoagulation
  • Discuss antithrombotics and their mechanism of action in regulating hemostasis and thrombosis
  • Update new horizons or approaches in the field of vascular disease, particularly as it pertains to platelets and coagulation

2016 Midwest Platelet Conference (main site) | MPC page on The University of Tennessee Health Science Center | The Westin Memphis Beale Street | Register | MPC FlyerAttendee Brochure

2014 Midwest Platelet Conference (previous conference Diapharma attended)

XXXII International Congress of the World Federation of Hemophilia (WFH)

diapharma chromogenic clotting elisa assay test kit


diapharma chromogenic clotting elisa assay test kit

The XXXII International Congress of the World Federation of Hemophilia (WFH) is expected to be the largest in the WFH’s history, with more than 6,000 attendees expected from over 125 countries. The WFH 2016 World Congress will be held right after National Hemophilia Foundation’s (NHF) 68th Annual Meeting. The NHF will host the largest international meeting dedicated to hemophilia, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders since it is the first time in over 25 years that the global community meets in the United States. This will be a unique opportunity for US healthcare providers, NHF chapters, as well as patients and their families to join the global bleeding disorders community.

Congress attendees include hematologists, pediatricians, orthopedic surgeons, geneticists, laboratory technicians, researchers, and scientists who represent the comprehensive care team for people with bleeding disorders. The WFH 2016 World Congress is also the global meeting place for national patient organization leaders, as well as people with bleeding disorders and their families. Presentations, workshops, symposia, and exhibits will feature cutting-edge trends in research and treatment for hemophilia and other inherited bleeding disorders.



diapharma chromogenic clotting elisa assay test kitAbout the WFH

The World Federation of Hemophilia (WFH) is an international non-profit organization dedicated to improving the lives of people with hemophilia and other genetic bleeding disorders. It educates hemophiliacs and lobbies for improved medical treatment. 75% of people in the world with bleeding disorders do not know it and do not receive care.

WFH, Twitter, Facebook, YouTubeGaylord Palms Resort & Convention Center


About the National Hemophilia Foundation’s (NHF)NHF

The National Hemophilia Foundation (NHF) is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research.

NHF, Twitter, Facebook, YouTube

1st International Workshop on NASH Biomarkers

NASH Biomarker ELISA NASH Biomarker ELISA NASH Biomarker ELISA

NASH Biomarker ELISADiapharma is proud to sponsor the 1st International Workshop on NASH Biomarkers to be held in Washington DC, USA on 29-30 April 2016.

This abstract-driven workshop will provide a much-needed forum for presentation and in-depth discussion of the latest research results on biomarkers for NASH. The nature of the program will be interactive, stimulating international and cross-disciplinary interchange, in-depth discussion and debate. The program is initiated by an expert steering committee in order to reach consensus, integrate efforts, develop strategies and advance this important field of research.

The workshop is endorsed by the The International Association for the Study of the Liver (IASL).


 

About NASH

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America, but the incidence is also increasing outside North America. It is a growing contributor to the burden of CLD requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which however may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality.

There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. In particular methods to identify the subjects and the validation of endpoints that reflect meaningful changes in health status in this population are needed.

 

American Association of Cancer Research (AACR) Annual Meeting 2016

New-Orleans-Ernest-N-Morial-Convention-Center2


The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year’s theme, “Delivering Cures Through Cancer Science,” reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients.


About the AACR

American Association for Cancer Research (AACR)


The AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.

The AACR publishes Cancer Discovery, Cancer Research, Clinical Cancer Research, Cancer Immunology Research, Molecular Cancer Therapeutics, Molecular Cancer Research, Cancer Prevention Research and Cancer Epidemiology, Biomarkers & Prevention, Cancer Reviews Online, the Cancer Prevention Journals Portal and Cancer Today.


Invitation PostcardAACR, Facebook, Twitter, YouTube

3rd Annual Summit of the Thrombosis & Hemostasis Societies of North America (THSNA)

diapharma chromogenic clotting elisa assay test kit


The Thrombosis and Hemostasis Societies of North America (THSNA) will hold its 3rd comprehensive scientific meeting dedicated to thrombosis and hemostasis issues in Chicago, IL from April 14-16, 2016.

This summit is a collaboration of the fourteen leading non-profit organizations in both fields. THSNA 2016 will provide a focused forum for over 1,500 attendees with an interest in bleeding and clotting disorders to network, learn, and share across disciplines and disease states.


THSNA, Twitter, Sheraton Chicago

diapharma chromogenic clotting elisa assay test kit

Society of Toxicology (SOT) 55th Annual Meeting and ToxExpo

New-Orleans-Ernest-N-Morial-Convention-Center3


The Society of Toxicology 55th Annual Meeting and ToxExpo, March 13–17, 2016, in New Orleans, Louisiana, promises stimulating lectures and presentations on scientific breakthroughs, important education and professional training opportunities, and time to connect with friends and create new collaborations.

Visit Diapharma at SOT ToxExpo Booth 219. Press Release.


Society of ToxicologySociety of Toxicology ToxExpo


Society of Toxicology

ABOUT THE SOT

Founded in 1961, the Society of Toxicology (SOT) is a professional and scholarly organization of scientists from academic institutions, government, and industry representing a variety of scientists who practice toxicology in the US and abroad. The Society’s mission is to create a safer and healthier world by advancing the science and increasing the impact of toxicology.

The society organizes an annual meeting (usually in the early spring) and several smaller colloquia via its special interest sections and groups. It publishes the journal Toxicological Sciences, the newsletter Communiqué, as well as public position papers and guidelines on conflicts of interest in toxicology.



SOT, Twitter, Facebook, YouTube, ToxExpo, Diapharma ToxExpo Booth info, Press Release

Western Trauma Association 46th Annual Meeting

diapharma chromogenic clotting elisa assay test kit diapharma chromogenic clotting elisa assay test kit


diapharma chromogenic clotting elisa assay test kit


About the WTA

western trauma

The Western Trauma Association is committed to the improvement of trauma care through research, education, sharing of clinical experiences, and the development of physicians of all specialties who are involved in the care of trauma patients. The goals of the Association are not only the intellectual growth attained through increased knowledge, but also the emotional growth attained through camaraderie and interaction with family and friends in an environment conducive to winter sports.

Together with the American Association for the Surgery of Trauma (AAST), National Trauma Institute (NTI) American College of Surgeons Committee on Trauma (COT), Eastern Association for the Surgery of Trauma (EAST) and American Trauma Society (ATS), the Western Trauma Association (WTA) launched the Coalition for National Trauma Research (CNTR) in September 2014. CNTR believes that a robust research infrastructure is long over-due, pointing to a 40-year history of federally acknowledged research funding inadequacies.


WTA, FacebookSquaw Creek

The Liver Meeting® 2015 – The 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

diapharma chromogenic clotting elisa assay test kit


The Liver Meeting® will host nearly 10,000 hepatologists and hepatology health professionals from around the world to exchange the latest liver diseases research, discuss treatment outcomes, and interact with colleagues at the annual must-attend even in the science and practice of hepatology.


Diapharma Peviva Liver Product Presentation “The Dead Cells Still Count! Keratin 18 Cell Death Products”


American Association for the Study of Liver Diseases


About the AASLD

The American Association for the Study of Liver Diseases (AASLD) is a scientific organization which attempts promote liver health and prevent and cure liver disease through hepatology.

The organization publishes podcasts, newsletters and the journals HEPATOLOGY, Clinical Liver Disease (CLD), and Liver Transplantation.


Society of Environmental Toxicology (SETAC) North America 36th Annual Meeting

diapharma chromogenic clotting elisa assay test kit


About SETACSociety of Environmental Toxicology and Chemistry (SETAC)

The Society of Environmental Toxicology (SETAC) is a global, non-profit organization which promotes the health of natural resources and study and management of environmental problems in the scientific field of environmental toxicology (entox) and ecotoxicology.

It publishes books, newsletters, educational webinars, and the journals Environmental Toxicology and Chemistry (ET&C) and Integrated Environmental Assessment and Management (IEAM).


 

XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH) and 61st Annual SSC Meeting

toronto7


diapharma chromogenic clotting elisa assay test kit

The International Society on Thrombosis and Haemostasis (ISTH) is a not-for-profit global membership organization of specialists in the field of blood coagulation and its disorders, such as thrombosis and hemophilia. ISTH initiates and promotes education and outreach initiatives, research activities, scientific meetings, peer-reviewed publications, expert committees and the development of standards allowing a common language and approach to basic and clinical science all over the world. It also publishes a medical journal, the Journal of Thrombosis and Haemostasis.

The mission of the International Society on Thrombosis and Haemostasis is to advance the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.


diapharma chromogenic clotting elisa assay test kit

About the ISTH Congress

At the International Society on Thrombosis and Haemostasis (ISTH) Congress, thousands of the world’s leading experts on thrombosis, hemostasis and vascular biology come together to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care.

Through an extensive lineup of educational sessions, poster and oral communications, state-of-the-art lectures, medical industry exhibits and professional networking opportunities, the Congress promotes important scientific discourse and advancement.


diapharma chromogenic clotting elisa assay test kit

About the SSC Meeting

The ISTH’s Scientific and Standardization Committee (SSC) holds annual meetings devoted to the discussion of diagnostic standards, disease nomenclature and classification, and the latest research on bleeding and throm­botic disorders.

In odd years, SSC Meetings are held jointly with the ISTH Congress.




ISTH, ISTH 2015, ISTH 2015 Program, Metro Toronto Convention Center
Twitter, Facebook, YouTube, Wikipedia